

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 February 2004 (19.02.2004) ✓

PCT

(10) International Publication Number
WO 2004/014865 A1 ✓

(51) International Patent Classification⁷: **C07D 237/24**,
237/08, 237/20, 237/14, 401/10, 405/10, 403/10, 403/12,
401/12, 409/04, 401/04, 405/14, 409/14, 401/14, 417/14,
403/04, A61K 31/4965, 31/497

(21) International Application Number:
PCT/GB2003/003376 ✓

(22) International Filing Date: 4 August 2003 (04.08.2003) ✓

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0218874.6 13 August 2002 (13.08.2002) GB
0229591.3 19 December 2002 (19.12.2002) GB

(71) Applicant (for all designated States except US): **MERCK
SHARP & DOHME LIMITED** [GB/GB]; Hertford Road,
Hoddesdon, Hertfordshire EN11 9BU (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BLACKABY, Wesley, Peter** [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). **BLURTON, Peter** [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). **BURKAMP, Frank** [DE/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). **FLETCHER, Stephen, Robert** [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). **JENNINGS, Andrew** [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). **LEWIS, Richard, Thomas** [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). **MACLEOD, Angus, Murray** [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex

CM20 2QR (GB). **STREET, Leslie, Joseph** [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). **THOMAS, Steve** [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). **VAN NIEL, Monique, Bodil** [NL/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). **WILSON, Kevin** [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).

(74) Agent: **COLE, William, Gwyn**; European Patent Department, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS



(I)

(57) Abstract: A class of 4-phenylpyridazine derivatives of Formula (I), being selective ligands for GABA_A receptors, in particular having high affinity for the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.



~~This Page Blank (uspto)~~
BEST AVAILABLE COPY

This Page Blank (uspto)

PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA
RECEPTORS

The present invention relates to a class of substituted pyridazine derivatives and to their use in therapy. More particularly, this invention is concerned with 4-phenylpyridazine analogues. These compounds are ligands for GABA_A receptors and are therefore useful in the therapy of deleterious neurological complaints.

Receptors for the major inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), are divided into two main classes: (1) GABA_A receptors, which are members of the ligand-gated ion channel superfamily; and (2) GABA_B receptors, which may be members of the G-protein linked receptor superfamily. Since the first cDNAs encoding individual GABA_A receptor subunits were cloned the number of known members of the mammalian family has grown to include at least six α subunits, four β subunits, three γ subunits, one δ subunit, one ϵ subunit and two ρ subunits.

Although knowledge of the diversity of the GABA_A receptor gene family represents a huge step forward in our understanding of this ligand-gated ion channel, insight into the extent of subtype diversity is still at an early stage. It has been indicated that an α subunit, a β subunit and a γ subunit constitute the minimum requirement for forming a fully functional GABA_A receptor expressed by transiently transfecting cDNAs into cells. As indicated above, δ , ϵ and ρ subunits also exist, but are present only to a minor extent in GABA_A receptor populations.

Studies of receptor size and visualisation by electron microscopy conclude that, like other members of the ligand-gated ion channel family, the native GABA_A receptor exists in pentameric form. The selection of at least one α , one β and one γ subunit from a repertoire of seventeen allows for the possible existence of more than 10,000 pentameric subunit combinations. Moreover, this calculation overlooks the additional

permutations that would be possible if the arrangement of subunits around the ion channel had no constraints (i.e. there could be 120 possible variants for a receptor composed of five different subunits).

Receptor subtype assemblies which do exist include, amongst many others, $\alpha 1\beta 2\gamma 2$, $\alpha 2\beta \gamma 1$, $\alpha 2\beta 2/3\gamma 2$, $\alpha 3\beta \gamma 2/3$, $\alpha 4\beta \delta$, $\alpha 5\beta 3\gamma 2/3$, $\alpha 6\beta \gamma 2$ and $\alpha 6\beta \delta$. Subtype assemblies containing an $\alpha 1$ subunit are present in most areas of the brain and are thought to account for over 40% of GABA_A receptors in the rat. Subtype assemblies containing $\alpha 2$ and $\alpha 3$ subunits respectively are thought to account for about 25% and 17% of GABA_A receptors in the rat. Subtype assemblies containing an $\alpha 5$ subunit are expressed predominantly in the hippocampus and cortex and are thought to represent about 4% of GABA_A receptors in the rat.

A characteristic property of all known GABA_A receptors is the presence of a number of modulatory sites, one of which is the benzodiazepine (BZ) binding site. The BZ binding site is the most explored of the GABA_A receptor modulatory sites, and is the site through which anxiolytic drugs such as diazepam and temazepam exert their effect. Before the cloning of the GABA_A receptor gene family, the benzodiazepine binding site was historically subdivided into two subtypes, BZ1 and BZ2, on the basis of radioligand binding studies. The BZ1 subtype has been shown to be pharmacologically equivalent to a GABA_A receptor comprising the $\alpha 1$ subunit in combination with a β subunit and $\gamma 2$. This is the most abundant GABA_A receptor subtype, and is believed to represent almost half of all GABA_A receptors in the brain.

Two other major populations are the $\alpha 2\beta \gamma 2$ and $\alpha 3\beta \gamma 2/3$ subtypes. Together these constitute approximately a further 35% of the total GABA_A receptor repertoire. Pharmacologically this combination appears to be equivalent to the BZ2 subtype as defined previously by radioligand binding, although the BZ2 subtype may also include certain $\alpha 5$ -containing subtype assemblies. The physiological role of these subtypes has hitherto

been unclear because no sufficiently selective agonists or antagonists were known.

It is now believed that agents acting as BZ agonists at $\alpha 1\beta\gamma 2$, $\alpha 2\beta\gamma 2$ or $\alpha 3\beta\gamma 2$ subtypes will possess desirable anxiolytic properties. Compounds which are modulators of the benzodiazepine binding site of the GABA_A receptor by acting as BZ agonists are referred to hereinafter as "GABA_A receptor agonists". The $\alpha 1$ -selective GABA_A receptor agonists alpidem and zolpidem are clinically prescribed as hypnotic agents, suggesting that at least some of the sedation associated with known anxiolytic drugs which act at the BZ1 binding site is mediated through GABA_A receptors containing the $\alpha 1$ subunit. Accordingly, it is considered that GABA_A receptor agonists which interact more favourably with the $\alpha 2$ and/or $\alpha 3$ subunit than with $\alpha 1$ will be effective in the treatment of anxiety with a reduced propensity to cause sedation. Moreover, agents which are inverse agonists of the $\alpha 5$ subunit are likely to be beneficial in enhancing cognition, for example in subjects suffering from dementing conditions such as Alzheimer's disease. Also, agents which are antagonists or inverse agonists at $\alpha 1$ might be employed to reverse sedation or hypnosis caused by $\alpha 1$ agonists.

The compounds of the present invention, being selective ligands for GABA_A receptors, are therefore of use in the treatment and/or prevention of a variety of disorders of the central nervous system. Such disorders include anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias including social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic and acute stress disorder, and generalized or substance-induced anxiety disorder; neuroses; convulsions; migraine; depressive or bipolar disorders, for example single-episode or recurrent major depressive disorder, dysthymic disorder, bipolar I and bipolar II manic disorders, and cyclothymic disorder; psychotic disorders including schizophrenia; neurodegeneration arising from cerebral

ischemia; attention deficit hyperactivity disorder; Tourette's syndrome; speech disorders, including stuttering; and disorders of circadian rhythm, e.g. in subjects suffering from the effects of jet lag or shift work.

Further disorders for which selective ligands for GABA_A receptors may be of benefit include pain and nociception; emesis, including acute, delayed and anticipatory emesis, in particular emesis induced by chemotherapy or radiation, as well as motion sickness, and post-operative nausea and vomiting; eating disorders including anorexia nervosa and bulimia nervosa; premenstrual syndrome; muscle spasm or spasticity, e.g. in paraplegic patients; hearing disorders, including tinnitus and age-related hearing impairment; urinary incontinence; and the effects of substance abuse or dependency, including alcohol withdrawal. Selective ligands for GABA_A receptors may be beneficial in enhancing cognition, for example in subjects suffering from dementing conditions such as Alzheimer's disease; and may also be effective as pre-medication prior to anaesthesia or minor procedures such as endoscopy, including gastric endoscopy.

In addition, the compounds in accordance with the present invention may be useful as radioligands in assays for detecting compounds capable of binding to the human GABA_A receptor.


The present invention provides a class of pyridazine derivatives which possess desirable binding properties at various GABA_A receptor subtypes. The compounds in accordance with the present invention have good affinity as ligands for the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit of the human GABA_A receptor. The compounds of this invention may interact more favourably with the $\alpha 2$ and/or $\alpha 3$ subunit than with the $\alpha 1$ subunit; and/or may interact more favourably with the $\alpha 5$ subunit than with the $\alpha 1$ subunit.

The compounds of the present invention are GABA_A receptor subtype ligands having a binding affinity (K_i) for the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit, as measured in the assay described hereinbelow, of 200 nM or

less, typically of 100 nM or less, and ideally of 20 nM or less. The compounds in accordance with this invention may possess at least a 2-fold, suitably at least a 5-fold, and advantageously at least a 10-fold, selective affinity for the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit relative to the $\alpha 1$ subunit.

5 However, compounds which are not selective in terms of their binding affinity for the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit relative to the $\alpha 1$ subunit are also encompassed within the scope of the present invention; such compounds will desirably exhibit functional selectivity in terms of zero or weak (positive or negative) efficacy at the $\alpha 1$ subunit and (i) a full or
10 partial agonist profile at the $\alpha 2$ and/or $\alpha 3$ subunit, and/or (ii) an inverse agonist profile at the $\alpha 5$ subunit.

The present invention provides a compound of formula I, or an *N*-oxide thereof or a pharmaceutically acceptable salt thereof:



(I)

15 wherein

X¹ represents hydrogen, halogen, C₁₋₆ alkyl, trifluoromethyl or C₁₋₆ alkoxy;

20 X² represents hydrogen or halogen;

Z represents hydrogen, halogen, cyano, cyanomethyl, trifluoromethyl, nitro, hydroxy, C₁₋₆ alkoxy, formyl, C₂₋₆ alkoxycarbonyl, or an optionally substituted aryl, heteroaryl or heteroaryl(C₁₋₆)alkoxy group;

R¹ represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -OSO₂CF₃, -SR^a, -SOR^a, -SO₂R^a,
25

-SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a, -CONR^aR^b or -CR^a=NOR^b;

R² represents hydrogen or C₂₋₆ alkoxy carbonyl; and

5 R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group.

The present invention also provides a compound of formula I as depicted above, or an *N*-oxide thereof or a pharmaceutically acceptable salt thereof, wherein

10 R¹ represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a, -CONR^aR^b or -CR^a=NOR^b; and

X¹, X², Z, R², R^a and R^b are as defined above.

Where Z in the compounds of formula I above represents aryl, 15 heteroaryl or heteroaryl(C₁₋₆)alkoxy, this group may be unsubstituted, or substituted by one or more substituents. Typically, the group Z will be unsubstituted, or substituted by one or two substituents. Typical substituents on the group Z include halogen, cyano, trifluoromethyl, nitro, C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, oxy, C₁₋₆ alkylsulphonyl, amino, 20 aminocarbonyl, formyl, C₂₋₆ alkoxy carbonyl and -CR^a=NOR^b, wherein R^a and R^b are as defined above. Illustrative substituents on Z include halogen, cyano, trifluoromethyl and C₁₋₆ alkyl.

For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts. Other salts may, however, be useful in 25 the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable 30 acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic

acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.

Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

The term "hydrocarbon" as used herein includes straight-chained, branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms, and conveniently up to 12 carbon atoms. Suitable hydrocarbon groups include C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl, indanyl, aryl and aryl(C₁₋₆)alkyl.

The expression "a heterocyclic group" as used herein includes cyclic groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur. The heterocyclic group suitably contains up to 15 carbon atoms and conveniently up to 12 carbon atoms, and is preferably linked through carbon. Examples of suitable heterocyclic groups include C₃₋₇ heterocycloalkyl, C₃₋₇ heterocycloalkenyl, C₃₋₇ heterocycloalkyl(C₁₋₆)alkyl, heteroaryl and heteroaryl(C₁₋₆)alkyl groups.

Suitable alkyl groups include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl, butyl and pentyl groups. Particular alkyl groups are methyl, ethyl, *n*-propyl, isopropyl, isobutyl, *tert*-butyl and 2,2-dimethylpropyl. Derived expressions such as "C₁₋₆ alkoxy", "C₁₋₆ alkylamino" and "C₁₋₆ alkylsulphonyl" are to be construed accordingly.

Suitable alkenyl groups include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl, allyl and dimethylallyl groups.

Suitable alkynyl groups include straight-chained and branched alkynyl groups containing from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.

5 Suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl.

Typical examples of C₃₋₇ cycloalkyl(C₁₋₆)alkyl groups include cyclopropylmethyl, cyclohexylmethyl and cyclohexylethyl.

Particular indanyl groups include indan-1-yl and indan-2-yl.

10 Particular aryl groups include phenyl and naphthyl, preferably phenyl.

Particular aryl(C₁₋₆)alkyl groups include benzyl, phenylethyl, phenylpropyl and naphthylmethyl.

Suitable heterocycloalkyl groups include azetidiny, pyrrolidiny, piperidiny, piperaziny, morpholiny and thiomorpholiny groups.

15 A typical heterocycloalkenyl group is dihydropyrrolyl.

Suitable heteroaryl groups include pyridiny, quinoliny, isoquinoliny, pyridaziny, pyrimidiny, pyraziny, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, 20 oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl groups.

The expression "heteroaryl(C₁₋₆)alkyl" as used herein includes furylmethyl, furylethyl, thienylmethyl, thienylethyl, pyrazolylmethyl, oxazolylmethyl, oxazolylethyl, thiazolylmethyl, thiazolylethyl, imidazolylmethyl, imidazolylethyl, oxadiazolylmethyl, oxadiazolylethyl, 25 thiadiazolylmethyl, thiadiazolylethyl, triazolylmethyl, triazolylethyl, tetrazolylmethyl, tetrazolylethyl, pyridinylmethyl, pyridinylethyl, pyrimidinylmethyl, pyrazinylmethyl, quinolinylmethyl and isoquinolinylmethyl.

30 The hydrocarbon and heterocyclic groups may in turn be optionally substituted by one or more groups selected from C₁₋₆ alkyl, adamantyl, phenyl, halogen, C₁₋₆ haloalkyl, C₁₋₆ aminoalkyl, trifluoromethyl, hydroxy,

C₁₋₆ alkoxy, aryloxy, keto, C₁₋₃ alkylenedioxy, nitro, cyano, carboxy, C₂₋₆ alkoxycarbonyl, C₂₋₆ alkoxycarbonyl(C₁₋₆)alkyl, C₂₋₆ alkylcarbonyloxy, arylcarbonyloxy, aminocarbonyloxy, C₂₋₆ alkylcarbonyl, arylcarbonyl, C₁₋₆ alkylthio, C₁₋₆ alkylsulphinyl, C₁₋₆ alkylsulphonyl, arylsulphonyl, -NR^vR^w,
5 -NR^vCOR^w, -NR^vCO₂R^w, -NR^vSO₂R^w, -CH₂NR^vSO₂R^w, -NHCONR^vR^w,
-CONR^vR^w, -SO₂NR^vR^w and -CH₂SO₂NR^vR^w, in which R^v and R^w independently represent hydrogen, C₁₋₆ alkyl, aryl or aryl(C₁₋₆)alkyl.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially fluoro or chloro.

10 Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion
15 are encompassed within the scope of the present invention.

Suitable values for the X¹ substituent include hydrogen, fluoro, chloro, methyl, trifluoromethyl and methoxy; in particular hydrogen or fluoro; and especially fluoro.

20 Typical values of X² include hydrogen and fluoro, especially hydrogen.

Typically, Z represents an optionally substituted aryl or heteroaryl group.

25 Selected values for the substituent Z include phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, any of which groups may be optionally substituted by one or more substituents.

30 In one favoured embodiment, Z represents an optionally substituted phenyl group, in particular monosubstituted or disubstituted phenyl. In another favoured embodiment, Z represents optionally substituted

pyridinyl, especially unsubstituted, monosubstituted or disubstituted pyridin-2-yl, pyridin-3-yl or pyridin-4-yl.

Examples of suitable substituents on the group Z include fluoro, chloro, cyano, trifluoromethyl, nitro, methyl, hydroxy, methoxy, oxy,
5 methanesulphonyl, amino, aminocarbonyl, formyl, methoxycarbonyl and -CH=NOH.

Examples of particular substituents on the group Z include fluoro, cyano, trifluoromethyl and methyl, especially fluoro or cyano.

Detailed values of Z include cyanophenyl, (cyano)(fluoro)phenyl,
10 (chloro)(cyano)phenyl, nitrophenyl, methoxyphenyl, methanesulphonyl-phenyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, (amino)(chloro)pyridinyl, cyano-pyridinyl, methyl-pyridinyl, hydroxy-pyridinyl, methoxy-pyridinyl, oxy-pyridinyl, aminocarbonyl-pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, cyano-thienyl, aminocarbonyl-thienyl,
15 formyl-thienyl, methoxycarbonyl-thienyl, thienyl-CH=NOH, thiazolyl, isothiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl and methyl-tetrazolyl. Additional values of Z include fluorophenyl, difluorophenyl and trifluoromethyl-phenyl.

Representative values of Z include hydrogen, fluoro, bromo, cyano,
20 cyanomethyl, trifluoromethyl, nitro, hydroxy, methoxy, isopropoxy, formyl, methoxycarbonyl, fluorophenyl, difluorophenyl, cyanophenyl, (cyano)(fluoro)phenyl, trifluoromethyl-phenyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, cyano-pyridinyl, triazolyl, (methyl)(trifluoromethyl)-pyrazolyl-methoxy, methyltriazolyl-methoxy and pyridinyl-methoxy.

25 Specific values of Z include hydrogen, fluoro, bromo, cyano, cyanomethyl, trifluoromethyl, nitro, hydroxy, methoxy, isopropoxy, formyl, methoxycarbonyl, (cyano)(fluoro)phenyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, triazolyl, (methyl)(trifluoromethyl)pyrazolyl-methoxy, methyltriazolyl-methoxy and pyridinyl-methoxy.

30 Suitably, R¹ represents hydrocarbon, a heterocyclic group, -OR^a, -OSO₂CF₃, -SR^a, -NR^aR^b or -CO₂R^a.

Typically, R^1 represents hydrocarbon, a heterocyclic group, $-OR^a$, $-NR^aR^b$ or $-CO_2R^a$.

Typical values of R^a include C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-7} cycloalkyl and aryl(C_{1-6})alkyl (optionally substituted by C_{1-6} alkoxy). Suitably, R^a represents methyl, ethyl, *n*-propyl, isopropyl, allyl, cyclopropyl, cyclohexyl, benzyl or methoxybenzyl. Additionally, R^a may represent *tert*-butyl.

Typical values of R^b include hydrogen and C_{1-6} alkyl. Suitably, R^b represents hydrogen or methyl, especially hydrogen.

Favourably, R^1 represents aryl or heteroaryl, either of which groups may be substituted by one or more substituents. Typically, the aryl or heteroaryl group R^1 will be unsubstituted, or substituted by one or two substituents. Typical substituents include halogen, C_{1-6} alkyl, trifluoromethyl, C_{1-6} alkoxy, cyano and oxo. Suitable substituents include halogen, C_{1-6} alkyl, trifluoromethyl, C_{1-6} alkoxy and cyano. Particular substituents include fluoro, chloro, methyl, trifluoromethyl, methoxy and cyano, especially fluoro.

Illustrative values of R^1 include phenyl, halophenyl, dihalophenyl, trihalophenyl, (C_{1-6} alkyl)(halo)phenyl, (trifluoromethyl)(halo)phenyl, C_{1-6} alkoxyphenyl, (C_{1-6} alkoxy)(halo)phenyl, cyanophenyl, (cyano)(halo)phenyl, C_{3-7} heterocycloalkyl (optionally substituted by oxo), C_{3-7} heterocycloalkenyl, heteroaryl (optionally substituted by one or more halogen atoms, and/or by oxo), C_{1-6} alkoxy, C_{2-6} alkenyloxy, aryl(C_{1-6})alkoxy, triflyloxy, C_{1-6} alkylthio, C_{1-6} alkylamino, C_{2-6} alkenylamino, C_{3-7} cycloalkylamino, aryl(C_{1-6})alkylamino (optionally substituted by C_{1-6} alkoxy) and C_{2-6} alkoxycarbonyl.

Typical values of R^1 include phenyl, halophenyl, dihalophenyl, (C_{1-6} alkyl)(halo)phenyl, (trifluoromethyl)(halo)phenyl, C_{1-6} alkoxyphenyl, (C_{1-6} alkoxy)(halo)phenyl, cyanophenyl, (cyano)(halo)phenyl, C_{3-7} heterocycloalkenyl, heteroaryl (optionally substituted by one or more halogen atoms), C_{1-6} alkoxy, C_{2-6} alkenyloxy, aryl(C_{1-6})alkoxy, triflyloxy, C_{1-6} alkylthio, C_{1-6} alkylamino, C_{2-6} alkenylamino, C_{3-7} cycloalkylamino,

aryl(C₁₋₆)alkylamino (optionally substituted by C₁₋₆ alkoxy) and C₂₋₆ alkoxycarbonyl.

Suitable values of R¹ include phenyl, halophenyl, dihalophenyl, C₁₋₆ alkoxyphenyl, cyanophenyl, (cyano)(halo)phenyl, C₃₋₇ heterocycloalkenyl, heteroaryl (optionally substituted by halo), C₁₋₆ alkoxy, C₂₋₆ alkenyloxy, aryl(C₁₋₆)alkoxy, C₁₋₆ alkylamino, C₂₋₆ alkenylamino, C₃₋₇ cycloalkylamino, aryl(C₁₋₆)alkylamino (optionally substituted by C₁₋₆ alkoxy) and C₂₋₆ alkoxycarbonyl.

Representative values of R¹ include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, (chloro)(fluoro)phenyl, trifluorophenyl, (fluoro)(methyl)phenyl, (fluoro)(trifluoromethyl)phenyl, methoxyphenyl, (fluoro)(methoxy)phenyl, cyanophenyl, (cyano)(fluoro)phenyl, oxo-pyrrolidinyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, oxo-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, triflyloxy, ethylthio, *tert*-butylthio, methylamino, ethylamino, propylamino, isopropylamino, allylamino, cyclopropylamino, cyclohexylamino, benzylamino, methoxybenzyl-amino and ethoxycarbonyl.

Particular values of R¹ include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, (chloro)(fluoro)phenyl, (fluoro)(methyl)phenyl, (fluoro)(trifluoromethyl)phenyl, methoxyphenyl, (fluoro)(methoxy)phenyl, cyanophenyl, (cyano)(fluoro)phenyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, triflyloxy, ethylthio, *tert*-butylthio, methylamino, ethylamino, propylamino, isopropylamino, allylamino, cyclopropylamino, cyclohexylamino, benzylamino, methoxybenzyl-amino and ethoxycarbonyl.

Individual values of R¹ include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, methoxyphenyl, cyanophenyl, (cyano)(fluoro)phenyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, methylamino,

ethylamino, propylamino, isopropylamino, allylamino, cyclopropylamino, cyclohexylamino, benzylamino, methoxybenzyl-amino and ethoxycarbonyl.

In one embodiment, R¹ represents fluorophenyl (especially 2-fluorophenyl).


5 In another embodiment, R¹ represents fluoro-pyridinyl (especially 3-fluoropyridin-2-yl).

In a further embodiment, R¹ represents difluoro-pyridinyl. In one aspect of this embodiment, R¹ represents 3,5-difluoropyridin-4-yl. In another aspect of this embodiment, R¹ represents 3,5-difluoropyridin-2-yl.

10 In an additional embodiment, R¹ represents trifluorophenyl (especially 2,4,6-trifluorophenyl).

Suitably, R² represents hydrogen, methoxycarbonyl or ethoxycarbonyl. In a particular embodiment, R² represents hydrogen.

15 A particular sub-class of compounds according to the invention is represented by the compounds of formula IIA, and *N*-oxides thereof and pharmaceutically acceptable salts thereof:



(IIA)

20 wherein

Z is as defined above;

X¹¹ represents hydrogen, fluoro, chloro, methyl, trifluoromethyl or methoxy;

X¹² represents hydrogen or fluoro; and

R¹¹ represents phenyl, halophenyl, dihalophenyl, trihalophenyl, (C₁₋₆ alkyl)(halo)phenyl, (trifluoromethyl)(halo)phenyl, C₁₋₆ alkoxyphenyl, (C₁₋₆ alkoxy)(halo)phenyl, cyanophenyl, (cyano)(halo)phenyl, C₃₋₇ heterocycloalkyl (optionally substituted by oxo), C₃₋₇ heterocycloalkenyl, heteroaryl (optionally substituted by one or more halogen atoms, and/or by oxo), C₁₋₆ alkoxy, C₂₋₆ alkenyloxy, aryl(C₁₋₆)alkoxy, triflyloxy, C₁₋₆ alkylthio, C₁₋₆ alkylamino, C₂₋₆ alkenylamino, C₃₋₇ cycloalkylamino, aryl(C₁₋₆)alkylamino (optionally substituted by C₁₋₆ alkoxy) or C₂₋₆ alkoxycarbonyl.

The present invention also provides a compound of formula IIA as depicted above, or an *N*-oxide thereof or a pharmaceutically acceptable salt thereof, wherein

R¹¹ represents phenyl, halophenyl, dihalophenyl, (C₁₋₆ alkyl)-(halo)phenyl, (trifluoromethyl)(halo)phenyl, C₁₋₆ alkoxyphenyl, (C₁₋₆ alkoxy)(halo)phenyl, cyanophenyl, (cyano)(halo)phenyl, C₃₋₇ heterocycloalkenyl, heteroaryl (optionally substituted by one or more halogen atoms), C₁₋₆ alkoxy, C₂₋₆ alkenyloxy, aryl(C₁₋₆)alkoxy, triflyloxy, C₁₋₆ alkylthio, C₁₋₆ alkylamino, C₂₋₆ alkenylamino, C₃₋₇ cycloalkylamino, aryl(C₁₋₆)alkylamino (optionally substituted by C₁₋₆ alkoxy) or C₂₋₆ alkoxycarbonyl; and

Z, X¹¹ and X¹² are as defined above.

The present invention further provides a compound of formula IIA as depicted above, or an *N*-oxide thereof or a pharmaceutically acceptable salt thereof, wherein

R¹¹ represents phenyl, halophenyl, dihalophenyl, C₁₋₆ alkoxyphenyl, cyanophenyl, (cyano)(halo)phenyl, C₃₋₇ heterocycloalkenyl, heteroaryl (optionally substituted by halo), C₁₋₆ alkoxy, C₂₋₆ alkenyloxy, aryl(C₁₋₆)alkoxy, C₁₋₆ alkylamino, C₂₋₆ alkenylamino, C₃₋₇ cycloalkylamino, aryl(C₁₋₆)alkylamino (optionally substituted by C₁₋₆ alkoxy) or C₂₋₆ alkoxycarbonyl; and

Z, X¹¹ and X¹² are as defined above.

Suitable values of X¹¹ include hydrogen and fluoro, especially fluoro.

In a favoured embodiment, X¹² represents hydrogen. In another embodiment, X¹² represents fluoro.

Where R¹¹ represents heteroaryl, this group is suitably pyridinyl,
5 pyrazinyl, furyl, thienyl, thiazolyl or triazolyl, especially pyridinyl.

Representative values of R¹¹ include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, (chloro)(fluoro)phenyl, trifluorophenyl, (fluoro)(methyl)phenyl, (fluoro)(trifluoromethyl)phenyl, methoxyphenyl, (fluoro)(methoxy)phenyl, cyanophenyl, (cyano)(fluoro)phenyl, oxo-
10 pyrrolidinyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, oxo-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, triflyloxy, ethylthio, *tert*-butylthio, methylamino, ethylamino, propylamino, isopropylamino, allylamino, cyclopropylamino, cyclohexylamino, benzylamino, methoxybenzyl-amino
15 and ethoxycarbonyl.

Particular values of R¹¹ include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, (chloro)(fluoro)phenyl, (fluoro)(methyl)phenyl, (fluoro)(trifluoromethyl)phenyl, methoxyphenyl, (fluoro)(methoxy)phenyl, cyanophenyl, (cyano)(fluoro)phenyl, dihydropyrrolyl, pyridinyl, fluoro-
20 pyridinyl, difluoro-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, triflyloxy, ethylthio, *tert*-butylthio, methylamino, ethylamino, propylamino, isopropylamino, allylamino, cyclopropylamino, cyclohexylamino, benzylamino, methoxybenzyl-amino and ethoxycarbonyl.

Individual values of R¹¹ include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, methoxyphenyl, cyanophenyl, (cyano)(fluoro)phenyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, methylamino, ethylamino, propylamino, isopropylamino, allylamino, cyclopropylamino,
30 cyclohexylamino, benzylamino, methoxybenzyl-amino and ethoxycarbonyl.


In one embodiment, R¹¹ represents fluorophenyl (especially 2-fluorophenyl).

In another embodiment, R¹¹ represents fluoro-pyridinyl (especially 3-fluoropyridin-2-yl).

5 In a further embodiment, R¹¹ represents difluoro-pyridinyl. In one aspect of this embodiment, R¹¹ represents 3,5-difluoropyridin-4-yl. In another aspect of this embodiment, R¹¹ represents 3,5-difluoropyridin-2-yl.

In an additional embodiment, R¹¹ represents trifluorophenyl (especially 2,4,6-trifluorophenyl).

10 One representative subset of the compounds of formula IIA above is represented by the compounds of formula IIB, and *N*-oxides thereof and pharmaceutically acceptable salts thereof:



(IIB)


15 wherein X¹¹, X¹² and R¹¹ are as defined above; and

R³ represents hydrogen or fluoro.

In one embodiment, R³ is hydrogen.

20 In another embodiment, R³ is fluoro, in which case the fluorine atom R³ is favourably attached to the phenyl ring at the 4-, 5- or 6-position (relative to the cyano group at position 2).

Another representative subset of the compounds of formula IIA above is represented by the compounds of formula IIC, and *N*-oxides thereof and pharmaceutically acceptable salts thereof:



(IIC)

wherein X^{11} , X^{12} and R^{11} are as defined above; and

5 R^4 represents hydrogen, fluoro, cyano or methyl.


In one embodiment, R^4 is hydrogen.

In an additional embodiment, R^4 is fluoro.

In another embodiment, R^4 is cyano.

In a further embodiment, R^4 is methyl.

10 A further representative subset of the compounds of formula IIA above is represented by the compounds of formula IID, and *N*-oxides thereof and pharmaceutically acceptable salts thereof:



(IID)

15


wherein X^{11} , X^{12} , R^4 and R^{11} are as defined above; and

R^5 represents hydrogen or fluoro.

Suitably, R⁵ represents hydrogen.

In another embodiment, R⁵ represents fluoro.

A favoured subset of the compounds of formula IID above is represented by the compounds of formula IIE, and *N*-oxides thereof and
 5 pharmaceutically acceptable salts thereof:



(IIE)

wherein

- 10 V represents N and W represents CF; or
 V represents CF and W represents N; or
 V and W both represent CF; and
 X¹² and R⁵ are as defined above.

15 The present invention also provides a compound of formula IIE as depicted above, or an *N*-oxide thereof or a pharmaceutically acceptable salt thereof, wherein

- V represents N and W represents CF; or
 V represents CF and W represents N; and
 X¹² and R⁵ are as defined above.
- 20 In one embodiment, V is N and W is CF.
 In another embodiment, V is CF and W is N.
 In a further embodiment, V and W are both CF.

Specific compounds within the scope of the present invention include:

- 3,5-diphenylpyridazine-4-carboxylic acid ethyl ester;
- 3,5-diphenylpyridazine-4-carboxylic acid methyl ester;
- 5 3,5-diphenylpyridazine;
- 5-[2-fluoro-3-(pyridin-3-yl)phenyl]-3-phenylpyridazine;
- 5-(3-isopropoxyphenyl)-3-phenylpyridazine;
- 3-(6-phenylpyridazin-4-yl)benzaldehyde;
- 4,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;
- 10 5-(3-cyanophenyl)-3-phenylpyridazine;
- 5-(3-bromophenyl)-3-phenylpyridazine;
- 3-phenyl-5-[3-(pyridin-3-yl)phenyl]pyridazine;
- 3-phenyl-5-(3-[1,2,4]triazol-4-ylphenyl)pyridazine;
- 5-[2,4-difluoro-3-(pyridin-4-yl)phenyl]-3-phenylpyridazine;
- 15 5-[3-(2-methyl-2*H*-[1,2,4]triazol-3-ylmethoxy)phenyl]-3-phenylpyridazine;
- 6,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;
- 5-[4-fluoro-3-(pyridin-4-yl)phenyl]-3-phenylpyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-phenylpyridazine;
- 3-phenyl-5-[3-(pyridin-2-ylmethoxy)phenyl]pyridazine;
- 20 5-[4-fluoro-3-(3-fluoropyridin-4-yl)phenyl]-3-phenylpyridazine;
- 5-[2-fluoro-3-(pyridin-4-yl)phenyl]-3-phenylpyridazine;
- 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-phenylpyridazine;
- 5-[4-fluoro-3-(pyridin-3-yl)phenyl]-3-phenylpyridazine;
- [3-(6-phenylpyridazin-4-yl)phenyl]acetonitrile;
- 25 2-fluoro-5-(6-phenylpyridazin-4-yl)benzonitrile;
- 5-(3-nitrophenyl)-3-phenylpyridazine;
- 3-(6-phenylpyridazin-4-yl)benzoic acid methyl ester;
- 3-(6-phenylpyridazin-4-yl)benzaldehyde;
- 5-(3-fluorophenyl)-3-phenylpyridazine;
- 30 3-phenyl-5-(3-trifluoromethylphenyl)pyridazine;
- 5-(3-methoxyphenyl)-3-phenylpyridazine;

- 5,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;
3,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;
5-(4-fluoro-3-methoxyphenyl)-3-phenylpyridazine;
6,2'-difluoro-5'-[6-(4-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
5 4-fluoro-3'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;
6,2'-difluoro-5'-[6-(thien-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
6,2'-difluoro-5'-[6-(4-methoxyphenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
5'-[6-(3-chlorophenyl)pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile;
6,2'-difluoro-5'-[6-(pyridin-3-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
10 5'-[6-(4-chlorophenyl)pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile;
6,2'-difluoro-5'-[6-(pyridin-4-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(4-fluorophenyl)-
pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(2-fluorophenyl)pyridazine;
15 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)-
pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-3-yl)pyridazine;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluorophenyl)-
pyridazine;
20 3-(2,4-difluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-
pyridazine;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-methoxyphenyl)-
pyridazine;
6,2'-difluoro-5'-[6-(2-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
25 6,2'-difluoro-5'-[6-(3-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
3-[6-(3-fluorophenyl)pyridazin-4-yl]benzonitrile;
3-[6-(2-fluorophenyl)pyridazin-4-yl]benzonitrile;
3-[6-(4-fluorophenyl)pyridazin-4-yl]benzonitrile;
3-[6-(4-methoxyphenyl)pyridazin-4-yl]benzonitrile;
30 3-[6-(3,4-difluorophenyl)pyridazin-4-yl]benzonitrile;
3-[6-(2,4-difluorophenyl)pyridazin-4-yl]benzonitrile;

- 5'-[6-(2-chlorophenyl)pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile;
3-(4-methoxyphenyl)-5-phenylpyridazine;
4-fluoro-3'-[6-(4-methoxyphenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(4-methoxyphenyl)-
5 pyridazine;
3-(4-chlorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-
pyridazine;
2-{5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazin-3-yl}-5-
fluorobenzonitrile;
10 3-(4-chlorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(furan-3-yl)pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(furan-2-yl)pyridazine;
3-(2,3-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-
pyridazine;
15 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thien-3-yl)pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thien-2-yl)pyridazine;
3-(2,5-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-
pyridazine;
3-(3,4-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-
20 pyridazine;
4-{5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazin-3-yl}benzonitrile;
N-[5-(3-bromophenyl)pyridazin-3-yl]-*N*-methylamine;
N-[5-(3-bromophenyl)pyridazin-3-yl]-*N*-isopropylamine;
N-[5-(3-bromophenyl)pyridazin-3-yl]-*N*-cyclopropylamine;
25 *N*-allyl-*N*-[5-(3-bromophenyl)pyridazin-3-yl]amine;
N-[5-(3-bromophenyl)pyridazin-3-yl]-*N*-ethylamine
N-benzyl-*N*-[5-(3-bromophenyl)pyridazin-3-yl]amine;
N-[5-(3-bromophenyl)pyridazin-3-yl]-*N*-(2-methoxybenzyl)amine;
5-(3-bromophenyl)-3-(2,5-dihydropyrrol-1-yl)pyridazine;
30 5-(3-bromophenyl)-3-ethoxypyridazine;
3-allyloxy-5-(3-bromophenyl)pyridazine;

- 3-(6-isopropylaminopyridazin-4-yl)benzonitrile;
3-(6-benzylaminopyridazin-4-yl)benzonitrile;
3-[6-(2-methoxybenzylamino)pyridazin-4-yl]benzonitrile;
3-(6-benzyloxy pyridazin-4-yl)benzonitrile;
5 3'-(6-ethylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
4-fluoro-3'-(6-isopropylaminopyridazin-4-yl)biphenyl-2-carbonitrile;
4-fluoro-3'-(6-propylaminopyridazin-4-yl)biphenyl-2-carbonitrile;
3'-(6-cyclopropylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
3'-(6-allylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
10 3'-(6-benzylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
4-fluoro-3'-(6-methylaminopyridazin-4-yl)biphenyl-2-carbonitrile;
4-fluoro-3'-(6-methoxy pyridazin-4-yl)biphenyl-2-carbonitrile;
3'-(6-ethoxy pyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
3'-(6-benzyloxy pyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
15 5-(4-fluoro-3-hydroxyphenyl)-3-phenylpyridazine;
5-[4-fluoro-3-(2-methyl-2*H*-[1,2,4]triazol-3-ylmethoxy)phenyl]-3-phenylpyridazine;
5-[4-fluoro-3-(1-methyl-3-trifluoromethyl-1*H*-pyrazol-4-ylmethoxy)phenyl]-3-phenylpyridazine;
20 5-[4-fluoro-3-(pyridin-4-ylmethoxy)phenyl]-3-phenylpyridazine;
5-[4-fluoro-3-(pyridin-3-ylmethoxy)phenyl]-3-phenylpyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-4-yl)pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyrazin-2-yl)pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thiazol-2-yl)pyridazine;
25 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-2-yl)pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-4-yl)pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(1*H*-[1,2,3]triazol-4-yl)pyridazine;
30 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine-3-carboxylic acid ethyl ester;

- 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)-pyridazine-1-oxide;
3-(2,6-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine;
5 3-(4-chloro-2-fluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-trifluoromethylphenyl)pyridazine;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-methylphenyl)-
10 pyridazine;
3-(3,5-difluoropyridin-2-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;
trifluoromethanesulfonic acid 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazin-3-yl ester;
15 3-ethylsulfanyl-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;
3-*tert*-butylsulfanyl-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-4-yl)-pyridazine;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-2-yl)-
20 pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-2-yl)-pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-4-yl)-pyridazine 1-oxide;
25 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoro-1-oxypyridin-4-yl)-pyridazine;
5-[2,4-difluoro-3-(3,5-difluoropyridin-2-yl)phenyl]-3-(3,5-difluoropyridin-4-yl)pyridazine;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-
30 methoxyphenyl)pyridazine;

- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(2-fluoro-4-methoxyphenyl)-pyridazine;
- 3-(3,5-difluoropyridin-4-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;
- 5 3-(3,5-difluoropyridin-2-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;
- 3-(3,5-difluoropyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;
- 3-(3,5-difluoro-1-oxypyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;
- 10 5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2'-fluorobiphenyl-2-carbonitrile;
- 5'-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]-2'-fluorobiphenyl-2-carbonitrile;
- 15 4,2'-difluoro-5'-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 4,2'-difluoro-5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 2-{5-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]-2-fluorophenyl}-nicotinonitrile;
- 20 2-{5-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2-fluorophenyl}-nicotinonitrile;
- 2'-fluoro-5'-[6-(2-oxopyrrolidin-1-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 2'-fluoro-5'-[6-(2-oxo-2*H*-pyridin-1-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 25 6,2'-difluoro-5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 3-(3,5-difluoropyridin-2-yl)-5-(4-fluoro-3-trifluoromethylphenyl)pyridazine;
- 3-(3,5-difluoropyridin-2-yl)-5-(6-fluoro-2'-trifluoromethylbiphenyl-3-yl)-pyridazine;
- 30 5-(6,2'-difluorobiphenyl-3-yl)-3-(3,5-difluoropyridin-2-yl)pyridazine;

3-(3,5-difluoropyridin-2-yl)-5-(6,2',4'-trifluorobiphenyl-3-yl)pyridazine;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2,4,6-trifluorophenyl)-
pyridazine;
and pharmaceutically acceptable salts thereof.

5 Also provided by the present invention is a method for the
treatment and/or prevention of anxiety which comprises administering to
a patient in need of such treatment an effective amount of a compound of
formula I as defined above or a pharmaceutically acceptable salt thereof.

10 Further provided by the present invention is a method for the
treatment and/or prevention of convulsions (e.g. in a patient suffering from
epilepsy or a related disorder) which comprises administering to a patient
in need of such treatment an effective amount of a compound of formula I
as defined above or a pharmaceutically acceptable salt thereof.

15 The binding affinity (K_i) of the compounds according to the present
invention for the $\alpha 3$ subunit of the human GABA_A receptor is conveniently
as measured in the assay described hereinbelow. The $\alpha 3$ subunit binding
affinity (K_i) of the anxiolytic compounds of the invention is ideally 50 nM
or less, preferably 10 nM or less, and more preferably 5 nM or less.

20 The anxiolytic compounds according to the present invention will
ideally elicit at least a 40%, preferably at least a 50%, and more preferably
at least a 60%, potentiation of the GABA EC₂₀ response in stably
transfected recombinant cell lines expressing the $\alpha 3$ subunit of the human
GABA_A receptor. Moreover, the compounds of the invention will ideally
elicit at most a 30%, preferably at most a 20%, and more preferably at
25 most a 10%, potentiation of the GABA EC₂₀ response in stably transfected
recombinant cell lines expressing the $\alpha 1$ subunit of the human GABA_A
receptor.

30 The potentiation of the GABA EC₂₀ response in stably transfected
cell lines expressing the $\alpha 3$ and $\alpha 1$ subunits of the human GABA_A receptor
can conveniently be measured by procedures analogous to the protocol
described in Wafford *et al.*, *Mol. Pharmacol.*, 1996, 50, 670-678. The

procedure will suitably be carried out utilising cultures of stably transfected eukaryotic cells, typically of stably transfected mouse Ltk-fibroblast cells.

5 The compounds according to the present invention may exhibit anxiolytic activity, as may be demonstrated by a positive response in the elevated plus maze and conditioned suppression of drinking tests (cf. Dawson *et al.*, *Psychopharmacology*, 1995, 121, 109-117). Moreover, the compounds of the invention are likely to be substantially non-sedating, as
10 may be confirmed by an appropriate result obtained from the response sensitivity (chain-pulling) test (cf. Bayley *et al.*, *J. Psychopharmacol.*, 1996, 10, 206-213).

The compounds according to the present invention may also exhibit anticonvulsant activity. This can be demonstrated by the ability to block pentylenetetrazole-induced seizures in rats and mice, following a protocol
15 analogous to that described by Bristow *et al.* in *J. Pharmacol. Exp. Ther.*, 1996, 279, 492-501.

In another aspect, the present invention provides a method for the treatment and/or prevention of cognitive disorders, including dementing conditions such as Alzheimer's disease, which comprises administering to
20 a patient in need of such treatment an effective amount of a compound of formula I as defined above or a pharmaceutically acceptable salt thereof.

Cognition enhancement can be shown by testing the compounds in the Morris watermaze as reported by McNamara and Skelton, *Psychobiology*, 1993, 21, 101-108. Further details of relevant methodology
25 are described in WO 96/25948.

Cognitive disorders for which the compounds of the present invention may be of benefit include delirium, dementia, amnesic disorders, and cognition deficits, including age-related memory deficits, due to traumatic injury, stroke, Parkinson's disease and Down Syndrome.
30 Any of these conditions may be attributable to substance abuse or withdrawal. Examples of dementia include dementia of the Alzheimer's

type with early or late onset, and vascular dementia, any of which may be uncomplicated or accompanied by delirium, delusions or depressed mood; and dementia due to HIV disease, head trauma, Parkinson's disease or Creutzfeld-Jakob disease.

5 In order to elicit their behavioural effects, the compounds of the invention will ideally be brain-penetrant; in other words, these compounds will be capable of crossing the so-called "blood-brain barrier". Preferably, the compounds of the invention will be capable of exerting their beneficial therapeutic action following administration by the oral route.


10 The invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid
15 sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as
20 corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these
25 preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described
30 above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for

example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.


The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

In the treatment of neurological disorders, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day.

The compounds in accordance with the present invention may be prepared by a process which comprises reacting a compound of formula III with a compound of formula IV:



(III)




(IV)

wherein X¹, X², Z, R¹ and R² are as defined above, L¹ represents a suitable leaving group, and M¹ represents a boronic acid moiety -B(OH)₂ or a cyclic ester thereof formed with an organic diol, e.g. pinacol, 1,3-propanediol or neopentyl glycol, or M¹ represents -Sn(Alk)₃ in which Alk represents a C₁-6 alkyl group, typically *n*-butyl or methyl, or M¹ represents -ZnHal in which Hal represents a halogen atom, e.g. chloro; in the presence of a transition metal catalyst.


The leaving group L¹ is typically a halogen atom, e.g. iodo, bromo or chloro.

The transition metal catalyst of use in the reaction between compounds III and IV is suitably tetrakis(triphenylphosphine)-palladium(0). The reaction is conveniently carried out at an elevated temperature in a solvent such as *N,N*-dimethylacetamide, 1,4-dioxane or tetrahydrofuran, advantageously in the presence of potassium phosphate, copper(I) iodide, sodium carbonate or cesium carbonate. Alternatively, the transition metal catalyst employed may be dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II), in which case the reaction is conveniently effected at an elevated temperature in a solvent such as *N,N*-dimethylformamide, advantageously in the presence of potassium phosphate.

In an alternative procedure, the compounds according to the present invention may be prepared by a process which comprises reacting a compound of formula V with a compound of formula VI:




(V)




(VI)

wherein X¹, X², Z, R¹, R², L¹ and M¹ are as defined above; in the presence of a transition metal catalyst; under conditions analogous to those described above for the reaction between compounds III and IV.

In another procedure, the compounds according to the present invention may be prepared by a process which comprises reacting a compound of formula VII with a compound of formula VIII:



(VII)




(VIII)


wherein X¹, X², Z, R¹, R², L¹ and M¹ are as defined above; in the presence of a transition metal catalyst; under conditions analogous to those described above for the reaction between compounds III and IV.

In the compounds of formula VI and VII above, the leaving group L¹ is typically trifluoromethanesulfonyloxy (triflyloxy); or a halogen atom, e.g. bromo.

Alternatively, the compounds according to the present invention may be prepared by a process which comprises reacting a compound of formula IX with a compound of formula X:




(IX)



(X)

wherein X^1 , X^2 , Z , R^1 , R^2 , L^1 and M^1 are as defined above; in the presence of a transition metal catalyst; under conditions analogous to those described above for the reaction between compounds III and IV.

In an additional procedure, the compounds according to the present invention in which Z represents C_{1-6} alkoxy or optionally substituted heteroaryl(C_{1-6})alkoxy may be prepared by a process which comprises reacting a compound of formula XI with a compound of formula XII:



(XI)



(XII)

wherein X^1 , X^2 , R^1 and R^2 are as defined above, and Z^1 represents C_{1-6} alkyl or optionally substituted heteroaryl(C_{1-6})alkyl; in the presence of triphenylphosphine and a dialkyl azodicarboxylate, e.g. diisopropyl azodicarboxylate (DIAD) or diethyl azodicarboxylate (DEAD).

The reaction is conveniently carried out by stirring in a solvent such as tetrahydrofuran.

Where M^1 in the intermediates of formula IV and IX above represents a boronic acid moiety $-B(OH)_2$ or a cyclic ester thereof formed


with pinacol or neopentyl glycol, the relevant compound IV or IX may be prepared by reacting bis(pinacolato)diboron or bis(neopentyl glycolato)diborane respectively with a compound of formula VI or VII as defined above; in the presence of a transition metal catalyst.

5 The transition metal catalyst of use in the reaction between bis(pinacolato)diboron or bis(neopentyl glycolato)diborane and compound VI or VII is suitably dichloro[1,1'-bis(diphenylphosphino)ferrocene]-palladium(II). The reaction is conveniently carried out at an elevated temperature in a solvent such as 1,4-dioxane, optionally in admixture with
10 dimethylsulfoxide, typically in the presence of 1,1'-bis(diphenylphosphino)ferrocene and/or potassium acetate.

 Where L^1 in the intermediates of formula VII above represents triflyloxy, the relevant compound VII may be prepared by reacting the appropriate compound of formula XI as defined above with triflic
15 anhydride, typically in the presence of pyridine. Analogous conditions may be utilised for preparing a compound of formula VI wherein L^1 represents triflyloxy from the corresponding hydroxy precursor.

 The intermediates of formula XI above may suitably be prepared from the appropriate methoxy-substituted precursor of formula XIII:

20




(XIII)


wherein X^1 , X^2 , R^1 and R^2 are as defined above; by treatment with boron tribromide, typically in chloroform or dichloromethane; or with hydrogen
25 bromide, typically in acetic acid at reflux.

Where M^1 in the intermediates of formula V above represents $-\text{Sn}(\text{Alk})_3$ and Alk is as defined above, this compound may be prepared by reacting a compound of formula III as defined above with a reagent of formula $(\text{Alk})_3\text{Sn-Hal}$, in which Hal represents a halogen atom, typically chloro. The reaction is conveniently effected by treating compound III with isopropylmagnesium chloride, typically in a solvent such as tetrahydrofuran, with subsequent addition of the stannyl reagent $(\text{Alk})_3\text{Sn-Hal}$.

In a further procedure, the compounds according to the present invention wherein R^1 represents an aryl or heteroaryl moiety may be prepared by a process which comprises reacting a compound of formula XIV with a compound of formula XV:



(XIV)



(XV)


wherein X^1 , X^2 , Z, R^2 , L^1 and M^1 are as defined above, and R^{1a} represents an aryl or heteroaryl moiety; in the presence of a transition metal catalyst; under conditions analogous to those described above for the reaction between compounds III and IV.

In the compounds of formula XV above, the leaving group L^1 is typically triflyloxy; or a halogen atom, e.g. chloro.


The transition metal catalyst of use in the reaction between compounds XIV and XV is suitably tetrakis(triphenylphosphine)-palladium(0), in which case the reaction is conveniently effected at an elevated temperature in a solvent such as tetrahydrofuran, 1,4-dioxane or

N,N-dimethylformamide, typically in the presence of sodium carbonate. Alternatively, the transition metal catalyst may suitably be palladium bis(diphenylphosphinylbutane)dichloride, in which case the reaction is conveniently effected at an elevated temperature in a solvent such as tetrahydrofuran, typically in the presence of sodium carbonate.

In a still further procedure, the compounds according to the present invention wherein R^1 represents an aryl or heteroaryl moiety may be prepared by a process which comprises reacting a compound of formula XVI with a compound of formula XVII:



(XVI)




(XVII)

wherein X^1 , X^2 , Z , R^{1a} , R^2 , L^1 and M^1 are as defined above; in the presence of a transition metal catalyst; under conditions analogous to those described above for the reaction between compounds III and IV.

The intermediates of formula XVII wherein M^1 represents $-\text{Sn}(\text{Alk})_3$ and Alk represents C_{1-6} alkyl, e.g. methyl, may be prepared by reacting a compound of formula XV as defined above with a reagent of formula $(\text{Alk})_3\text{Sn}-\text{Sn}(\text{Alk})_3$. The reaction is conveniently effected in the presence of a transition metal catalyst, e.g. tetrakis(triphenylphosphine)palladium(0), with heating in a solvent such as 1,4-dioxane, typically in the presence of lithium chloride.

In a yet further procedure, the compounds according to the present invention wherein R^1 represents 1*H*-[1,2,3]triazol-4-yl may be prepared by a process which comprises reacting a compound of formula XVIII:



(XVIII)

wherein X¹, X², Z and R² are as defined above, and TMS is an abbreviation
5 for trimethylsilyl; with sodium azide.

The reaction is conveniently effected by stirring the reactants in a solvent such as *N,N*-dimethylformamide.

The intermediates of formula XVIII may be prepared by reacting a compound of formula XV with TMS-acetylene, in the presence of a
10 transition metal catalyst such as bis(triphenylphosphine)palladium(II) chloride. The reaction is conveniently effected by stirring in a solvent such as tetrahydrofuran, typically in the presence of triethylamine, triphenylphosphine and copper(I) chloride.

The compounds according to the present invention wherein R¹
15 represents -OR^a may be prepared by a process which comprises reacting a compound of formula XV as defined above with a compound of formula R^a-OH, wherein R^a is as defined above. The reaction is conveniently carried out in the presence of a base such as sodium hydride or sodium ethoxide.

20 The compounds according to the present invention wherein R¹ represents -SR^a may be prepared by a process which comprises reacting a compound of formula XV as defined above with a salt of formula R^aS-Na⁺, wherein R^a is as defined above. The reaction is conveniently carried out in the presence of a solvent such as *N,N*-dimethylformamide.


The compounds according to the present invention wherein R¹ represents -NR^aR^b may be prepared by a process which comprises reacting a compound of formula XV as defined above with a compound of formula H-NR^aR^b, wherein R^a and R^b are as defined above. The reaction is
5 conveniently effected by stirring at an elevated temperature, typically in a solvent such as tetrahydrofuran.

The compounds according to the present invention wherein R¹ represents -CO₂R^a may be prepared by a process which comprises reacting a compound of formula XV as defined above with carbon monoxide and a
10 compound of formula R^a-OH, wherein R^a is as defined above; in the presence of a transition metal catalyst.

The transition metal catalyst of use in the foregoing reaction is ideally [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride, in which case the reaction is conveniently carried out at an elevated
15 temperature in a solvent such as *N,N*-dimethylformamide, optionally in admixture with dichloromethane, typically in the presence of sodium acetate.

The intermediates of formula XV wherein L¹ represents triflyloxy may be prepared by reacting a compound of formula XIX:

20




(XIX)

wherein X¹, X², Z and R² are as defined above; with *N*-phenyltriflylimide, typically in the presence of triethylamine, in a solvent such as

dichloromethane; or with triflic anhydride, typically in the presence of pyridine.

Moreover, the intermediates of formula XV wherein L^1 represents chloro may be prepared by treating the requisite compound of formula XIX with phosphorus oxychloride at an elevated temperature.


The intermediates of formula XIX may be prepared by reacting a compound of formula IV as defined above with a compound of formula XX:



(XX)

wherein R^2 and L^1 are as defined above; in the presence of a transition metal catalyst; under conditions analogous to those described above for the reaction between compounds III and IV.

Alternatively, the intermediates of formula XIX may be prepared by reacting a compound of formula XXI:




(XXI)

wherein X^1 , X^2 , Z and R^2 are as defined above; with hydrazine hydrate, typically in ethanol at reflux.

The compounds according to the present invention wherein Z represents cyano may be prepared by a process which comprises reacting a compound of formula VII above wherein L¹ represents a halogen atom, e.g. bromo, with zinc cyanide; in the presence of a transition metal catalyst.

5 The transition metal catalyst of use in the foregoing reaction is ideally tetrakis(triphenylphosphine)palladium(0), in which case the reaction is conveniently effected at an elevated temperature in a solvent such as *N,N*-dimethylformamide.

10 The compounds according to the present invention wherein R² represents methoxycarbonyl may be prepared by a process which comprises reacting a compound of formula XXII:




15 wherein X¹, X², Z and R¹ are as defined above; with diazomethane.

The reaction is conveniently accomplished by stirring in a solvent such as diethyl ether.

20 The intermediates of formula XXII may be prepared by saponifying a compound of formula I wherein R² represents C₂₋₆ alkoxycarbonyl, typically by treatment with potassium hydroxide in refluxing aqueous methanol.

The compounds according to the present invention wherein R² represents C₂₋₆ alkoxycarbonyl may be prepared by a process which comprises reacting a compound of formula XXIII:



(XXIII)

wherein X¹, X², Z and R¹ are as defined above, and R²ᵃ represents C₂₋₆ alkoxycarbonyl; with diazomethane.

5 The reaction is conveniently effected by stirring in a solvent such as diethyl ether.

10 The compounds of formula XI and XIII above correspond to compounds of formula I as defined above wherein Z represents hydroxy and methoxy respectively, and they may therefore be prepared by any of the methods described above for the preparation of the compounds according to the invention. Moreover, where L¹ in compounds VII and XV above represents a halogen atom, or where L¹ in compound XV represents triflyloxy, these compounds correspond to compounds of formula I as defined above, and they therefore constitute compounds in accordance with the invention in their own right.

15 Where they are not commercially available, the starting materials of formula III, VIII, X, XII, XIV, XVI, XX, XXI and XXIII may be prepared by methods analogous to those described in the accompanying Examples, or by standard methods well known from the art.

20 It will be understood that any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula I by techniques known from the art. For example, a compound of formula I initially obtained may be converted into the *N*-oxide derivative thereof by treatment with *m*-chloroperbenzoic acid. A compound of formula I

25

wherein R^1 represents $-C(O-Alk^1)_2R^a$ initially obtained, wherein Alk^1 is C_{1-6} alkyl, typically methyl or ethyl, may be converted into the corresponding compound of formula I wherein R^1 represents $-COR^a$ by hydrolysis with a mineral acid, typically aqueous hydrochloric acid. A compound wherein R^1 represents formyl may be reduced with sodium triacetoxyborohydride to the corresponding compound wherein R^1 represents hydroxymethyl. A compound of formula I wherein R^1 represents C_{2-6} alkoxy carbonyl may be reduced with lithium aluminium hydride to the corresponding compound of formula I wherein R^1 represents hydroxymethyl. A compound of formula I wherein R^1 represents hydroxymethyl may be oxidised to the corresponding compound of formula I wherein R^1 represents formyl by treatment with manganese dioxide. The formyl derivative thereby obtained may be condensed with a hydroxylamine derivative of formula H_2N-OR^b to provide a compound of formula I wherein R^1 represents $-CH=NOR^b$. Furthermore, a compound of formula I wherein R^1 represents $-CH=NOH$ may be treated with triethylamine in the presence of 1,1'-carbonyldiimidazole to afford a corresponding compound of formula I wherein R^1 represents cyano. Alternatively, the compound of formula I wherein R^1 represents formyl may be reacted with a Grignard reagent of formula R^aMgBr to afford a compound of formula I wherein R^1 represents $-CH(OH)R^a$, and this compound may in turn be oxidised using manganese dioxide to the corresponding compound of formula I wherein R^1 represents $-COR^a$. The latter compound may then be condensed with a hydroxylamine derivative of formula H_2N-OR^b to provide a compound of formula I wherein R^1 represents $-CR^a=NOR^b$. A compound of formula I wherein R^1 represents $-CH(OH)R^a$ may be converted into the corresponding compound of formula I wherein R^1 represents $-CHFR^a$ by treatment with (diethylamino)sulfur trifluoride (DAST). Similarly, a compound of formula I wherein R^1 represents $-COR^a$ may be converted into the corresponding compound of formula I wherein R^1 represents $-CF_2R^a$ by treatment with DAST. A

compound of formula I wherein R¹ represents amino may be converted into the corresponding compound of formula I wherein R¹ represents chloro by diazotisation, using sodium nitrite, followed by treatment with copper(I) chloride. A compound of formula I wherein R¹ represents -COCH₃ may be treated with thioacetamide in the presence of pyridinium tribromide to furnish the corresponding compound of formula I wherein R¹ represents 2-methylthiazol-5-yl. Moreover, a compound of formula I wherein R¹ is formyl may be treated with (*p*-tolylsulfonyl)methyl isocyanide (TosMIC) in the presence of potassium carbonate to afford the corresponding compound of formula I wherein R¹ represents oxazol-5-yl. A compound of formula I wherein R¹ represents hydroxymethyl may be treated with carbon tetrabromide and triphenylphosphine to afford the corresponding compound of formula I wherein R¹ represents bromomethyl, which may then be reacted (typically *in situ*) with the sodium salt of imidazole or 1*H*-[1,2,4]triazole to provide a compound of formula I wherein R¹ represents imidazol-1-ylmethyl or [1,2,4]triazol-1-ylmethyl respectively; or with the sodium salt of 1*H*-[1,2,3]triazole to provide a mixture of compounds of formula I wherein R¹ represents [1,2,3]triazol-1-ylmethyl and [1,2,3]triazol-2-ylmethyl; or with morpholine to provide a compound of formula I wherein R¹ represents morpholin-4-ylmethyl. A compound of formula I wherein R¹ represents chloro may be converted into the corresponding compound wherein R¹ represents 2-oxopyrrolidin-1-yl by treatment with pyrrolidin-2-one in the presence of sodium hydride. A compound of formula I wherein R¹ represents chloro may be converted into the corresponding compound wherein R¹ represents 2-oxopyridin-1-yl by treatment with 2-hydroxypyridine in the presence of copper(I) iodide. A compound of formula I wherein Z is substituted with methoxy may be converted to the corresponding compound wherein Z is substituted with hydroxy by treatment with boron tribromide.

Where a mixture of products is obtained from any of the processes described above for the preparation of compounds according to the

invention, the desired product can be separated therefrom at an appropriate stage by conventional methods such as preparative HPLC; or column chromatography utilising, for example, silica and/or alumina in conjunction with an appropriate solvent system.

5 Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The novel compounds may be prepared in racemic form, or individual enantiomers may be prepared
10 either by enantiospecific synthesis or by resolution. The novel compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-*p*-toluoyl-d-tartaric acid and/or (+)-di-*p*-toluoyl-l-tartaric acid,
15 followed by fractional crystallization and regeneration of the free base. The novel compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

 During any of the above synthetic sequences it may be necessary
20 and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons,
25 3rd edition, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

 The following Examples illustrate the preparation of compounds according to the invention.

 The compounds in accordance with this invention potently inhibit
30 the binding of [³H]-flumazenil to the benzodiazepine binding site of human

GABA_A receptors containing the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit stably expressed in Ltk⁻ cells.

Reagents

- 5 • Phosphate buffered saline (PBS).
- Assay buffer: 10 mM KH₂PO₄, 100 mM KCl, pH 7.4 at room temperature.
- [³H]-Flumazenil (18 nM for $\alpha 1\beta 3\gamma 2$ cells; 18 nM for $\alpha 2\beta 3\gamma 2$ cells; 10 nM for $\alpha 3\beta 3\gamma 2$ cells; 10 nM for $\alpha 5\beta 3\gamma 2$ cells) in assay buffer.
- Flunitrazepam 100 μ M in assay buffer.
- 10 • Cells resuspended in assay buffer (1 tray to 10 ml).

Harvesting Cells

Supernatant is removed from cells. PBS (approximately 20 ml) is added. The cells are scraped and placed in a 50 ml centrifuge tube. The procedure is repeated with a further 10 ml of PBS to ensure that most of the cells are removed. The cells are pelleted by centrifuging for 20 min at 3000 rpm in a benchtop centrifuge, and then frozen if desired. The pellets are resuspended in 10 ml of buffer per tray (25 cm x 25 cm) of cells.

20 *Assay*

Can be carried out in deep 96-well plates or in tubes. Each tube contains:

- 300 μ l of assay buffer.
- 50 μ l of [³H]-flumazenil (final concentration for $\alpha 1\beta 3\gamma 2$: 1.8 nM; for $\alpha 2\beta 3\gamma 2$: 1.8 nM; for $\alpha 3\beta 3\gamma 2$: 1.0 nM; for $\alpha 5\beta 3\gamma 2$: 1.0 nM).
- 50 μ l of buffer or solvent carrier (e.g. 10% DMSO) if compounds are dissolved in 10% DMSO (total); test compound or flunitrazepam (to determine non-specific binding), 10 μ M final concentration.
- 100 μ l of cells.

30 Assays are incubated for 1 hour at 40°C, then filtered using either a Tomtec or Brandel cell harvester onto GF/B filters followed by 3 x 3 ml

washes with ice cold assay buffer. Filters are dried and counted by liquid scintillation counting. Expected values for total binding are 3000-4000 dpm for total counts and less than 200 dpm for non-specific binding if using liquid scintillation counting, or 1500-2000 dpm for total counts and less than 200 dpm for non-specific binding if counting with meltilex solid scintillant. Binding parameters are determined by non-linear least squares regression analysis, from which the inhibition constant K_i can be calculated for each test compound.

The compounds of the accompanying Examples were tested in the above assay, and all were found to possess a K_i value for displacement of [^3H]-flumazenil from the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit of the human GABA_A receptor of 100 nM or less.

EXAMPLE 1

3,5-Diphenylpyridazine-4-carboxylic acid ethyl ester

2,3-Diphenylcycloprop-2-enecarboxylic acid ethyl ester (3.5 g, 13.2 mmol) in diethyl ether (20 ml) was added to a solution of diazomethane (66.4 mmol) in 125 ml ether and stirred in the absence of light for 3 days. Acetic acid was added dropwise until evolution of N_2 gas had ceased. Further portions of acetic acid were added before heating to reflux for 4 h. The reaction was concentrated and purified by column chromatography using 10-30% ethyl acetate/hexanes to give the *title compound* as a pale yellow solid (1.77 g). δ_{H} (400 MHz, d^6 DMSO) 0.84 (3H, t, J 7.0), 4.02 (2H, q, J 7.0), 7.54-7.58 (8H, m), 7.62-7.65 (2H, m), 9.48 (1H, s); m/z (ES⁺) 305.

EXAMPLE 2

3,5-Diphenylpyridazine-4-carboxylic acid methyl ester

The product from Example 1 (1.17 g, 3.84 mmol) and potassium hydroxide (0.86 g, 15.3 mmol) were heated to reflux in methanol/ H_2O (25

ml/3 ml) for 18 h. The reaction was cooled to room temperature and acidified with 2N HCl to give 3,5-diphenylpyridazine-4-carboxylic acid as a pale yellow solid which was collected by filtration (0.94 g). δ_{H} (400 MHz, d^6 DMSO) 7.55-7.57 (6H, m), 7.60-7.63 (2H, m), 7.71-7.73 (2H, m), 9.40 (1H, s); m/z (ES^+) 277.

A solution of diazomethane (0.6 mmol) in diethyl ether (5 ml) was added dropwise to the product from above (0.1 g, 0.36 mmol) suspended in diethyl ether (10 ml). The resultant clear solution was stirred for 18 h. Acetic acid was added and the reaction stirred for 1 h before concentrating. The *title compound* was obtained as a pale yellow solid by recrystallising from ethyl acetate-hexanes (78 mg). δ_{H} (400 MHz, d^6 DMSO) 3.54 (3H, s), 7.53-7.58 (8H, m), 7.62-7.66 (2H, m), 9.49 (1H, s); m/z (ES^+) 291.

EXAMPLE 3

3,5-Diphenylpyridazine

3-Phenyl-5-(tri-*n*-butylstannyl)pyridazine (100 mg, 0.22 mmol), bromobenzene (32 μl , 0.27 mmol) and tetrakis(triphenylphosphine)-palladium(0) (5 mg) in tetrahydrofuran (2 ml) were combined and heated to 150°C for 600 s in a Smith Synthesiser microwave reactor (Personal Chemistry, Uppsala, Sweden). The reaction was diluted with CH_2Cl_2 (6 ml) and H_2O (2 ml) then poured into a PTFE (5 μM) fritted syringe barrel. The organic phase was collected and concentrated to leave 100 mg of crude product. Part of the sample was purified by HPLC with mass triggered fraction collection to give the *title compound* as a gum (3.1 mg). δ_{H} (400 MHz, d^6 DMSO) 7.55-7.64 (6H, m), 8.06 (2H, dd, J 8.0, 1.6), 8.28 (2H, dd, J 8.0, 1.6), 8.46-8.47 (1H, d, J 4.0), 9.62 (1H, d, J 4.0); m/z (ES^+) 233 (MH^+).

EXAMPLE 4


5-[2-Fluoro-3-(pyridin-3-yl)phenyl]3-phenylpyridazine





5-Iodo-3-phenylpyridazine (60 mg, 0.14 mmol), 2-fluoro-3-(pyridin-3-yl)phenylboronic acid (32 mg), tetrakis(triphenylphosphine)palladium(0) (5 mg) and 2N Na₂CO₃ (1 ml) in tetrahydrofuran (4 ml) were combined and heated to 150°C for 600 s in a Smith Synthesiser microwave reactor. The reaction was diluted with CH₂Cl₂ (6 ml) and H₂O (2 ml) then poured into a PTFE (5 µM) fritted syringe barrel. The organic phase was collected, concentrated and recrystallised from methanol-CH₂Cl₂-isopropanol to give the *title compound* as a colourless solid (36 mg). δ_{H} (400 MHz, d⁶ DMSO) 7.55-7.66 (5H, m), 7.77-7.81 (1H, m), 7.91-7.95 (1H, m), 8.08-8.11 (1H, m), 8.25-8.27 (2H, m), 8.48 (1H, m), 8.66 (1H, dd, *J* 1.6, 4.7), 8.87 (1H, d, *J* 2.0), 9.53 (1H, t, *J* 2.2); *m/z* (ES⁺) 328 (MH⁺).





EXAMPLES 5 TO 32





The compounds in Table 1 were prepared, using the aryl halide, boronic acid or ester starting materials shown, in an analogous manner to that described in Example 3 or 4. Samples were purified as described in Example 3 or by recrystallisation from methanol-ethyl acetate, CH₂Cl₂ or CH₂Cl₂-isopropanol.





Table 1









EX. NO.	STARTING MATERIAL	PRODUCT	δ_{H} (400 MHz, d ⁶ DMSO)	<i>m/z</i> (ES ⁺)
5		5-(3-Isopropoxy-phenyl)-3-pyridazine	1.32 (6H, d, <i>J</i> 8), 4.80 (1H, quin, <i>J</i> 8), 7.10-7.12 (1H, m), 7.48-7.61 (7H, m), 8.26-8.28 (1H, m), 8.43 (1H, d, <i>J</i> 2), 9.58 (1H, d, <i>J</i> 2).	291

6		3-(6-Phenylpyridazin-4-yl)-benzaldehyde	7.56-7.69 (4H, m), 7.77 (1H, d, <i>J</i> 8), 7.84 (1H, d, <i>J</i> 8), 8.09 (1H, dd, <i>J</i> 1.2, 8), 8.23 (2H, m), 8.32 (1H, d, <i>J</i> 2), 9.29 (1H, d, <i>J</i> 2), 10.00 (1H, s).	261
7		4,2'-Difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile	7.56-7.67 (4H, m), 7.79-7.86 (2H, m), 8.05-8.08 (1H, m), 8.26-8.32 (4H, m), 8.55 (1H, d, <i>J</i> 4), 9.69 (1H, d, <i>J</i> 4)	370
8		5-(3-Cyanophenyl)-3-phenylpyridazine	7.57-7.64 (3H, m), 7.81 (1H, t, <i>J</i> 8), 8.03 (1H, d, <i>J</i> 8), 8.30-8.35 (2H, m), 8.41 (1H, d, <i>J</i> 8), 8.59 (1H, d, <i>J</i> 4), 8.63 (1H, s), 9.69 (1H, d, <i>J</i> 4).	258
9		5-(3-Bromophenyl)-3-phenylpyridazine	7.53-7.62 (4H, m), 7.76 (1H, d, <i>J</i> 12), 8.06 (1H, d, <i>J</i> 12), 8.28-8.33 (3H, m), 8.51 (1H, d, <i>J</i> 4), 9.62 (1H, d, <i>J</i> 4).	312
10		3-Phenyl-5-[3-(pyridin-3-yl)-phenyl]-pyridazine	7.48-7.66 (4H, m), 7.73 (1H, t, <i>J</i> 7.8), 7.92-7.94 (1H, m), 8.12-8.13 (1H, m),	310

			8.26-8.33 (3H, m), 8.41 (1H, t, <i>J</i> 1.8), 8.62-8.64 (2H, m), 9.10 (1H, dd, <i>J</i> 2.0, 0.8), 9.75 (1H, d, <i>J</i> 2.3).	
11		3-Phenyl-5-(3-[1,2,4]triazol-4-ylphenyl)pyridazine	7.56-7.66 (4H, m), 7.79 (1H, t, <i>J</i> 7.8), 7.90-7.93 (1H, m), 8.14-8.16 (1H, m), 8.29-8.31 (1H, dd, <i>J</i> 0.8, 0.8), 8.42 (1H, t, <i>J</i> 2.0), 8.61 (1H, d, <i>J</i> 2.0), 9.29 (2H, s), 9.76 (1H, d, <i>J</i> 2.3).	300
12		5-[2,4-Difluoro-3-(pyridin-4-yl)-phenyl]-3-phenylpyridazine	7.53-7.64 (6H, m), 8.04-8.10 (1H, m), 8.26 (2H, dd, <i>J</i> 1.8, 8.0), 8.46 (1H, d, <i>J</i> 0.8), 8.77 (2H, dd, <i>J</i> 1.4, 4.5), 9.50 (1H, t, <i>J</i> 1.8).	346
13		5-[3-(2-Methyl-2H-[1,2,4]triazol-3-ylmethoxy)-phenyl]-3-phenylpyridazine	3.94 (3H, s), 5.46 (2H, s), 7.25 (1H, dd, <i>J</i> 2.0, 7.6), 7.52-7.62 (4H, m), 7.70 (1H, d, <i>J</i> 8.4), 7.79-7.80 (1H, m), 7.96 (1H, s), 8.28- 8.30 (2H, m), 8.48 (1H, d, <i>J</i> 4.0), 9.63	344

			(1H, s).	
14		6,2'-Difluoro-5'-(6-phenylpyridazin-4-yl)-biphenyl-2-carbonitrile	7.54-7.87 (6H, m), 7.98 (1H, dd, <i>J</i> 1.2, 7.4), 8.28-8.31 (2H, m), 8.34-8.38 (1H, m), 8.48 (1H, dd, <i>J</i> 2.5, 6.8), 8.55 (1H, d, <i>J</i> 2.0), 9.69 (1H, d, <i>J</i> 2.0).	312
15		5-[4-Fluoro-3-(pyridin-4-yl)-phenyl]-3-phenylpyridazine	7.54-7.68 (3H, m), 7.75-7.77 (2H, m), 8.21-8.25 (1H, m), 8.29-8.36 (3H, m), 8.60 (1H, d, <i>J</i> 2.3), 8.73-8.74 (2H, m), 9.73 (1H, d, <i>J</i> 2.3).	328
16		5-[4-Fluoro-3-(3-fluoropyridin-2-yl)-phenyl]-3-phenylpyridazine	7.53-7.68 (5H, m), 7.92-7.97 (1H, m), 8.26-8.35 (4H, m), 8.55 (1H, d, <i>J</i> 2.3), 8.63-8.65 (1H, m), 9.67 (1H, d, <i>J</i> 2.3).	346
17		3-Phenyl-5-[3-(pyridin-2-ylmethoxy)-phenyl]pyridazine	5.33 (2H, s), 7.21-7.24 (1H, m), 7.30-7.40 (1H, m), 7.50-7.67 (6H, m), 7.76 (1H, t, <i>J</i> 2.0), 7.85-7.89 (1H, m), 8.29 (2H, d, <i>J</i> 1.6), 8.48 (1H, d, <i>J</i> 2.3), 8.60-8.65 (1H,	340

			m), 9.63 (1H, d, <i>J</i> 2.3).	
18		5-[4-Fluoro-3-(3-fluoropyridin-4-yl)phenyl]-3-phenylpyridazine	7.54-7.68 (4H, m), 7.77 (1H, dd, <i>J</i> 5.1, 6.3), 8.29-8.36 (4H, m), 8.57 (1H, d, <i>J</i> 2.3), 8.63 (1H, dd, <i>J</i> 1.2, 5.1), 8.77 (1H, d, <i>J</i> 2.0), 9.71 (1H, d, <i>J</i> 2.3).	346
19		5-[2-Fluoro-3-(pyridin-4-yl)phenyl]-3-phenylpyridazine	7.50-7.71 (6H, m), 7.79-7.83 (1H, m), 7.94-7.99 (1H, m), 8.25-8.27 (2H, m), 8.48 (1H, dd, <i>J</i> 0.8, 1.2), 8.72-8.73 (2H, m), 9.53 (1H, t, <i>J</i> 2.0).	328
20		5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-phenylpyridazine	7.54-7.68 (4H, m), 8.16-8.22 (1H, m), 8.27-8.33 (4H, m), 8.54 (1H, d, <i>J</i> 2.0), 8.75 (1H, d, <i>J</i> 2.3), 9.66 (1H, d, <i>J</i> 2.3).	364
21		5-[4-Fluoro-3-(pyridin-3-yl)phenyl]-3-phenylpyridazine	7.54-7.64 (5H, m), 8.13-8.22 (2H, m), 8.30-8.33 (3H, m), 8.60 (1H, d, <i>J</i> 2.5), 8.68 (1H, dd, <i>J</i> 1.6, 4.7), 8.94 (1H, s), 9.73 (1H, d, <i>J</i> 2.5).	328

22		[3-(6-Phenyl- pyridazin-4- yl)phenyl]- acetonitrile	272
23		2-Fluoro-5-(6- phenyl- pyridazin-4- yl)benzonitrile	276
24		5-(3-Nitro- phenyl)-3- phenyl- pyridazine	278
25		3-(6-Phenyl- pyridazin-4- yl)benzoic acid methyl ester	291
26		1-[3-(6-Phenyl- pyridazin-4-yl)- phenyl]- ethanone	275
27		5-(3-Fluoro- phenyl)-3- phenyl- pyridazine	251
28		3-Phenyl-5-(3- trifluoro- methylphenyl)- pyridazine	301
29		5-(3-Methoxy- phenyl)-3- phenyl-	263

		pyridazine		
30		5,2'-Difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile	7.54-7.80 (6H, m), 8.15-8.20 (1H, m), 8.29-8.36 (4H, m), 8.58 (1H, d, <i>J</i> 2.3), 9.72 (1H, d, <i>J</i> 2.3).	370
31		3,2'-Difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile	7.54-7.62 (3H, m), 7.65-7.71 (3H, m), 7.95-8.00 (1H, m), 8.29-8.38 (4H, m), 8.60-8.65 (1H, m), 9.70 (1H, d, <i>J</i> 2.4).	370
32		5-(4-Fluoro-3-methoxyphenyl)-3-phenylpyridazine	4.01 (3H, s), 7.25-7.27 (3H, m), 7.52-7.58 (3H, m), 7.94 (1H, d, <i>J</i> 2.0), 8.15 (2H, dd, <i>J</i> 1.6, 7.8), 9.37 (1H, d, <i>J</i> 2.3).	281

EXAMPLE 33**6,2'-Difluoro-5'-[6-(4-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile**

5 5-Chloropyridazin-3-one (22 mg, 0.169 mmol), palladium bis-(diphenylphosphinylbutane)dichloride (10 mg), 6,2'-difluoro-5'-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)biphenyl-2-carbonitrile (50 mg, 0.15 mmol) and 2N Na₂CO₃ (0.3 ml) in toluene (3 ml) were combined and heated to 150°C for 600 s in a Smith Synthesiser microwave reactor. The

reaction was diluted with CH₂Cl₂ (6 ml) and H₂O (2 ml) then poured into PTFE (5 μM) fritted syringe barrels. The organic phase was collected, concentrated and recrystallised from isopropanol to give 29 mg (62%) 6,2'-difluoro-5'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile.

5 The product from above was stirred with triethylamine (20 μl) and *N*-phenyltrifluoromethanesulfonimide (40 mg) in CH₂Cl₂ (5 ml) for 18 h. Further reagents were added and stirring continued for an additional 18 h. The reaction was concentrated and purified by column chromatography using 1:1 ethyl acetate/hexanes as eluent. Trifluoromethanesulfonic acid
10 5-(2'-cyano-6,6'-difluorobiphenyl-3-yl)pyridazin-3-yl ester was obtained as a yellow oil. *m/z* (ES⁺) 442.

 The product from above, 4-fluorophenylboronic acid (14 mg), palladium bis(diphenylphosphinylbutane)dichloride (4 mg) and 2N Na₂CO₃ (0.5 ml) in tetrahydrofuran (2 ml) were combined and heated to
15 150°C for 600 s in a Smith Synthesiser microwave reactor. The reaction was diluted with CH₂Cl₂ (6 ml) and H₂O (2 ml) then poured into a PTFE (5 μM) fritted syringe barrel. The organic phase was collected, concentrated and purified by column chromatography using 1:1 ethyl acetate/hexanes as eluent. The *title compound* was recrystallised from isopropanol to give a
20 colourless solid (3.9 mg). δ_H (400 MHz, d⁶ DMSO) 7.42 (2H, t, *J* 8.8), 7.70 (1H, t, *J* 9.2), 7.76-7.87 (2H, m), 7.98 (1H, dd, *J* 1.0, 7.6), 8.34-8.39 (3H, m), 8.35-8.40 (1H, m), 8.45-8.48 (1H, m), 9.69 (1H, d, *J* 2.0); *m/z* (ES⁺) 388.

EXAMPLE 34

25

4-Fluoro-3'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile

 4-Fluoro-3'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile (0.35 g, 1.20 mmol) was suspended in phosphorus oxychloride (10 ml) and heated to 70°C for 1 h. The reaction was cooled to room temperature,
30 poured onto ice water and stirred vigorously for 1 h. The beige solid was collected by filtration and azeotroped with methanol to give 3'-(6-

chloropyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile (0.24 g). δ_{H} (400 MHz, d^6 DMSO) 7.73-7.82 (3H, m), 7.83-7.87 (1H, m), 8.04 (1H, dd, J 2.7, 9.0), 8.12 (1H, dt, J 1.6, 7.8), 8.22 (1H, t, J 1.6), 8.40 (1H, d, J 2.0), 9.77 (1H, d, J 2.0); m/z (ES⁺) 310.

5 The product from above (40 mg, 0.129 mmol), benzenboronic acid (24 mg, 0.197 mmol), tetrakis(triphenylphosphine)palladium(0) and 2N Na_2CO_3 (0.5 ml) in tetrahydrofuran (1.5 ml) were combined and heated to 150°C for 10 min in a Smith Synthesiser microwave reactor. The reaction was diluted with CH_2Cl_2 (6 ml) and NH_4Cl (2 ml) then poured into a PTFE
10 (5 μM) fritted syringe barrel. The organic phase was concentrated while loading onto silica. Column chromatography using 40:50% ethyl acetate/hexanes gave the *title compound* as a white solid (20 mg). δ_{H} (400 MHz, d^6 DMSO) 7.56-7.62 (3H, m), 7.74-7.80 (3H, m), 7.85-7.89 (1H, m), 8.03-8.06 (1H, m), 8.19 (1H, dt, J 1.8, 7.0), 8.29-8.32 (3H, m), 8.58 (1H, d, J
15 2.0), 9.71 (1H, d, J 2.0); m/z (ES⁺) 352.

EXAMPLES 35 TO 70

20 The compounds in Table 2 were prepared using the requisite boronic acids in an analogous manner to that described in Examples 33 and 34.

Table 2

EX. NO.	PRODUCT	δ_{H} (400 MHz, d^6 DMSO unless specified otherwise)	m/z (ES ⁺)
35	6,2'-Difluoro-5'-[6-(thien-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile	7.27 (1H, dd, J 4.7, 3.9), 7.71 (1H, t, J 9.2), 7.79-7.87 (3H, m), 7.97 (1H, d, J 7.0), 8.13 (1H, d, J 3.1), 8.33-8.35 (1H, m), 8.41 (1H, dd, J 1.2, 4.7),	376

		8.59 (1H, d, <i>J</i> 1.2), 9.58 (1H, d, <i>J</i> 1.2).	
36	6,2'-Difluoro-5'-[6-(4-methoxyphenyl)-pyridazin-4-yl]biphenyl-2-carbonitrile	3.86 (3H, s), 7.13 (2H, d, <i>J</i> 9.0), 7.69 (1H, t, <i>J</i> 9.2), 7.76-7.87 (2H, m), 7.97 (1H, dd, <i>J</i> 1.4, 7.6), 8.27 (2H, d, <i>J</i> 9.0), 8.32-8.36 (1H, m), 8.45 (1H, dd, <i>J</i> 2.3, 6.7), 8.48 (1H, d, <i>J</i> 2.0), 9.61 (1H, d, <i>J</i> 2.3).	400
37	5'-[6-(3-Chlorophenyl)-pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile	7.62-7.63 (2H, m), 7.69-7.73 (1H, m), 7.76-7.87 (2H, m), 7.96 (1H, d, <i>J</i> 1.6), 8.28-8.31 (1H, m), 8.36-8.40 (2H, m), 8.48 (1H, dd, <i>J</i> 2.5, 6.8), 8.62 (1H, d, <i>J</i> 2.0), 9.73 (1H, d, <i>J</i> 2.3).	404
38	6,2'-Difluoro-5'-[6-(pyridin-3-yl)pyridazin-4-yl]biphenyl-2-carbonitrile	7.63 (1H, dd, <i>J</i> 4.7, 7.8), 7.70-7.88 (3H, m), 7.98 (1H, dd, <i>J</i> 1.2, 7.4), 8.36-8.40 (1H, m), 8.49 (1H, dd, <i>J</i> 2.3, 6.7), 8.64-8.68 (2H, m), 8.76 (1H, dd, <i>J</i> 1.2, 4.7), 9.45 (1H, d, <i>J</i> 1.6), 9.76 (1H, d, <i>J</i> 2.3).	371
39	5'-[6-(4-Chlorophenyl)-pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile	7.56-7.92 (5H, m), 7.98 (1H, dd, <i>J</i> 1.2, 7.4), 8.28-8.50 (4H, m), 8.59 (1H, d, <i>J</i> 2.3), 9.71 (1H, d, <i>J</i> 2.3).	404
40	6,2'-Difluoro-5'-[6-(pyridin-4-yl)pyridazin-4-yl]biphenyl-2-carbonitrile	7.70-7.88 (3H, m), 7.97 (1H, d, <i>J</i> 7.4), 8.28 (2H, dd, <i>J</i> 1.4, 4.5), 8.37-8.41 (1H, m), 8.49	371

		(1H, dd, <i>J</i> 2.5, 6.8), 8.70 (1H, d, <i>J</i> 2.3), 8.81-8.84 (2H, m), 9.80 (1H, d, <i>J</i> 2.3).	
41	5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(4-fluorophenyl)pyridazine	7.42 (2H, t, <i>J</i> 9.0), 7.62 (1H, dd, <i>J</i> 8.6, 0.8), 8.17-8.22 (1H, m), 8.27-8.39 (4H, m), 8.55 (1H, d, <i>J</i> 2.3), 8.75 (1H, d, <i>J</i> 2.3), 9.66 (1H, d, <i>J</i> 2.3).	382
42	5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(2-fluorophenyl)pyridazine	7.41-7.46 (2H, m), 7.53-7.66 (3H, m), 7.91-8.02 (2H, m), 8.20-8.27 (2H, m), 8.37 (1H, t, <i>J</i> 2.0), 8.63-8.64 (1H, m), 9.72 (1H, d, <i>J</i> 2.3).	364
43	5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)pyridazine	(CDCl ₃): 7.20-7.24 (1H, m), 7.34-7.41 (3H, m), 7.47-7.53 (1H, m), 7.80-7.84 (1H, m), 7.96 (1H, dd, <i>J</i> 2.3, 6.7), 8.13 (1H, t, <i>J</i> 2.0), 8.19-8.24 (1H, m), 8.52 (1H, d, <i>J</i> 2.3), 9.44 (1H, d, <i>J</i> 2.0).	382
44	5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-3-yl)pyridazine	7.60-7.67 (3H, m), 7.92-7.97 (1H, m), 8.28-8.38 (2H, m), 8.64-8.68 (3H, m), 8.76 (1H, dd, <i>J</i> 1.6, 4.7), 9.46 (1H, d, <i>J</i> 2.0), 9.74 (1H, d, <i>J</i> 2.0).	347
45	5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluorophenyl)pyridazine	(CDCl ₃): 7.20-7.25 (1H, m), 7.36-7.43 (2H, m), 7.50-7.55 (1H, m), 7.81-8.00 (5H, m), 8.52 (1H, d, <i>J</i> 2.3), 9.45 (1H, d, <i>J</i> 2.0).	382

46	3-(2,4-Difluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-pyridazine	(CDCl ₃): 6.96-7.02 (1H, m), 7.08-7.13 (1H, m), 7.36-7.42 (2H, m), 7.79-7.83 (1H, m), 7.95 (1H, dd, <i>J</i> 2.3, 6.3), 8.09 (1H, t, <i>J</i> 2.2), 8.23-8.29 (1H, m), 8.52 (1H, d, <i>J</i> 2.3), 9.44 (1H, d, <i>J</i> 2.3).	400
47	5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-methoxyphenyl)-pyridazine	(CDCl ₃): 3.93 (3H, s), 7.06-7.09 (1H, m), 7.36-7.47 (3H, m), 7.64 (1H, d, <i>J</i> 1.6), 7.79-7.84 (2H, m), 7.97 (1H, dd, <i>J</i> 2.3, 6.7), 8.01 (1H, d, <i>J</i> 2.3), 8.52 (1H, d, <i>J</i> 2.3), 9.43 (1H, d, <i>J</i> 2.3).	394
48	6,2'-Difluoro-5'-[6-(2-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile	7.41-7.46 (2H, m), 7.59-7.72 (2H, m), 7.75-7.86 (2H, m), 7.94-8.01 (2H, m), 8.27-8.31 (1H, m), 8.39 (2H, q, <i>J</i> 2.1), 9.73 (1H, d, <i>J</i> 2.3).	388
49	6,2'-Difluoro-5'-[6-(3-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile	7.38-7.43 (1H, m), 7.61-7.88 (4H, m), 7.96-8.05 (1H, m), 8.13-8.19 (2H, m), 8.35-8.40 (1H, m), 8.48 (1H, dd, <i>J</i> 2.5, 6.7), 8.61 (1H, d, <i>J</i> 2.1), 9.73 (1H, d, <i>J</i> 1.8).	388
50	3-[6-(3-Fluorophenyl)-pyridazin-4-yl]-benzonitrile	7.40-7.45 (1H, m), 7.66 (1H, td, <i>J</i> 6.3, 8.0), 7.81 (1H, t, <i>J</i> 7.8), 8.04 (1H, dt, <i>J</i> 1.2, 7.8), 8.15-8.19 (1H, m), 8.19-8.22	276

		(1H, m), 8.42-8.45 (1H, m), 8.66 (1H, m), 8.67 (1H, d, <i>J</i> 2.3), 9.74 (1H, d, <i>J</i> 2.3).	
51	3-[6-(2-Fluorophenyl)-pyridazin-4-yl]-benzonitrile	7.43-7.48 (2H, m), 7.60-7.66 (1H, m), 7.80 (1H, t, <i>J</i> 7.8), 7.98-8.02 (1H, m), 8.02-8.04 (1H, m), 8.34-8.37 (1H, m), 8.42 (1H, t, <i>J</i> 2.0), 8.56-8.57 (1H, m), 9.75 (1H, d, <i>J</i> 2.0).	276
52	3-[6-(4-Fluorophenyl)-pyridazin-4-yl]-benzonitrile	7.41-7.47 (2H, m), 7.81 (1H, t, <i>J</i> 7.8), 8.02-8.05 (1H, m), 8.37-8.41 (2H, m), 8.41-8.49 (1H, m), 8.62 (1H, d, <i>J</i> 2.0), 8.64-8.65 (1H, m), 9.70 (1H, d, <i>J</i> 2.0).	276
53	3-[6-(4-Methoxyphenyl)-pyridazin-4-yl]-benzonitrile	3.87 (3H, s), 7.13-7.16 (2H, m), 7.80 (1H, t, <i>J</i> 7.8), 8.01-8.04 (1H, m), 8.28-8.31 (2H, m), 8.39-8.42 (1H, m), 8.54 (1H, d, <i>J</i> 2.0), 8.62-8.64 (1H, m), 9.62 (1H, d, <i>J</i> 2.0).	288
54	3-[6-(3,4-Difluorophenyl)pyridazin-4-yl]-benzonitrile	7.69 (1H, td, <i>J</i> 8.6, 10.6), 7.82 (1H, t, <i>J</i> 7.8), 8.03-8.06 (1H, m), 8.22-8.26 (1H, m), 8.39-8.42 (1H, m), 8.42-8.45 (1H, m), 8.65-8.66 (1H, m), 8.66 (1H, d, <i>J</i> 2.0), 9.73 (1H, d, <i>J</i> 2.0).	294
55	3-[6-(2,4-Difluorophenyl)pyridazin-4-yl]-	7.33-7.38 (1H, m), 7.50-7.56 (1H, m), 7.80 (1H, t, <i>J</i> 7.8),	294

	benzonitrile	8.20-8.05 (1H, m), 8.08 (1H, td, <i>J</i> 7.0, 9.0), 8.34-8.37 (1H, m), 8.41 (1H, t, <i>J</i> 2.0), 8.55-8.57 (1H, m), 9.75 (1H, d, <i>J</i> 2.0).	
56	5'-[6-(2-Chlorophenyl)-pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile	7.60-7.65 (2H, m), 7.73 (1H, t, <i>J</i> 9.1), 7.78-7.90 (2H, m), 7.98-8.05 (1H, m), 8.33 (2H, dd, <i>J</i> 1.9, 7.5), 8.36-8.41 (1H, m), 8.50 (1H, dd, <i>J</i> 2.3, 6.8), 8.58 (1H, d, <i>J</i> 2.1), 9.72 (1H, d, <i>J</i> 2.1).	
57	3-(4-Methoxyphenyl)-5-phenylpyridazine	3.86 (3H, s), 7.13 (2H, d, <i>J</i> 8.9), 7.56-7.62 (3H, m), 8.02-8.05 (2H, m), 8.25 (2H, d, <i>J</i> 8.9), 8.39 (1H, d, <i>J</i> 2.1), 9.53 (1H, d, <i>J</i> 2.1).	
58	4-Fluoro-3'-[6-(4-methoxy-phenyl)pyridazin-4-yl]-biphenyl-2-carbonitrile	3.86 (3H, s), 7.14 (2H, d, <i>J</i> 8.8), 7.73-7.79 (3H, m), 7.85-7.89 (1H, m), 8.03-8.06 (1H, m), 8.17 (1H, dt, <i>J</i> 2.0, 7.0), 8.27-8.28 (1H, m), 8.28 (2H, d, <i>J</i> 8.8), 8.51 (1H, d, <i>J</i> 2.3), 9.63 (1H, d, <i>J</i> 2.3).	382
59	5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(4-methoxyphenyl)-pyridazine	(CDCl ₃): 3.90 (3H, s), 7.07 (2H, d, <i>J</i> 9.0), 7.36-7.41 (2H, m), 7.79-7.82 (1H, m), 7.94-7.96 (2H, m), 8.13 (1H, q, <i>J</i> 5.0), 8.12 (1H, d, <i>J</i> 9.0), 8.52 (1H, d, <i>J</i> 2.3), 9.36 (1H, d, <i>J</i>	394

		2.3).	
60	3-(4-Chlorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-pyridazine	7.62-7.67 (3H, m), 8.17-8.22 (1H, m), 8.27-8.36 (4H, m), 8.58 (1H, d, <i>J</i> 2.0), 8.75 (1H, d, <i>J</i> 2.3), 9.68 (1H, d, <i>J</i> 2.3).	398
61	2-{5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]pyridazin-3-yl}-5-fluorobenzonitrile	(CDCl ₃): 7.36-7.45 (2H, m), 7.50-7.59 (2H, m), 7.84-7.87 (1H, m), 7.99 (1H, dd, <i>J</i> 2.3, 6.3), 8.15 (1H, dd, <i>J</i> 5.5, 8.6), 8.18 (1H, d, <i>J</i> 2.0), 8.51 (1H, d, <i>J</i> 2.3), 9.54 (1H, d, <i>J</i> 2.3).	398
62	3-(4-Chlorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine	(CDCl ₃): 7.38-7.46 (2H, m), 7.52-7.61 (3H, m), 7.80-7.84 (1H, m), 8.00 (1H, d, <i>J</i> 1.6), 8.01 (1H, d, <i>J</i> 2.3), 8.11 (2H, d, <i>J</i> 8.2), 8.60 (1H, d, <i>J</i> 4.3), 9.44 (1H, d, <i>J</i> 2.0).	380
63	5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(furan-3-yl)pyridazine	(CDCl ₃): 7.08-7.10 (1H, m), 7.36-7.46 (2H, m), 7.55-7.61 (2H, m), 7.76-7.81 (2H, m), 7.98 (1H, dd, <i>J</i> 2.5, 6.5), 8.23 (1H, s), 8.59-8.61 (1H, m), 9.34 (1H, d, <i>J</i> 2.3).	336
64	5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(furan-2-yl)pyridazine	(CDCl ₃): 6.63 (1H, q, <i>J</i> 1.8), 7.36-7.45 (3H, m), 7.55-7.60 (1H, m), 7.63-7.64 (1H, m), 7.80-7.84 (1H, m), 8.01 (1H, dd, <i>J</i> 2.5, 6.5), 8.04 (1H, d, <i>J</i> 2.0), 8.59-8.61 (1H, m), 9.34	336

		(1H, d, <i>J</i> 2.3).	
65	3-(2,3-Difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine	(CDCl ₃): 7.24-7.45 (4H, m), 7.52-7.60 (1H, m), 7.80-7.84 (1H, m), 7.94-8.02 (2H, m), 8.13 (1H, t, <i>J</i> 2.2), 8.59-8.61 (1H, m), 9.48 (1H, d, <i>J</i> 2.0).	382
66	5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thien-3-yl)pyridazine	(CDCl ₃): 7.37-7.52 (3H, m), 7.55-7.61 (1H, m), 7.79-7.83 (1H, m), 7.86 (1H, dd, <i>J</i> 1.2, 5.1), 7.92 (1H, d, <i>J</i> 2.3), 7.99 (1H, dd, <i>J</i> 2.3, 6.3), 8.14 (1H, q, <i>J</i> 1.4), 8.59-8.61 (1H, m), 9.37 (1H, d, <i>J</i> 2.0).	352
67	5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thien-2-yl)pyridazine	(CDCl ₃): 7.19 (1H, dd, <i>J</i> 3.7, 4.9), 7.37-7.46 (2H, m), 7.52-7.61 (2H, m), 7.77-7.82 (2H, m), 7.94 (1H, d, <i>J</i> 2.3), 7.99 (1H, dd, <i>J</i> 2.5, 6.5), 8.59-8.61 (1H, m), 9.33 (1H, d, <i>J</i> 2.0).	352
68	3-(2,5-Difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine	(CDCl ₃): 7.14-7.23 (2H, m), 7.37-7.45 (2H, m), 7.52-7.60 (1H, m), 7.80-7.84 (1H, m), 7.96-8.01 (2H, m), 8.16 (1H, t, <i>J</i> 2.2), 8.59-8.61 (1H, m), 9.47 (1H, d, <i>J</i> 2.3).	382
69	3-(3,4-Difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine	(CDCl ₃): 7.31-7.46 (3H, m), 7.56-7.61 (1H, m), 7.80-7.84 (1H, m), 7.87-7.91 (1H, m), 7.97-8.09 (3H, m), 8.59-8.61	382

		(1H, m), 9.45 (1H, d, <i>J</i> 2.3).	
70	4-{5-[4-Fluoro-3-(3-fluoro-pyridin-2-yl)phenyl]-pyridazin-3-yl}-benzonitrile	(CDCl ₃): 7.39-7.47 (2H, m), 7.57-7.61 (1H, m), 7.82-7.87 (3H, m), 8.03 (1H, dd, <i>J</i> 2.5, 6.5), 8.06 (1H, d, <i>J</i> 2.0), 8.28 (1H, s), 8.30 (1H, t, <i>J</i> 1.8), 8.59-8.61 (1H, m), 9.51 (1H, d, <i>J</i> 2.3).	371

EXAMPLE 71*N*-[5-(3-Bromophenyl)pyridazin-3-yl]-*N*-methylamine

5 Lead tetraacetate (363.3 g, 819 mmol) and trifluoroacetic acid (825 ml) were combined and cooled to 0°C before adding 1-bromo-3-vinylbenzene (150 g, 819 mmol) in CH₂Cl₂ (1 l) dropwise so as to maintain a temperature of <10°C. The reaction was then allowed to warm to room temperature and stirred for 2 h. The reaction was diluted with CH₂Cl₂

10 (500 ml), poured into H₂O (3 l), and stirred vigorously before filtering through a pad of Hyflo. The organic phase was separated and the cake rinsed with a further portion of CH₂Cl₂ (1 l), which was subsequently washed with the separated aqueous phase. The combined organic extracts were washed with H₂O (750 ml), NaHCO₃ (750 ml) and H₂O (750 ml),

15 dried over MgSO₄ and concentrated to give (3-bromophenyl)acetaldehyde (163 g), which was used directly.

6N HCl (139 ml) was added dropwise to a solution of morpholine (75 ml, 860 mmol) in 1,4-dioxane (1140 ml). On complete addition, glyoxylic acid (72 g, 778 mmol) and the product from above (163 g, 819 mmol) were

20 added and the reaction heated to reflux for 15 h. The reaction was cooled to room temperature, diluted with H₂O (800 ml) and the products extracted into ethyl acetate (2 x 800 ml). The combined organic extracts were washed with brine (125 ml), dried over MgSO₄ and concentrated. 4-

(3-Bromophenyl)-5-hydroxy-5*H*-furan-2-one was obtained as a cream solid by crystallising from diethyl ether/hexanes (95.6 g). δ_{H} (360 MHz, d^6 DMSO) 6.64 (1H, d, J 8.8), 6.88 (1H, s), 7.48 (1H, t, J 8.1), 7.70-7.73 (1H, m), 7.78-7.81 (1H, m), 8.00-8.01 (1H, m), 8.04 (1H, d, J 8.8).

5 The product from above (95.6 g, 375 mmol) and hydrazine hydrate (45.5 ml, 937 mmol) in ethanol (1.9 l) were combined and heated to reflux for 12 h. The reaction was cooled to room temperature, diluted with H_2O (960 ml) and cooled in an ice bath. 5-(3-Bromophenyl)-2*H*-pyridazin-3-one was obtained as a pale yellow solid, which was collected by filtration (34
10 g). The filtrate was concentrated to a smaller volume and a further 16 g of product was collected by filtration. δ_{H} (360 MHz, d^6 DMSO) 7.20 (1H, d, J 2.1), 7.48 (1H, t, J 7.9), 7.70-7.73 (1H, m), 7.81-7.84 (1H, m), 8.04 (1H, t, J 1.8), 8.30 (1H, d, J 2.1), 13.15 (1H, s).

15 The product from above (10 g, 39.8 mmol) was suspended in phosphorus oxychloride (60 ml) and heated to 70°C for 3 h. The reaction was concentrated to half the volume before pouring onto ice water and stirring vigorously for 1 h. 5-(3-Bromophenyl)-3-chloropyridazine was obtained as an orange solid, which was collected by filtration and azeotroped with toluene (10.6 g). δ_{H} (360 MHz, d^6 DMSO) 7.54 (1H, t, J
20 7.9), 7.76-7.79 (1H, m), 7.99-8.02 (1H, m), 8.25 (1H, t, J 1.8), 8.35 (1H, d, J 2.1), 9.70 (1H, d, J 2.1).

25 The product from above (0.5 g, 1.86 mmol) was added to a 2M solution of methylamine in tetrahydrofuran (3 ml) and heated to 170°C for 1 h in a Smith Synthesiser microwave reactor. The organic phase was diluted with ethyl acetate, washed with water, dried over MgSO_4 and concentrated while loading onto silica. Column chromatography using 50% ethyl acetate/hexanes followed by ethyl acetate as eluent gave the
30 *title compound* as an orange solid (0.1 g). δ_{H} (360 MHz, d^6 DMSO) 2.92 (3H, d, J 4.9), 6.85 (1H, q, J 4.9), 7.00 (1H, d, J 2.1), 7.49 (1H, t, J 7.9), 7.68-7.71 (1H, m), 7.75-7.78 (1H, m), 7.97 (1H, t, J 1.8), 8.80 (1H, d, J 2.1); m/z (ES^+) 264, 266.

EXAMPLES 72 TO 78

5 The compounds in Table 3 were prepared in an analogous manner to that described in Example 71.

Table 3

EX. NO.	PRODUCT	δ_H (400 MHz, d^6 DMSO)	m/z (ES ⁺)
72	<i>N</i> -[5-(3-Bromophenyl)-pyridazin-3-yl]- <i>N</i> -isopropylamine	1.21 (6H, d, <i>J</i> 6.3), 4.13-4.22 (1H, m), 6.70 (1H, d, <i>J</i> 7.4), 6.97 (1H, d, <i>J</i> 2.1), 7.49 (1H, t, <i>J</i> 7.9), 7.68-7.71 (1H, m), 7.72-7.75 (1H, m), 7.93 (1H, t, <i>J</i> 1.8), 8.76 (1H, d, <i>J</i> 2.1).	292, 294
73	<i>N</i> -[5-(3-Bromophenyl)-pyridazin-3-yl]- <i>N</i> -cyclopropylamine	0.47-0.51 (2H, m), 0.75-0.80 (2H, m), 2.65-2.73 (1H, m), 7.08 (1H, d, <i>J</i> 2.0), 7.33-7.35 (1H, m), 7.50 (1H, t, <i>J</i> 7.9), 7.69-7.72 (1H, m), 7.77-7.80 (1H, m), 7.99 (1H, t, <i>J</i> 1.8), 8.86 (1H, d, <i>J</i> 2.0).	290, 292
74	<i>N</i> -Allyl- <i>N</i> -[5-(3-bromophenyl)-pyridazin-3-yl]amine	4.04-4.08 (2H, m), 5.10-5.13 (1H, m), 5.22-5.28 (1H, m), 5.93-6.02 (1H, m), 7.04 (1H, d, <i>J</i> 2.0), 7.05-7.07 (1H, m), 7.49 (1H, t, <i>J</i> 7.8), 7.68-7.71 (1H, m), 7.74-7.77 (1H, m), 7.95 (1H, t, <i>J</i> 1.8), 8.82 (1H, d, <i>J</i> 2.0).	290, 292
75	<i>N</i> -[5-(3-Bromophenyl)-	1.20 (3H, t, <i>J</i> 7.0), 3.41 (2H, qd,	278, 280

	pyridazin-3-yl]- <i>N</i> -ethylamine	<i>J</i> 5.5, 7.0), 6.84 (1H, t, <i>J</i> 5.5), 6.99 (1H, d, <i>J</i> 2.0), 7.49 (1H, t, 7.8), 7.68-7.71 (1H, m), 7.74-7.77 (1H, m), 7.95 (1H, t, <i>J</i> 1.8), 8.79 (1H, d, <i>J</i> 2.0).	
76	<i>N</i> -Benzyl- <i>N</i> -[5-(3-bromophenyl)-pyridazin-3-yl]amine	4.64 (2H, d, <i>J</i> 5.9), 7.08 (1H, d, <i>J</i> 2.0), 7.22-7.26 (1H, m), 7.31-7.35 (2H, m), 7.37-7.42 (3H, m), 7.49 (1H, t, 7.8), 7.68-7.71 (1H, m), 7.73-7.76 (1H, m), 7.94 (1H, t, <i>J</i> 2.0), 8.82 (1H, d, <i>J</i> 2.0).	340, 342
77	<i>N</i> -[5-(3-Bromophenyl)-pyridazin-3-yl]- <i>N</i> -(2-methoxybenzyl)-amine	3.85 (3H, s), 4.59 (2H, d, <i>J</i> 5.9), 6.87-6.91 (1H, m), 7.00-7.03 (1H, m), 7.11 (1H, d, <i>J</i> 2.0), 7.18 (1H, t, <i>J</i> 5.9), 7.22-7.29 (2H, m), 7.49 (1H, t, <i>J</i> 7.8), 7.68-7.71 (1H, m), 7.73-7.76 (1H, m), 7.93-7.94 (1H, m), 8.81 (1H, d, <i>J</i> 2.0).	370, 372
78	5-(3-Bromophenyl)-3-(2,5-dihydropyrrol-1-yl)pyridazine	4.36 (4H, s), 6.09 (2H, s), 7.11 (1H, d, <i>J</i> 2.0), 7.50 (1H, t, <i>J</i> 7.8), 7.69-7.72 (1H, m), 7.87-7.90 (1H, m), 8.12 (1H, t, <i>J</i> 1.8), 8.90 (1H, d, <i>J</i> 2.0).	302, 304

EXAMPLE 79**5-(3-Bromophenyl)-3-ethoxypyridazine**

5 Sodium metal (0.13 g, 5.65 mmol) was added portionwise to dry ethanol (10 ml) under external cooling (water bath). On addition of all the sodium, the reaction was allowed to attain room temperature and the solution stirred for 1 h before adding 5-(3-bromophenyl)-3-chloropyridazine

(0.15 g, 0.557 mmol) in ethanol (5 ml). The suspension was stirred for 18 h before adding water and removing the ethanol *in vacuo*. The products were extracted into CH₂Cl₂, dried over MgSO₄ and concentrated. The *title compound* was obtained as a white solid following preparative TLC using 25% ethyl acetate/hexanes as eluent (30 mg). δ_{H} (400 MHz, d⁶ DMSO) 1.41 (3H, t, *J* 7.0), 4.55 (2H, q, *J* 7.0), 7.50 (1H, t, *J* 8.0), 7.55 (1H, d, *J* 2.0), 7.71-7.74 (1H, m), 7.91-7.94 (1H, m), 8.14 (1H, t, *J* 1.8), 9.30 (1H, d, *J* 2.0); *m/z* (ES⁺) 279, 281.

EXAMPLE 80

3-Allyloxy-5-(3-bromophenyl)pyridazine

Sodium hydride as a 60% dispersion in mineral oil (0.175 g, 4.38 mmol) was added to a solution of allyl alcohol (0.25 ml, 3.79 mmol) in tetrahydrofuran (4 ml) and stirred for 30 min before adding 5-(3-bromophenyl)-3-chloropyridazine (0.5 g, 1.86 mmol). The suspension was heated to 170°C for 30 min in a Smith Synthesiser microwave reactor. The reaction was diluted with ethyl acetate, washed with H₂O, dried over MgSO₄ and concentrated while loading onto silica. Column chromatography using 20% ethyl acetate/hexanes as eluent gave the *title compound* as a white solid (0.2 g). δ_{H} (400 MHz, d⁶ DMSO) 5.03-5.05 (2H, m), 5.29-5.32 (1H, m), 5.44-5.50 (1H, m), 6.10-6.20 (1H, m), 7.51 (1H, t, *J* 8.0), 7.61 (1H, d, *J* 2.0), 7.72-7.75 (1H, m), 7.92-7.95 (1H, m), 8.16 (1H, t, *J* 1.8), 9.33 (1H, d, *J* 2.0); *m/z* (ES⁺) 291, 293.

EXAMPLE 81

3-(6-Isopropylaminopyridazin-4-yl)benzonitrile

N-[5-(3-Bromophenyl)pyridazin-3-yl]-*N*-isopropylamine (0.1 g, 0.342 mmol), zinc cyanide (52 mg, 0.443 mmol) and tetrakis(triphenylphosphine)palladium(0) (10 mg) were taken up in *N,N*-dimethylformamide

(2 ml). The reaction was heated to 150°C for 10 min in a Smith Synthesiser microwave reactor. The reaction was diluted with CH₂Cl₂ (6 ml) and H₂O (2 ml) then poured into a PTFE (5 μM) fritted syringe barrel. The organic phase was concentrated and purified by column chromatography using 50-75% ethyl acetate/hexanes as eluent. The *title compound* was obtained as a white solid by recrystallising from ethyl acetate (36 mg). δ_H (400 MHz, d⁶ DMSO) 1.21 (6H, d, *J* 6.7), 4.13-4.21 (1H, m), 6.76 (1H, d, *J* 7.4), 7.01 (1H, d, *J* 2.0), 7.74 (1H, t, *J* 7.8), 7.95-7.97 (1H, m), 8.05-8.08 (1H, m), 8.25-8.26 (1H, m), 8.81 (1H, d, *J* 2.0); *m/z* (ES⁺) 238.

EXAMPLES 82 TO 84

The compounds in Table 4 were prepared in an analogous manner to that described in Example 81.

Table 4

EX. NO.	PRODUCT	δ _H (400 MHz, d ⁶ DMSO)	<i>m/z</i> (ES ⁺)
82	3-(6-Benzylamino-pyridazin-4-yl)-benzonitrile	4.65 (2H, d, <i>J</i> 5.9), 7.13 (1H, d, <i>J</i> 1.6), 7.22-7.26 (1H, m), 7.31-7.35 (2H, m), 7.38-7.40 (2H, m), 7.47 (1H, t, <i>J</i> 5.9), 7.74 (1H, t, <i>J</i> 7.8), 7.94-7.97 (1H, m), 8.06-8.09 (1H, m), 8.26-8.28 (1H, m), 8.87 (1H, d, <i>J</i> 1.6).	287
83	3-[6-(2-Methoxy-benzylamino)-pyridazin-4-yl]-benzonitrile	3.84 (3H, s), 4.60 (2H, d, <i>J</i> 5.9), 6.87-6.91 (1H, m), 7.00-7.03 (1H, m), 7.16 (1H, d, <i>J</i> 2.0), 7.22-7.28 (3H, m), 7.74 (1H, t,	317

		<i>J</i> 7.8), 7.95-7.97 (1H, m), 8.06-8.09 (1H, m), 8.26-8.27 (1H, m), 8.86 (1H, d, <i>J</i> 2.0).	
84	3-(6-Benzyloxy-pyridazin-4-yl)-benzonitrile	5.59 (2H, s), 7.34-7.38 (1H, m), 7.40-7.44 (2H, m), 7.52-7.55 (2H, m), 7.72 (1H, d, <i>J</i> 2.0), 7.76 (1H, t, <i>J</i> 7.8), 7.98-8.01 (1H, m), 8.26-8.29 (1H, m), 8.46-8.47 (1H, m), 9.40 (1H, d, <i>J</i> 2.0).	288

EXAMPLE 85**3'-(6-Ethylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile**

- 5 *N*-[5-(3-Bromophenyl)pyridazin-3-yl]-*N*-ethylamine (0.1 g, 0.360 mmol), 2-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)-5-fluorobenzonitrile (0.1 g, 0.429 mmol), 2N Na₂CO₃ (0.5 ml) and tetrakis(triphenylphosphine)-palladium(0) (10 mg) in tetrahydrofuran (1.5 ml) were combined and heated to 150°C for 10 min in a Smith Synthesiser microwave reactor.
- 10 The reaction was diluted with CH₂Cl₂ (6 ml) and NH₄Cl (2 ml) then poured into a PTFE (5 μM) fritted syringe barrel. The organic phase was concentrated while loading onto silica and purified by column chromatography using 50% ethyl acetate/hexanes followed by ethyl acetate as eluent. The *title compound* was obtained as a white solid by
- 15 recrystallising from ethyl acetate (46 mg). δ_H (400 MHz, d⁶ DMSO) 1.19 (3H, t, *J* 7.0), 3.41 (2H, qd, *J* 5.1, 7.0), 6.88 (1H, t, *J* 5.1), 7.05 (1H, d, *J* 1.6), 7.69-7.76 (3H, m), 7.79-7.83 (1H, m), 7.85-7.88 (1H, m), 7.94-7.95 (1H, m), 8.01-8.04 (1H, m), 8.85 (1H, d, *J* 1.6); *m/z* (ES⁺) 319.

The compounds in Table 5 were prepared in an analogous manner to that described in Example 85.

Table 5

EX. NO.	PRODUCT	δ_H (400 MHz, d^6 DMSO)	m/z (ES ⁺)
86	4-Fluoro-3'-(6-isopropylamino-pyridazin-4-yl)-biphenyl-2-carbonitrile	1.21 (6H, d, J 6.3), 4.14-4.22 (1H, m), 6.74 (1H, d, J 7.8), 7.03 (1H, d, J 2.0), 7.69-7.76 (3H, m), 7.79-7.82 (1H, m), 7.84-7.86 (1H, m), 7.92-7.94 (1H, m), 8.01-8.04 (1H, m), 8.83 (1H, d, J 2.0).	333
87	4-Fluoro-3'-(6-propylaminopyridazin-4-yl)biphenyl-2-carbonitrile	0.95 (3H, d, J 7.2), 1.56-1.67 (2H, m), 3.33-3.37 (2H, m), 6.89-6.93 (1H, m), 7.06-7.07 (1H, m), 7.69-7.88 (5H, m), 7.93-7.95 (1H, m), 8.00-8.04 (1H, m), 8.84-8.85 (1H, m).	333
88	3'-(6-Cyclopropyl-aminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile	0.48-0.52 (2H, m), 0.75-0.80 (2H, m), 2.65-2.71 (1H, m), 7.16 (1H, d, J 2.0), 7.35-7.37 (1H, m), 7.70-7.76 (3H, m), 7.80-7.84 (1H, m), 7.88-7.91 (1H, m), 7.98-7.99 (1H, m), 8.01-8.04 (1H, m), 8.92 (1H, d, J 2.0).	331
89	3'-(6-Allylamino-pyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile	4.04-4.07 (2H, m), 5.09-5.13 (1H, m), 5.23-5.28 (1H, m), 5.93-6.02 (1H, m), 7.07-7.09 (1H, m), 7.10 (1H, d, J 1.6), 7.70-7.76 (3H, m), 7.79-7.83 (1H, m), 7.85-	331

		7.88 (1H, m), 7.94-7.95 (1H, m), 8.01-8.04 (1H, m), 8.80 (1H, d, <i>J</i> 1.6).	
90	3'-(6-Benzylamino-pyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile	4.64 (2H, d, <i>J</i> 5.9), 7.14 (1H, d, <i>J</i> 2.0), 7.22-7.26 (1H, m), 7.31-7.35 (2H, m), 7.38-7.41 (2H, m), 7.45 (1H, t, <i>J</i> 5.2), 7.69-7.76 (3H, m), 7.78-7.82 (1H, m), 7.84-7.87 (1H, m), 7.92-7.94 (1H, m), 8.01-8.04 (1H, m), 8.89 (1H, d, <i>J</i> 2.0).	381
91	4-Fluoro-3'-(6-methylamino-pyridazin-4-yl)-biphenyl-2-carbonitrile	2.92 (3H, d, <i>J</i> 5.1), 6.88 (1H, t, <i>J</i> 5.1), 7.06 (1H, d, <i>J</i> 2.0), 7.69-7.76 (3H, m), 7.79-7.83 (1H, m), 7.86-7.89 (1H, m), 7.95-7.96 (1H, m), 8.00-8.04 (1H, m), 8.87 (1H, d, <i>J</i> 2.0).	305
92	4-Fluoro-3'-(6-methoxypyridazin-4-yl)biphenyl-2-carbonitrile	4.09 (3H, s), 7.61 (1H, d, <i>J</i> 2.0), 7.70-7.77 (3H, m), 7.82-7.86 (1H, m), 8.01-8.04 (2H, m), 8.13 (1H, t, <i>J</i> 1.6), 9.39 (1H, d, <i>J</i> 2.0).	306
93	3'-(6-Ethoxypyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile	1.42 (3H, t, <i>J</i> 7.0), 4.55 (2H, q, <i>J</i> 7.0), 7.59 (1H, d, <i>J</i> 2.0), 7.70-7.77 (3H, m), 7.83-7.86 (1H, m), 8.01-8.04 (2H, m), 8.13-8.14 (1H, m), 9.37 (1H, d, <i>J</i> 2.0).	320
94	3'-(6-Benzyloxy-pyridazin-4-yl)-4-fluorobiphenyl-2-	5.59 (2H, s), 7.34-7.44 (3H, m), 7.52-7.55 (2H, m), 7.70 (1H, d, <i>J</i> 2.0), 7.71-7.77 (3H, m), 7.82-	382

	carbonitrile	7.86 (1H, m), 8.01-8.06 (2H, m), 8.14-8.15 (1H, m), 9.41 (1H, d, <i>J</i> 2.0).	
--	--------------	---	--

EXAMPLE 95

5-(4-Fluoro-3-hydroxyphenyl)-3-phenylpyridazine

5 To a solution of 5-(4-fluoro-3-methoxyphenyl)-3-phenylpyridazine
(0.6 g, 2.14 mmol) in dichloromethane cooled to -70°C was added boron
tribromide (0.81 ml, 8.56 mmol). The reaction mixture was stirred at
-70°C for 30 min then allowed to warm to room temperature and stirred
for 2 h. The reaction was cooled to 0°C, then 1 ml of methanol was added.
10 The reaction mixture was poured onto a solution of sodium
hydrogencarbonate, the precipitate obtained was collected by filtration,
washed with water and dried (MgSO₄) to give the *title compound* (400 mg).
 δ_{H} (400 MHz, CDCl₃) 7.37 (1H, dd, *J* 8.4, 11.2), 7.47-7.61 (5H, m), 8.26-8.28
(2H, m), 8.37 (1H, d, *J* 2.0), 9.50 (1H, d, *J* 2.0), 10.25-10.40 (1H, br s); *m/z*
15 (ES⁺) 267.

EXAMPLE 96

5-[4-Fluoro-3-(2-methyl-2*H*-[1,2,4]triazol-3-ylmethoxy)phenyl]-3-phenylpyridazine

20 To a solution of 5-(4-fluoro-3-hydroxyphenyl)-3-phenylpyridazine (80
mg, 0.3 mmol) in *N,N*-dimethylformamide (2 ml) was added sodium
hydride (30 mg, 0.6 mmol). After stirring for 10 min (2-methyl-2*H*-
[1,2,4]triazol-3-yl)methanol (50 mg, 0.3 mmol) was added. The reaction
25 mixture was heated at 60°C for 30 min. The reaction mixture was poured
into water, and the precipitate obtained was collected by filtration, washed
with water and dried (MgSO₄). The solid was dissolved in ethyl acetate,
adsorbed onto silica and purified by flash chromatography using ethyl

acetate/hexane (20:1) as eluent. The appropriate fractions were combined and evaporated under reduced pressure to give the *title compound* as a solid. δ_{H} (400 MHz, CDCl_3) 4.05 (3H, s), 5.44 (2H, s), 7.27-7.37 (3H, m), 7.51-7.61 (3H, m), 7.92 (2H, dd, J 11.3, 2.3), 8.16 (2H, dd, J 6.3, 1.6), 9.34 (1H, d, J 1.6); m/z (ES^+) 362.

EXAMPLE 97

5-[4-Fluoro-3-(1-methyl-3-trifluoromethyl-1*H*-pyrazol-4-yl)methoxy]-phenyl]-3-phenylpyridazine

To a slurry of 5-(4-fluoro-3-hydroxyphenyl)-3-phenylpyridazine (80 mg, 0.3 mmol), (1-methyl-3-trifluoromethyl-1*H*-pyrazol-4-yl)methanol (81 mg, 0.45 mmol) and triphenylphosphine (118 mg, 0.45 mmol) in tetrahydrofuran (2 ml) was added diisopropyl azodicarboxylate (91 mg, 0.45 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was adsorbed onto silica and purified by flash chromatography using a gradient elution of isohexane/ethyl acetate 20:1 to 1:20 as eluent. The appropriate fractions were combined and evaporated under reduced pressure to give a solid which was recrystallized from acetonitrile to give the *title compound* (45 mg). δ_{H} (400 MHz, CDCl_3) 3.96 (3H, s), 5.21 (2H, s), 7.27-7.34 (3H, m), 7.51-7.61 (4H, m), 7.91 (1H, d, J 2.3), 8.13-8.14 (2H, m), 9.35 (1H, d, J 2.3); m/z (ES^+) 429.

EXAMPLES 98 AND 99

The compounds in Table 6 were prepared in an analogous manner to that described in Example 96.

Table 6

EX.	PRODUCT	δ_{H} (400 MHz, CDCl_3)	m/z
-----	---------	---	-------

NO.			(ES ⁺)
98	5-[4-Fluoro-3-(pyridin-4-ylmethoxy)phenyl]-3-phenylpyridazine	5.27 (2H, s), 7.28-7.34 (3H, m), 7.42 (2H, d, <i>J</i> 6.3), 7.51-7.59 (3H, m), 7.88 (1H, d, <i>J</i> 2.0), 8.11-8.13 (2H, m), 8.66-8.68 (2H, m), 9.32 (1H, d, <i>J</i> 2.0).	358
99	5-[4-Fluoro-3-(pyridin-3-ylmethoxy)phenyl]-3-phenylpyridazine	5.26 (2H, s), 7.27-7.39 (4H, m), 7.51-7.59 (3H, m), 7.83-7.86 (1H, m), 7.90 (1H, d, <i>J</i> 2.3), 8.12-8.14 (2H, m), 8.63 (1H, d, <i>J</i> 3.9), 8.74 (1H, s), 9.33 (1H, d, <i>J</i> 2.0).	358

EXAMPLE 100

5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-4-yl)pyridazine

5 To 3-chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (0.2 g, 0.66 mmol) in 1,4-dioxane (2 ml) was added 4-tri-*n*-butylstannylpyridine (0.484 g, 1.31 mmol) followed by tetrakis(triphenylphosphine)palladium(0) (0.076 g, 0.065 mmol) and the mixture heated at 150°C in a Smith

10 Synthesiser microwave reactor for 12 min. The reaction was diluted with dichloromethane, filtered and evaporated to give a brown solid. The crude product was chromatographed on silica eluting with 1-5%

15 methanol/CH₂Cl₂. Appropriate fractions were pooled and evaporated to give the *title compound* as a cream-coloured solid. δ_H (400 MHz, CDCl₃) 7.40-7.47 (2H, m), 7.57-7.61 (1H, m), 7.82-7.86 (1H, m), 8.02-8.09 (4H, m), 8.60-8.62 (1H, m), 8.82-8.84 (2H, m), 9.53 (1H, d, *J* 2.3); *m/z* (ES⁺) 347.

EXAMPLES 101 TO 104

The compounds in Table 7 were prepared using the requisite heterocyclic stannanes in an analogous manner to that described in Example 100 above.

5

Table 7

EX. NO.	PRODUCT	δ_H (400 MHz, CDCl ₃)	m/z (ES ⁺)
101	5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyrazin-2-yl)-pyridazine	7.38-7.46 (2H, m), 7.56-7.61 (1H, m), 7.87-7.92 (1H, m), 8.09 (1H, dd, <i>J</i> 2.3, 6.7), 8.59 (1H, m), 8.68-8.75 (3H, m), 9.55 (1H, d, <i>J</i> 2.3), 9.97 (1H, d, <i>J</i> 1.2).	348
102	5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thiazol-2-yl)pyridazine	7.37-7.46 (2H, m), 7.55-7.61 (2H, m), 7.86-7.90 (1H, m), 8.02 (1H, d, <i>J</i> 3.5), 8.08 (1H, dd, <i>J</i> 2.3, 6.7), 8.56 (1H, d, <i>J</i> 2.3), 8.59-8.61 (1H, m), 9.49 (1H, d, <i>J</i> 2.3).	353
103	5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-2-yl)pyridazine	7.54-7.67 (3H, m), 7.92-7.97 (1H, m), 8.05-8.09 (1H, m), 8.24 (1H, s), 8.26 (1H, s), 8.61-8.66 (2H, m), 8.78 (1H, d, <i>J</i> 2.3), 8.80 (1H, dd, <i>J</i> 0.8, 4.3), 9.77 (1H, d, <i>J</i> 2.3).	347
104	5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-4-yl)-pyridazine	7.39-7.46 (2H, m), 7.56-7.61 (1H, m), 7.81-7.85 (1H, m), 8.02 (1H, dd, <i>J</i> 2.5, 6.5), 8.23 (2H, s), 8.60 (1H, d, <i>J</i> 4.3), 8.67 (2H, dd, <i>J</i> 0.8, 7.0), 9.54 (1H, d, <i>J</i> 1.6).	365

EXAMPLE 1055-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(1*H*-[1,2,3]triazol-4-yl)pyridazine

5 A degassed solution of 3-chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)-phenyl]pyridazine (200 mg, 0.66 mmol) was formed in tetrahydrofuran (3 ml). (Trimethylsilyl)acetylene (0.14 ml, 0.99 mmol), triethylamine (0.14 ml, 1 mmol), bis(triphenylphosphine)palladium(II) chloride (23 mg, 0.03 mmol) and triphenylphosphine (4 mg, 0.015 mmol) were added in that
10 order and the mixture left to stir for 20 min at room temperature.

 Copper(I) iodide (2 mg, 0.01 mmol) was added and the mixture stirred at room temperature for 18 h. The solvent was removed and the residue purified by flash column chromatography over silica using 80% ethyl acetate:20% isohexane as eluent to give 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-trimethylsilanylethynylpyridazine as a brown solid (210 mg).
15 δ_{H} (400 MHz, CDCl_3) 0.31 (9H, s), 7.34-7.45 (2H, m), 7.55-7.60 (1H, m), 7.74-7.78 (1H, m), 7.79 (1H, d, J 2.3), 7.95 (1H, dd, J 2.5, 6.5), 8.58-8.61 (1H, m), 9.39 (1H, d, J 2.3).

 Sodium azide (19 mg, 0.29 mmol) was added to a solution of 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-trimethylsilanylethynylpyridazine (100 mg, 0.26 mmol) in *N,N*-dimethylformamide (1 ml) and the mixture stirred at room temperature for 16 h, then at 70°C for 4 h. The reaction mixture was allowed to cool to room temperature and was added to water (20 ml) then extracted with ethyl acetate (5 x 10 ml). The combined
25 organics were dried over anhydrous magnesium sulphate, filtered and evaporated to a brown solid. Purification by preparative thin-layer chromatography using 10% methanol:90% dichloromethane as eluent gave the *title compound* as a tan solid. δ_{H} (400 MHz, d^6 -DMSO) 7.63 (1H, t, J 9.8), 8.16-8.27 (3H, m), 8.49 (1H, d, J 2.3), 8.69 (1H, s), 8.75 (1H, d, J 2.3),
30 9.66 (1H, d, J 2.0); m/z (ES^+) 355.

EXAMPLE 106**5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine-3-carboxylic acid ethyl ester**

5 A solution of 3-chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine (100 mg, 0.33 mmol) was formed in ethanol (10 ml) with *N,N*-dimethylformamide (2 ml). Sodium acetate (54 mg, 0.66 mmol) was added and the mixture degassed with nitrogen. [1,1'-Bis(diphenylphosphino)-ferrocene]palladium(II) chloride (1:1 complex with dichloromethane) (20
10 mg, 0.03 mmol) was added and carbon monoxide was bubbled through the solution as the mixture was heated to 90°C and maintained at that temperature for 45 min. The mixture was allowed to cool to room temperature and the solvent was removed. The residue was purified by flash column chromatography over silica, using 80% ethyl acetate:20%
15 isohexane as eluent, then recrystallisation from dichloromethane and isohexane, to give the *title compound* as a white solid (30 mg). δ_H (400 MHz, CDCl₃) 1.51 (3H, t, *J* 7.0), 4.59 (2H, q, *J* 7.2), 7.38-7.46 (2H, m), 7.55-7.61 (1H, m), 7.81-7.86 (1H, m), 8.03 (1H, dd, *J* 2.5, 6.5), 8.41 (1H, d, *J* 2.3), 8.59-8.61 (1H, m), 9.62 (1H, d, *J* 2.3); *m/z* (ES⁺) 342.

20

EXAMPLE 107**5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)-pyridazine-1-oxide**

25 To a mixture of 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)pyridazine (50 mg, 0.13 mmol) in CH₂Cl₂ (2 ml) was added *m*-chloroperbenzoic acid (50%; 68 mg, 0.20 mmol). The solution was left to stand at room temperature for 22 h. 10% Sodium carbonate solution (1 ml) was added and the solution poured into a PTFE (5 μ M) fritted syringe
30 barrel. The organic phase was evaporated and the crude product purified by preparative TLC using a solvent system of 5% methanol in CH₂Cl₂ to

yield a white solid. The solid was further purified by prep HPLC using a solvent system of 30-80% acetonitrile in 0.1% trifluoroacetic acid in water. Appropriate fractions were combined to give the *title compound* as a white solid (3 mg). δ_{H} (400 MHz, CDCl_3) 7.19-7.25 (1H, m), 7.29-7.41 (3H, m),
5 7.47-7.53 (1H, m), 7.73-7.76 (1H, m), 7.78 (1H, t, J 1), 7.91 (1H, dd, J 3, 7), 8.06-8.10 (1H, m), 8.42 (1H, d, J 1), 8.51 (1H, d, J 2); m/z (ES^+) 398.

EXAMPLE 108

10 3-(2,6-Difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine

To a degassed mixture of 3-chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (0.25 g, 0.82 mmol), hexamethylditin (0.323 g, 0.98 mmol) and lithium chloride (0.1024 g, 2.46 mmol) in 1,4-dioxane (12 ml) was added tetrakis(triphenylphosphine)palladium(0) (0.048 g, 0.041
15 mmol) and the mixture heated at 100°C for 3 h. Mass spectroscopy showed formation of the intended stannane. 1-Bromo-2,6-difluorobenzene (0.3177 g, 0.187 ml, 1.65 mmol) was added, followed by tetrakis(triphenylphosphine)palladium(0) (0.01 g, 0.0082 mmol), and the mixture heated at 100°C for 6 h. The reaction was cooled to room
20 temperature, filtered and evaporated and the crude product purified by preparative TLC (2 plates; 4% methanol- CH_2Cl_2). Appropriate bands were collected and processed to give the *title compound* as an off-white solid which was recrystallised from ethyl acetate/isohexane to give a white solid (42 mg). δ_{H} (400 MHz, CDCl_3) 7.05-7.12 (2H, m), 7.32-7.59
25 (4H, m), 7.79-7.85 (2H, m), 8.00 (1H, dd, J 2.5, 6.5), 8.58-8.60 (1H, m), 9.51 (1H, d, J 2.3).

EXAMPLE 109

30 3-(4-Chloro-2-fluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine

3-Chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine was coupled to 1-bromo-4-chloro-2-fluorobenzene by the method of Example 108 to give 3-(4-chloro-2-fluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine as a white solid: δ_{H} (500 MHz, DMSO) 7.54 (1H, m), 7.61-7.65 (1H, m), 7.70 (1H, dd, J 10.0, 0.5), 8.03-8.06 (1H, m), 8.16-8.24 (3H, m), 8.37 (1H, s), 8.74 (1H, s), 9.73 (1H, s); m/z (ES⁺) 416:418 (3:1).

EXAMPLE 110

5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-trifluoromethylphenyl)pyridazine

3-Chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine was coupled to 4-bromo-3-fluorobenzotrifluoride by the method of Example 108 to give 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-trifluoromethylphenyl)pyridazine as a white solid: δ_{H} (500 MHz, DMSO) 7.64 (1H, t, J 9.0), 7.82 (1H, d, J 8.1), 7.95 (1H, d, J 10.5), 8.16-8.26 (3H, m), 8.24 (1H, s), 8.46 (1H, s), 8.74 (1H, s), 9.78 (1H, s); m/z (ES⁺) 450.

EXAMPLE 111

5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-methylphenyl)-pyridazine

3-Chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine was coupled to 4-bromo-3-fluorotoluene by the method of Example 108 to give 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-methylphenyl)pyridazine as a white solid: δ_{H} (500 MHz, DMSO) 2.42 (3H, s), 7.25 (2H, s), 7.62 (1H, t, J 9.4), 7.93 (1H, m), 8.21 (3H, m), 8.30 (1H, s), 8.74 (1H, d, J 0.5), 9.68 (1H, s); m/z (ES⁺) 396.

EXAMPLE 112**3-(3,5-Difluoropyridin-2-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine**

5 3-Chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine was coupled to 2-bromo-3,5-difluoropyridine by the method of Example 108 to give 3-(3,5-difluoropyridin-2-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine as a white solid: δ_H (500 MHz, DMSO) 7.61-7.65 (1H, m), 8.16-8.24 (4H, m), 8.48 (1H, s), 8.75 (2H, d, J 12.2), 9.79 (1H, s);
10 m/z (ES⁺) 401.

EXAMPLE 113**Trifluoromethanesulfonic acid 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazin-3-yl ester**

15 A suspension of 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-2H-pyridazin-3-one (1.29 g, 4.52 mmol) was formed in dry pyridine (20 ml) and cooled to 0°C. Trifluoromethanesulfonic anhydride (1.14 ml, 6.78 mmol) was added dropwise. The mixture was then allowed to warm to
20 room temperature and after 30 min formed a dark red solution. The mixture was poured into water (100 ml) and extracted with dichloromethane (2 x 100 ml). The combined organics were dried over anhydrous magnesium sulphate, filtered and evaporated to a brown solid. Purification by flash column chromatography over silica using 80%
25 dichloromethane:20% ethyl acetate as eluent then recrystallization from dichloromethane using isohexane gave trifluoromethanesulfonic acid 5-[4-fluoro-3-(3-fluoro-pyridin-2-yl)phenyl]pyridazin-3-yl ester as a white solid: δ_H (400 MHz, CDCl₃) 7.40-7.47 (2H, m), 7.56-7.61 (2H, m), 7.78-7.82 (1H, m), 8.00 (1H, dd, J 2 and 6), 8.59-8.61 (1H, m), 9.55 (1H, d, J 2); m/z (ES⁺)
30 418.

EXAMPLE 1143-Ethylsulfanyl-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine

A solution of 3-chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-
pyridazine (50 mg, 0.16 mmol) was formed in *N,N*-dimethylformamide (1
ml). Sodium ethanethiolate (28 mg, 0.33 mmol) was added and the
mixture stirred at room temperature for 8 h. The reaction was poured into
water (20 ml) and extracted with ethyl acetate (2 x 20 ml). The combined
organics were dried over anhydrous magnesium sulphate, filtered and
evaporated to an orange solid. Purification by preparative thin layer
chromatography using ethyl acetate as eluent gave 3-ethylsulfanyl-5-[4-
fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine as a white solid (10 mg):
 δ_{H} (400 MHz, CDCl_3) 1.47 (3H, t, J 7), 3.43 (2H, q, J 7), 7.35 (1H, t, J 9),
7.40-7.44 (1H, m), 7.48 (1H, d, J 2), 7.54-7.59 (1H, m), 7.70-7.74 (1H, m),
7.92 (1H, dd, J 2 and 6), 8.57-8.60 (1H, m), 9.17 (1H, d, J 2); m/z (ES^+) 330.

EXAMPLE 1153-tert-Butylsulfanyl-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine

3-Chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (50
mg, 0.16 mmol) and sodium 2-methyl-2-propanethiolate (37 mg, 0.33
mmol) were reacted as in Example 114 to give 3-tert-butylsulfanyl-5-[4-
fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine as a tan solid (13 mg): δ_{H}
(400 MHz, CDCl_3) 1.66 (9H, s), 7.35 (1H, t, J 9), 7.40-7.44 (1H, m), 7.53
(1H, d, J 2), 7.54-7.59 (1H, m), 7.70-7.74 (1H, m), 7.91 (1H, dd, J 3 and 7),
8.58-8.60 (1H, m), 9.21 (1H, d, J 2); m/z (ES^+) 302 ($\text{M}+\text{H}-t\text{Bu}$) and 358
($\text{M}+\text{H}$).

EXAMPLE 116**5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-4-yl)-pyridazine**

5 3-Chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine (100 mg, 0.31 mmol) was coupled to 3-fluoro-4-tributylstannylpyridine (144 mg, 0.37 mmol) using the method in Example 100 to give 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-4-yl)pyridazine as a white solid (31 mg): δ_H (400 MHz, $CDCl_3$) 7.36-7.44 (2H, m), 7.81-7.85 (1H, m), 7.97 (1H, dd, J 2 and 7), 8.21-8.24 (2H, m), 8.52 (1H, d, J 2), 8.64-8.68 (2H, m), 9.53 (1H, d, J 2); m/z (ES^+) 383.

10

EXAMPLE 117

15 **5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-2-yl)-pyridazine**

 3-Chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine (139 mg, 0.43 mmol) was coupled to 3-fluoro-2-tributylstannylpyridine (200 mg, 0.51 mmol) using the method in Example 100 to give 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-2-yl)pyridazine as a white solid (70 mg): δ_H (500 MHz, $CDCl_3$) 7.36-7.41 (2H, m), 7.46-7.49 (1H, m), 7.66 (1H, t, J 10), 7.85-7.89 (1H, m), 8.01 (1H, dd, J 2 and 7), 8.41 (1H, s), 8.52 (1H, s), 8.61 (1H, d, J 4), 9.53 (1H, s); m/z (ES^+) 383.

20

25 **EXAMPLE 118**

5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-2-yl)-pyridazine

 3-Chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (216 mg, 0.71 mmol) was coupled to 3-fluoro-2-tributylstannylpyridine (300 mg, 0.78 mmol) using the method in Example 100 to give 5-[4-fluoro-3-(3-

30

fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-2-yl)pyridazine as a white solid (106 mg): δ_H (400 MHz, $CDCl_3$) 7.35-7.48 (3H, m), 7.55-7.61 (1H, m), 7.63-7.68 (1H, m), 7.84-7.89 (1H, m), 8.05 (1H, dd, J 3 and 7), 8.41 (1H, d, J 2), 8.58-8.62 (2H, m), 9.54 (1H, d, J 2); m/z (ES^+) 365.

5

EXAMPLE 119

5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-4-yl)-pyridazine 1-oxide

10 A solution of 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-4-yl)pyridazine (100 mg, 0.27 mmol) was formed in dichloromethane (4 ml). A solution of *m*-chloroperoxybenzoic acid (74 mg, 77%, 0.33 mmol) in dichloromethane (1 ml) was added and the mixture stirred at room temperature overnight. The reaction was quenched into
15 aqueous sodium carbonate (2M, 10 ml) and extracted with dichloromethane (10 ml). The organic phase was washed with aqueous sodium carbonate (1M, 2 x 10 ml) then dried over anhydrous magnesium sulphate, filtered and evaporated to a tan solid. Purification by preparative HPLC gave 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-
20 fluoropyridin-4-yl)pyridazine 1-oxide as a white solid (14 mg): δ_H (400 MHz, $CDCl_3$) 7.39-7.47 (2H, m), 7.56-7.61 (1H, m), 7.74-7.78 (1H, m), 7.86 (1H, s), 7.96 (1H, dd, J 3 and 7), 8.02 (1H, t, J 5), 8.49 (1H, d, J 1), 8.58-8.68 (3H, m); m/z (ES^+) 381.

25

EXAMPLE 120

5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoro-1-oxypyridin-4-yl)-pyridazine

30 A solution of 3-fluoro-4-tributylstannylpyridine (1.0 g, 2.6 mmol) was formed in dichloromethane (5 ml). A solution of *m*-chloroperoxybenzoic acid (696 mg, 77%, 3.1 mmol) in dichloromethane (3 ml) was added

and the mixture stirred at room temperature for 2 h. A further 10 ml of dichloromethane was added and the mixture was washed with saturated aqueous sodium bicarbonate (2 x 20 ml) then dried over anhydrous magnesium sulphate, filtered and evaporated to a yellow oil. Purification by flash column chromatography over silica using ethyl acetate as eluent gave 3-fluoro-4-tributylstannylpyridine 1-oxide as a colourless oil (1.0 g).

3-Chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (80 mg, 0.26 mmol) was coupled to 3-fluoro-4-tributylstannylpyridine 1-oxide (117 mg, 0.29 mmol) using the method in Example 100 to give 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoro-1-oxypyridin-4-yl)pyridazine as a tan solid (31 mg): δ_H (400 MHz, $CDCl_3$) 7.39-7.47 (2H, m), 7.56-7.62 (1H, m), 7.80-7.84 (1H, m), 8.00 (1H, dd, *J* 3 and 7), 8.18-8.22 (2H, m), 8.29 (1H, dd, *J* 2 and 7), 8.39 (1H, dd, *J* 7 and 9), 8.59-8.61 (1H, m), 9.50 (1H, d, *J* 2); *m/z* (ES^+) 381.

EXAMPLE 121

5-[2,4-Difluoro-3-(3,5-difluoropyridin-2-yl)phenyl]-3-(3,5-difluoropyridin-4-yl)pyridazine

A degassed solution of 2-bromo-3,5-difluoropyridine (4.0 g, 20.6 mmol), 2,6-difluorophenylboronic acid (3.9 g, 24.7 mmol) and potassium fluoride (4.3 g, 74.2 mmol) was formed in tetrahydrofuran (40 ml) with water (4 ml). Tris(dibenzylideneacetone)dipalladium(0) (189 mg, 0.21 mmol) followed by tri-*tert*-butylphosphine (0.8 ml, 0.51M in hexane, 0.42 mmol) were added and the mixture heated to 60°C for 18 h. The solvent was removed and the residue purified by flash column chromatography over silica using dichloromethane 60%:isohexane 40% as eluent to give 3,5-difluoro-2-(2,6-difluorophenyl)pyridine as a white solid (2.2 g): δ_H (400 MHz, $CDCl_3$) 6.99-7.06 (2H, m), 7.32-7.46 (2H, m), 8.50 (1H, d, *J* 2.3).

A solution of 3,5-difluoro-2-(2,6-difluorophenyl)pyridine (1.65 g, 7.26 mmol) was formed in concentrated sulphuric acid (10 ml) and cooled to

0°C. 1,3-Dibromo-5,5-dimethylhydantoin (2.08 g, 7.26 mmol) was added portionwise and the mixture left to stir at 0°C for 2 h. The reaction was quenched into ice (250 ml) and extracted with dichloromethane (2 x 100 ml). The combined organics were dried over anhydrous magnesium sulphate, filtered and evaporated to a yellow oil. Purification by flash column chromatography over silica using 60% isohexane:40% dichloromethane as eluent gave 2-(3-bromo-2,6-difluorophenyl)-3,5-difluoropyridine as a colourless oil (1.95 g): δ_H (400 MHz, $CDCl_3$) 6.94-6.99 (1H, m), 7.34-7.39 (1H, m), 7.61-7.67 (1H, m), 8.50 (1H, d, J 2.3).

A degassed solution of 2-(3-bromo-2,6-difluorophenyl)-3,5-difluoropyridine (1.95 g, 6.37 mmol), bis(neopentyl glycolato)diborane (1.58 g, 7.01 mmol) and potassium acetate (1.25 g, 12.7 mmol) was formed in 1,4-dioxane (20 ml) with dimethylsulphoxide (0.4 ml). [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1:1) (100 mg) was added and the mixture heated at 80°C for 18 h. The solvent was removed and the residue stirred with aqueous sodium hydroxide (2N, 100 ml) for 30 min, then filtered. The filtrate was washed with diethyl ether (2 x 50 ml) then cooled to 0°C before being neutralised with concentrated aqueous hydrochloric acid, then extracted with dichloromethane (2 x 50 ml). The combined organics were dried over anhydrous magnesium sulphate, filtered and evaporated to give 3,5-difluoro-2-[2,6-difluoro-3-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)phenyl]pyridine as a pale yellow oil: δ_H (400 MHz, $CDCl_3$) 1.03 (6H, s), 3.78 (4H, s), 5.30 (1H, s), 6.97-7.02 (1H, m), 7.29-7.35 (1H, m), 7.80-7.86 (1H, m), 8.48 (1H, d, J 2.3).

A degassed solution of 3-chloro-5-methoxypyridazine (473 mg, 3.27 mmol), 3,5-difluoro-4-trimethylstannanylpyridine (1.0 g, 3.6 mmol), copper(I) iodide (31 mg, 0.2 mmol) and lithium chloride (416 mg, 9.8 mmol) was formed in 1,4-dioxane (10 ml). Tetrakis(triphenylphosphine)-palladium(0) (100 mg) was added and the mixture heated to 80°C for 16 h. The solvent was removed and the residue was purified by flash column

chromatography over silica using 40% isohexane:60% ethyl acetate to give 3-(3,5-difluoropyridin-4-yl)-5-methoxypyridazine as a pale yellow solid (220 mg): δ_H (400 MHz, $CDCl_3$) 7.10-7.12 (1H, m), 8.54 (2H, s), 9.02 (1H, d, J 3.1); m/z (ES⁺) 224.

5 A solution of 3-(3,5-difluoropyridin-4-yl)-5-methoxypyridazine (210 mg, 0.94 mmol) was formed in aqueous hydrobromic acid (5 ml, 48%) and refluxed for 2 h. The mixture was cooled in an ice bath and neutralised with aqueous sodium hydroxide to ~ pH 2 then with solid sodium hydrogencarbonate to neutral. The resulting white precipitate was
10 filtered and dried under vacuum over phosphorus pentoxide to give 6-(3,5-difluoropyridin-4-yl)-1*H*-pyridazin-4-one as a white solid (110 mg): m/z (ES⁺) 210.

A suspension of 6-(3,5-difluoropyridin-4-yl)-1*H*-pyridazin-4-one (60 mg, 0.28 mmol) was formed in phosphorus oxychloride (0.8 ml) and heated
15 to 80°C for 30 min to give a yellow solution. The phosphorus oxychloride was removed under reduced pressure and the residue diluted with dichloromethane (5 ml) and washed with water (3 x 10 ml) and saturated aqueous sodium hydrogencarbonate (10 ml) then dried over anhydrous magnesium sulphate, filtered and evaporated to give 5-chloro-3-(3,5-
20 difluoropyridin-4-yl)pyridazine as a yellow solid (63 mg): δ_H (400 MHz, $CDCl_3$) 7.76-7.78 (1H, m), 8.58 (2H, s), 9.31 (1H, d, J 2.3).

A solution of 5-chloro-3-(3,5-difluoropyridin-4-yl)pyridazine (107 mg, 0.47 mmol) and 3,5-difluoro-2-[2,6-difluoro-3-(5,5-dimethyl-
[1,3,2]dioxaborinan-2-yl)phenyl]pyridine (191 mg, 0.56 mmol) was formed
25 in 1,4-dioxane (4 ml) with aqueous sodium carbonate (1 ml, 2 M). Tetrakis(triphenylphosphine)palladium(0) (50 mg) was added and the mixture heated to 150°C for 700 s in a Smith Synthesiser microwave reactor. The solvent was evaporated and the residue purified by flash
column chromatography over silica using dichloromethane:ethyl acetate
30 (1:1). Recrystallization from dichloromethane using isohexane gave 5-[2,4-difluoro-3-(3,5-difluoropyridin-2-yl)phenyl]-3-(3,5-difluoropyridin-4-

yl)pyridazine as a white solid (106 mg): δ_{H} (400 MHz, CDCl_3) 7.25-7.29 (1H, m), 7.38-7.43 (1H, m), 7.66-7.72 (1H, m), 7.90-7.91 (1H, m), 8.54 (1H, d, J 2.3), 8.57 (2H, s), 9.50-9.51 (1H, m); m/z (ES^+) 419.

5

EXAMPLES 122 AND 123

The compounds in Table 2A were prepared using the requisite boronic acids in an analogous manner to that described in Examples 33 and 34.

10

Table 2A

EX. NO.	PRODUCT	δ_{H}	m/z (ES^+)
122	5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-methoxyphenyl)-pyridazine	(500 MHz, DMSO): 3.98 (3H, s), 7.42 (1H, s), 7.65 (1H, dd, J 8.7, 9.2), 7.89-7.91 (1H, m), 8.05 (1H, d, J 8.1), 8.17-8.21 (1H, m), 8.29 (1H, s), 8.30 (1H, s), 8.55 (1H, s), 8.75 (1H, s), 9.65 (1H, s).	412
123	5-[4-Fluoro-3-(3-fluoropyridin-2-yl)-phenyl]-3-(2-fluoro-4-methoxyphenyl)-pyridazine	(400 MHz, CDCl_3): 3.89 (3H, s), 6.77 (1H, dd, J 2.3, 13.3), 6.91 (1H, dd, J 2.3, 8.6), 7.36-7.44 (2H, m), 7.55-7.60 (1H, m), 7.79-7.82 (1H, m), 7.99 (1H, dd, J 2.3, 6.7), 8.10 (1H, t, J 2.0), 8.21 (1H, t, J 9.0), 8.58-8.60 (1H, m), 9.39 (1H, d, J 2.0).	394

EXAMPLES 124 TO 126

The compounds in Table 7A were prepared using the requisite heterocyclic stannanes in an analogous manner to that described in

5 Example 100.

Table 7A

EX. NO.	PRODUCT	δ_H	m/z (ES ⁺)
124	3-(3,5-Difluoropyridin-4-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine	(400 MHz, d ₆ DMSO) 7.63-7.68 (2H, m), 7.95 (1H, m), 8.23-8.29 (2H, m), 8.55 (1H, br s), 8.64 (1H, m), 8.81 (2H, s), 9.88 (1H, d, <i>J</i> 1.8).	383
125	3-(3,5-Difluoropyridin-2-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine	(400 MHz, d ₆ DMSO) 7.61-7.67 (2H, m), 7.95 (1H, m), 8.22-8.27 (3H, m), 8.49 (1H, d, <i>J</i> 1.8), 8.65 (1H, m), 8.77 (1H, d, <i>J</i> 1.8), 9.81 (1H, d, <i>J</i> 1.9).	383
126	3-(3,5-Difluoropyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine	(400 MHz, CDCl ₃): 7.36-7.43 (2H, m), 7.80-7.84 (1H, m), 7.89 (1H, t, <i>J</i> 1.0), 7.97 (1H, dd, <i>J</i> 2.3, 6.7), 8.51 (1H, d, <i>J</i> 2.3), 8.57 (2H, s), 9.57 (1H, d, <i>J</i> 2.3).	401

EXAMPLE 127**3-(3,5-Difluoro-1-oxypyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine**

5 A solution of 3,5-difluoro-4-trimethylstannanylpyridine (2.0 g, 7.2 mmol) was formed in dichloromethane (10 ml). A solution of 3-chloroperoxybenzoic acid (1.94 g, approx. 8.6 mmol) in dichloromethane (10 ml) was added dropwise and the solution stirred overnight at room temperature. The reaction mixture was poured into aqueous sodium
10 carbonate (2M, 50 ml) and extracted with dichloromethane (2 x 50 ml). The combined organic phases were washed with water (50 ml), dried over anhydrous magnesium sulphate, filtered and evaporated to give crude 3,5-difluoro-4-trimethylstannanylpyridine 1-oxide as a white solid (1.31 g). 3,5-Difluoro-4-trimethylstannanylpyridine 1-oxide (438 mg, 1.5 mmol) was
15 coupled to 3-chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-pyridazine (400 mg, 1.24 mmol) using the method in Example 100 to give 3-(3,5-difluoro-1-oxypyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine as a white solid (50 mg): δ_H (400 MHz, $CDCl_3$) 7.36-7.44 (2H, m), 7.79-7.83 (1H, m), 7.86-7.87 (1H, m), 7.95 (1H, dd, J 2.5, 6.5),
20 8.18-8.21 (2H, m), 8.51 (1H, d, J 2.3), 9.55 (1H, d, J 2.3); m/z (ES^+) 417.

EXAMPLE 128**5'-[6-(3,5-Difluoropyridin-2-yl)pyridazin-4-yl]-2'-fluorobiphenyl-2-carbonitrile**

25 2'-Fluoro-5'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)biphenyl-2-carbonitrile (2.50 g, 7.8 mmol) was coupled to 5-chloro-2*H*-pyridazin-3-one (1.32 g, 10.0 mmol) using the method in Example 33 to give 2'-fluoro-5'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile (2.36 g): m/z
30 (ES^+) 292.

2'-Fluoro-5'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile (2.36 g) was reacted with phosphorus oxychloride (50 ml) using the method in Example 34 to give 5'-(6-chloropyridazin-4-yl)-2'-fluoro-biphenyl-2-carbonitrile (1.89 g): m/z (ES⁺) 310.

5 A solution of 3,5-difluoro-4-trimethylsilylpyridine (202 mg, 1.08 mmol) in dry diethyl ether (2 ml) was added dropwise to a pre-formed solution of butyllithium (0.7 ml, 1.6M in hexanes, 1.13 mmol) and dry *N,N,N',N'*-tetramethylethylenediamine (0.2 ml, 1.35 mmol) in dry diethyl ether (2 ml) at -78°C. The yellow solution was stirred at -78°C for 1 h
10 before dropwise addition of zinc chloride (1.6 ml, 1M in ether, 1.6 mmol). The resulting white precipitate was stirred at -78°C for 30 min then allowed to warm to room temperature over 2 h to give a solution of 3,5-difluoro-4-trimethylsilylpyridin-2-ylzinc chloride. A degassed solution of 5'-(6-chloropyridazin-4-yl)-2'-fluorobiphenyl-2-carbonitrile (200 mg, 0.65
15 mmol) and tetrakis(triphenylphosphine)palladium(0) (20 mg) in *N,N*-dimethylformamide (5 ml) was added to this solution and after further degassing the mixture was stirred at 80°C for 18 h. The mixture was poured into water (50 ml) and extracted with dichloromethane (2 x 50 ml). The combined organics were dried over anhydrous magnesium sulphate,
20 filtered and evaporated to a brown oil. Purification by flash column chromatography over silica, using a mixture of 20% ethyl acetate:80% dichloromethane as eluent, gave 5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2'-fluorobiphenyl-2-carbonitrile as a tan solid (80 mg): δ_H (400 MHz, CDCl₃) 7.41-7.48 (2H, m), 7.54-7.60 (2H, m), 7.71-7.75 (1H, m), 7.81-7.87
25 (3H, m), 8.35 (1H, d, *J* 2.3), 8.52 (1H, d, *J* 2.3), 9.52 (1H, d, *J* 2.3); m/z (ES⁺) 389.

EXAMPLE 129

30 5'-[6-(3,5-Difluoropyridin-4-yl)pyridazin-4-yl]-2'-fluorobiphenyl-2-carbonitrile

5'-(6-Chloropyridazin-4-yl)-2'-fluorobiphenyl-2-carbonitrile (500 mg, 1.6 mmol) was coupled to 3,5-difluoro-4-trimethylstannanylpyridine (538 mg, 1.9 mmol) using the method in Example 100 to give 5'-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]-2'-fluorobiphenyl-2-carbonitrile as a tan solid (327 mg): δ_H (400 MHz, $CDCl_3$) 7.43-7.48 (1H, m), 7.55-7.60 (2H, m), 7.71-7.75 (1H, m), 7.78-7.89 (4H, m), 8.58 (2H, s), 9.57 (1H, d, J 1.6); m/z (ES^+) 389.

EXAMPLE 130

10

4,2'-Difluoro-5'-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]biphenyl-2-carbonitrile

4,2'-Difluoro-5'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-biphenyl-2-carbonitrile (5 g, 14.7 mmol) was coupled to 5-chloro-2H-pyridazin-3-one (1.59 g, 12.2 mmol) using the method in Example 33 to give 4,2'-difluoro-5'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile: m/z (ES^+) 310.

4,2'-Difluoro-5'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile (4 g) was reacted with phosphorus oxychloride (20 ml) using the method in Example 34 to give 5'-(6-chloropyridazin-4-yl)-4,2'-difluorobiphenyl-2-carbonitrile: m/z (ES^+) 328.

5'-(6-Chloropyridazin-4-yl)-4,2'-difluorobiphenyl-2-carbonitrile (200 mg, 0.61 mmol) was coupled to 3,5-difluoro-4-trimethylstannanylpyridine (204 mg, 0.73 mmol) using the method in Example 100 to give 4,2'-difluoro-5'-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]biphenyl-2-carbonitrile as a tan solid (75 mg): δ_H (400 MHz, d^6 -DMSO) 7.65-7.70 (1H, m), 7.77-7.85 (2H, m), 8.08 (1H, dd, J 2.3, 8.6), 8.22-8.25 (2H, m), 8.54-8.55 (1H, m), 8.82 (2H, s), 9.90 (1H, d, J 2.3); m/z (ES^+) 407.

EXAMPLE 131**4,2'-Difluoro-5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile**

5 5'-(6-Chloropyridazin-4-yl)-4,2'-difluorobiphenyl-2-carbonitrile (300 mg, 0.92 mmol) was coupled to 3,5-difluoro-4-trimethylsilylpyridin-2-yl-zinc chloride (1.55 mmol) using the method in Example 128 to give 4,2'-difluoro-5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile as a pale pink solid (88 mg): δ_H (400 MHz, $CDCl_3$) 7.42-7.48 (3H, m), 7.53-7.60 (2H, m), 7.80 (1H, dd, J 2.5, 6.8), 7.83-7.88 (1H, m), 8.34 (1H, d, J 2.0), 8.52 (1H, d, J 2.3), 9.52 (1H, d, J 2.3); m/z (ES^+) 407.

10

EXAMPLE 132

15 **2-{5-[6-(3,5-Difluoropyridin-4-yl)pyridazin-4-yl]-2-fluorophenyl}-nicotinonitrile**

 2-[2-Fluoro-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]-nicotinonitrile (4.86 g, 15 mmol) was coupled to 5-chloro-2*H*-pyridazin-3-one (1.78 g, 13.7 mmol) using the method in Example 33 to give 2-[2-fluoro-5-(6-oxo-1,6-dihydropyridazin-4-yl)phenyl]nicotinonitrile (2.4 g): m/z (ES^+) 293.

20

 2-[2-Fluoro-5-(6-oxo-1,6-dihydropyridazin-4-yl)phenyl]-nicotinonitrile (2.4 g, 8.2 mmol) was reacted with phosphorus oxychloride (20 ml) using the method in Example 34 to give 2-[5-(6-chloropyridazin-4-yl)-2-fluorophenyl]nicotinonitrile (1.39 g): m/z (ES^+) 311.

25

 2-[5-(6-Chloropyridazin-4-yl)-2-fluorophenyl]nicotinonitrile (300 mg, 0.97 mmol) was coupled to 3,5-difluoro-4-trimethylstannanylpyridine (322 mg, 1.16 mmol) using the method in Example 100 to give 2-{5-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]-2-fluorophenyl}nicotinonitrile as a tan solid (95 mg): δ_H (400 MHz, $CDCl_3$) 7.46-7.55 (2H, m), 7.86-7.90 (2H, m),

30

7.97 (1H, dd, *J* 2.3, 6.7), 8.15 (1H, dd, *J* 1.6, 7.8), 8.58 (2H, s), 8.96 (1H, dd, *J* 1.8, 4.9), 9.58 (1H, d, *J* 2.3); *m/z* (ES⁺) 390.

EXAMPLE 133

5

2-{5-[6-(3,5-Difluoropyridin-2-yl)pyridazin-4-yl]-2-fluorophenyl}-nicotinonitrile

2-[5-(6-Chloropyridazin-4-yl)-2-fluorophenyl]nicotinonitrile (300 mg, 0.97 mmol) was coupled to 3,5-difluoro-4-trimethylsilylpyridin-2-ylzinc chloride (1.93 mmol) using the method in Example 128 to give 2-{5-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2-fluorophenyl}nicotinonitrile as a white solid (70 mg): δ_{H} (400 MHz, CDCl₃) 7.43-7.54 (3H, m), 7.90-7.94 (1H, m), 8.01 (1H, dd, *J* 2.3, 6.7), 8.15 (1H, dd, *J* 2.0, 7.8), 8.37 (1H, d, *J* 2.0), 8.52 (1H, d, *J* 2.3), 8.96 (1H, dd, *J* 1.8, 4.9), 9.54 (1H, d, *J* 2.3); *m/z* (ES⁺) 390.

15

EXAMPLE 134

2'-Fluoro-5'-[6-(2-oxopyrrolidin-1-yl)pyridazin-4-yl]biphenyl-2-carbonitrile

A solution of 2-pyrrolidinone (60 mg, 0.71 mmol) was formed in *N,N*-dimethylformamide (5 ml) and cooled to 0°C. Sodium hydride (60% in mineral oil, 28 mg, approx. 0.71 mmol) was added and the suspension stirred at room temperature for 30 min. 5'-(6-Chloropyridazin-4-yl)-2'-fluorobiphenyl-2-carbonitrile (200 mg, 0.64 mmol) was added and the mixture heated at 50°C overnight. The reaction was quenched into water (50 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organics were dried over anhydrous magnesium sulphate, filtered and evaporated to a brown oil. Purification by flash column chromatography over silica using a mixture of 20% ethyl acetate:80% dichloromethane as eluent, then recrystallization from dichloromethane using isohexane, gave 2'-fluoro-5'-[6-(2-oxopyrrolidin-1-yl)pyridazin-4-yl]biphenyl-2-carbonitrile

20

25

30

as a tan solid (18 mg): δ_H (400 MHz, $CDCl_3$) 2.21-2.27 (2H, m), 2.72 (2H, t, J 8.1), 4.33 (2H, t, J 7.2), 7.40 (1H, t, J 9.0), 7.53-7.58 (2H, m), 7.69-7.84 (4H, m), 8.94 (1H, d, J 2.0), 9.23 (1H, d, J 2.0); m/z (ES^+) 359.

5

EXAMPLE 135

2'-Fluoro-5'-[6-(2-oxo-2H-pyridin-1-yl)pyridazin-4-yl]biphenyl-2-carbonitrile

A mixture of 5'-(6-chloropyridazin-4-yl)-2'-fluorobiphenyl-2-carbonitrile (310 mg, 1.0 mmol), 2-hydroxypyridine (143 mg, 1.5 mmol), copper(I) iodide (19 mg, 0.1 mmol) and potassium carbonate (207 mg, 1.5 mmol) in *N,N*-dimethylformamide were heated to 150°C overnight. Mixture was allowed to cool to room temperature then aqueous ammonia (50 ml, ~5%) was added and the mixture extracted with ethyl acetate (2 x 50 ml). The combined organics were washed with brine (50 ml) then dried over anhydrous magnesium sulphate, filtered and evaporated to a brown solid. Purification by flash column chromatography over silica using ethyl acetate as eluent, then recrystallization from ethyl acetate, gave 2'-fluoro-5'-[6-(2-oxo-2H-pyridin-1-yl)pyridazin-4-yl]biphenyl-2-carbonitrile: δ_H (400 MHz, $CDCl_3$) 6.38-6.42 (1H, m), 6.68 (1H, d, J 8.8), 7.40-7.50 (2H, m), 7.54-7.58 (2H, m), 7.70-7.74 (1H, m), 7.78-7.85 (3H, m), 8.12-8.14 (1H, m), 8.45 (1H, d, J 2.0), 9.45 (1H, d, J 2.2); m/z (ES^+) 369.

25

EXAMPLE 136

6,2'-Difluoro-5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile

6,2'-Difluoro-5'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-biphenyl-2-carbonitrile (5.0 g, 14.7 mmol) was coupled to 5-chloro-2H-pyridazin-3-one (1.74 g, 13.3 mmol) using the method in Example 33 to

30

give 6,2'-difluoro-5'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile (4.2 g): m/z (ES^+) 310.

6,2'-Difluoro-5'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile (4.2 g, 13.6 mmol) was reacted with phosphorus oxychloride (30 ml) using the method in Example 34 to give 5'-(6-chloropyridazin-4-yl)-6,2'-difluorobiphenyl-2-carbonitrile (2.02 g): m/z (ES^+) 328.

5'-(6-Chloropyridazin-4-yl)-6,2'-difluorobiphenyl-2-carbonitrile (500 mg, 1.53 mmol) was coupled to 3,5-difluoro-4-trimethylsilylpyridin-2-yl-zinc chloride (3.05 mmol) using the method in Example 128 to give 6,2'-difluoro-5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile as a tan solid (100 mg): δ_H (400 MHz, $CDCl_3$) 7.42-7.51 (3H, m), 7.55-7.60 (1H, m), 7.65-7.67 (1H, m), 7.82 (1H, dd, J 2.3, 6.3), 7.87-7.91 (1H, m), 8.34 (1H, d, J 2.0), 8.52 (1H, d, J 2.3), 9.52 (1H, d, J 2.3); m/z (ES^+) 407.

EXAMPLE 137

3-(3,5-Difluoropyridin-2-yl)-5-(4-fluoro-3-trifluoromethylphenyl)pyridazine
2-(4-Fluoro-3-trifluoromethylphenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (3.0 g, 10.3 mmol) was coupled to 5-chloro-2H-pyridazin-3-one (1.13 g, 8.62 mmol) using the method in Example 33 to give 5-(4-fluoro-3-trifluoromethylphenyl)-2H-pyridazin-3-one (1.93 g): m/z (ES^+) 259.

5-(4-Fluoro-3-trifluoromethylphenyl)-2H-pyridazin-3-one (1.93 g, 7.48 mmol) was reacted with phosphorus oxychloride (10 ml) using the method in Example 34 to give 3-chloro-5-(4-fluoro-3-trifluoromethylphenyl)pyridazine (1.42 g): m/z (ES^+) 277.

3-Chloro-5-(4-fluoro-3-trifluoromethylphenyl)pyridazine (500 mg, 1.81 mmol) was coupled to 3,5-difluoro-4-trimethylsilylpyridin-2-ylzinc chloride (3.62 mmol) using the method in Example 128 to give 3-(3,5-difluoropyridin-2-yl)-5-(4-fluoro-3-trifluoromethylphenyl)pyridazine as a

light brown solid (40 mg): δ_H (400 MHz, $CDCl_3$) 7.41-7.49 (2H, m), 7.93-8.01 (2H, m), 8.34 (1H, d, J 2.3), 8.54 (1H, d, J 2.3), 9.49 (1H, d, J 2.0); m/z (ES⁺) 356.

5

EXAMPLE 138

3-(3,5-Difluoropyridin-2-yl)-5-(6-fluoro-2'-trifluoromethylbiphenyl-3-yl)-pyridazine

4-Fluorophenylboronic acid was coupled to 5-chloro-2*H*-pyridazin-3-one using the method in Example 33 to give 5-(4-fluorophenyl)-2*H*-pyridazin-3-one: m/z (ES⁺) 191.

5-(4-Fluorophenyl)-2*H*-pyridazin-3-one was reacted with phosphorus oxychloride using the method in Example 34 to give 3-chloro-5-(4-fluorophenyl)pyridazine: m/z (ES⁺) 209.

3-Chloro-5-(4-fluorophenyl)pyridazine was coupled to 3,5-difluoro-4-trimethylsilylpyridin-2-ylzinc chloride using the method in Example 128 to give 3-(3,5-difluoropyridin-2-yl)-5-(4-fluorophenyl)pyridazine: m/z (ES⁺) 288.

3-(3,5-Difluoropyridin-2-yl)-5-(4-fluorophenyl)pyridazine (0.314 g, 1.1 mmol) was dissolved in concentrated sulfuric acid (4 ml) and 1,3-dibromo-5,5-dimethylhydantoin (0.311 g, 1.1 mmol) added and the mixture stirred for 20 min. The reaction mixture was poured onto ice (50 g) and adjusted to pH 11 with sodium hydroxide solution. The aqueous phase was extracted with dichloromethane (2 x 100 ml), and the combined organics dried over $MgSO_4$, filtered and evaporated to give a brown solid. The crude product was chromatographed on silica eluting with ethyl acetate to give 5-(3-bromo-4-fluorophenyl)-3-(3,5-difluoropyridin-2-yl)-pyridazine as a white solid (0.111 g): m/z (ES⁺) 366:368 (1:1).

5-(3-Bromo-4-fluorophenyl)-3-(3,5-difluoropyridin-2-yl)pyridazine was coupled to 2-trifluoromethylphenylboronic acid by the method of Example 34 to give 3-(3,5-difluoropyridin-2-yl)-5-(6-fluoro-2'-

trifluoromethylbiphenyl-3-yl)pyridazine: δ_H (500 MHz, $CDCl_3$) 7.35 (1H, t, J 8.7), 7.40-7.47 (2H, m), 7.58 (1H, t, J 7.8), 7.63-7.69 (2H, m), 7.79-7.84 (2H, m), 8.31 (1H, d, J 2.0), 8.51 (1H, d, J 1.5), 9.49 (1H, d, J 1.7); m/z (ES⁺) 432.

5

EXAMPLE 139

5-(6,2'-Difluorobiphenyl-3-yl)-3-(3,5-difluoropyridin-2-yl)pyridazine

5-(3-Bromo-4-fluorophenyl)-3-(3,5-difluoropyridin-2-yl)pyridazine
10 was coupled to 2-fluorophenylboronic acid by the method of Example 34 to give 5-(6,2'-difluorobiphenyl-3-yl)-3-(3,5-difluoropyridin-2-yl)pyridazine: δ_H (500 MHz, $CDCl_3$) 7.21-7.24 (1H, m), 7.28-7.29 (1H, m), 7.36-7.47 (4H, m), 7.75-7.83 (2H, m), 8.33 (1H, d, J 2.2), 8.52 (1H, d, J 2.2), 9.51 (1H, d, J 2.2); m/z (ES⁺) 382.

15

EXAMPLE 140

3-(3,5-Difluoropyridin-2-yl)-5-(6,2',4'-trifluorobiphenyl-3-yl)pyridazine

5-(3-Bromo-4-fluorophenyl)-3-(3,5-difluoropyridin-2-yl)pyridazine
20 was coupled to 2,4-difluorophenylboronic acid by the method of Example 34 to give 3-(3,5-difluoropyridin-2-yl)-5-(6,2',4'-trifluorobiphenyl-3-yl)-pyridazine: δ_H (500 MHz, $CDCl_3$) 6.96-7.05 (2H, m), 7.36-7.47 (3H, m), 7.75-7.80 (2H, m), 8.33 (1H, d, J 2.2), 8.52 (1H, d, J 2.2), 9.50 (1H, d, J 2.4); m/z (ES⁺) 400.

25

EXAMPLE 141

5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(2,4,6-trifluorophenyl)-pyridazine

30 3-Chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine was coupled to 1-bromo-2,4,6-trifluorobenzene by the method of Example

108 to give 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2,4,6-trifluorophenyl)pyridazine: δ_H (500 MHz, $CDCl_3$) 6.86 (2H, t, J 8.2), 7.34-7.41 (2H, m), 7.81 (2H, t, J 6.4), 7.94 (1H, dd, J 2.2, 6.4), 8.51 (1H, d, J 2.2), 9.47-9.57 (1H, m); m/z (ES^+) 418.

5

EXAMPLE 142

3-(3,5-Difluoropyridin-2-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine

10

3-Chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine was prepared via the coupling of 5-chloro-2*H*-pyridazin-3-one with 3-(3-fluoropyridin-2-yl)-4-fluorophenylboronic acid (prepared according to WO 0238568), according to the method of Example 126.

15

3-chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (0.2g, 0.66 mmol), dry dioxane (5 ml), lithium chloride (0.22g), and Copper (I) iodide (0.020g), were combined and degassed under nitrogen. 3,5-difluoro-2-trimethylstannylpyridine (0.318g; 1.11mmol) was added followed by tetrakis(triphenylphosphine)palladium (0) (0.100g), the mixture thoroughly degassed under a nitrogen atmosphere, then heated at 85°C for 48 h. The reaction was cooled to ambient temperature, diluted with dichloromethane (30 ml), and washed with 25% aqueous ammonium hydroxide (30 ml). The organic phase was separated and evaporated at reduced pressure. The residue was subjected to chromatography on silica gel eluent 5% methanol in dichloromethane. The product was dissolved in warm methanol and applied to an SCX acidic ion exchange resin cartridge. Elution with methanol, followed by a solution of ammonia in methanol (2 molar), afforded clean product, which was recrystallised from hot aqueous methanol. (400 MHz, d_6DMSO) 7.61-7.67 (2H, m), 7.95 (1H, m), 8.22-8.27 (3H, m), 8.49 (1H, d, J 1.8), 8.65 (1H, m), 8.77 (1H, d, J 1.8), 9.81 (1H, d, J 1.9); m/z (ES^+) 383.

20

25

30

EXAMPLE 143**3-(3,5-Difluoropyridin-4-yl)-5-[3-(3,5-difluoro-pyridin-2-yl)-4-fluorophenyl]pyridazine**

To a degassed suspension of 5-chloro-2*H*-pyridazin-3-one (7.1198g; 54.54mmol) and 3-(3,5-difluoro-pyridin-2-yl)-4-fluorophenylboronic acid (prepared according to WO 0238568) (11.5g; 45.45mmol) in dioxan (300 g ml) was added degassed sodium carbonate solution (60 ml, 2N) followed by dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (1.85g; 2.27mmol) mixture heated at reflux for 18 h. The mixture was cooled in an ice bath with stirring for 30 min and the solid collected by filtration washing with water and dried under vacuum over P₂O₅ to give 5-[3-(3,5-difluoro-pyridin-2-yl)-4-fluoro-phenyl]-2*H*-pyridazin-3-one as a beige powdery solid. (9.5 g) *m/z* (ES⁺) 304.

5-[3-(3,5-Difluoro-pyridin-2-yl)-4-fluoro-phenyl]-2*H*-pyridazin-3-one (4.5g; 14.8397mmol) was added to phosphorus oxychloride (80 ml) and the mixture placed in an oil bath pre-heated at 80°C. After stirring for 40 minutes volatiles were removed under vacuum and the brown residue treated with ice (150 g), trituration of the brown oil gave a powdery solid. The mixture was neutralised by the addition of saturated sodium hydrogen carbonate solution. The aqueous phase was extracted with ethyl acetate (3x300 ml), and the combined organics washed with brine (200 ml), dried over MgSO₄, filtered and evaporated to give 3-chloro-5-[3-(3,5-difluoro-pyridin-2-yl)-4-fluoro-phenyl]-pyridazine as a beige coloured powdery solid. *m/z* (ES⁺) 322:324 (2:1).

To a degassed suspension of 3-chloro-5-[3-(3,5-difluoro-pyridin-2-yl)-4-fluoro-phenyl]-pyridazine (3.045g; 9.46mmol), 3,5-difluoro-4-trimethylstannylpyridine (3.15g; 11.35mmol), copper (I) iodide (0.09g ; 0.473mmol) and lithium chloride (0.80g ; 18.93mmol) in dioxan (30ml) was added tetrakis(triphenylphosphine)palladium (0) (0.5469g;

0.473mmol) and the mixture heated at 85°C for 18 h. The reaction was cooled to ambient temperature, diluted with ethyl acetate (70 ml) and filtered through a catalyst filter. The filtrate was absorbed onto silica and chromatographed eluting with ethyl acetate:iso-hexane 1:1, to give the product as an off white solid. Recrystallisation from ethyl acetate iso-hexane gave a white solid (3.13g). (400 MHz, CDCl₃): 7.36-7.43 (2H, m), 7.80-7.84 (1H, m), 7.89 (1H, t, *J* 1.0), 7.97 (1H, dd, *J* 2.3, 6.7), 8.51 (1H, d, *J* 2.3), 8.57 (2H, s), 9.57 (1H, d, *J* 2.3); *m/z* (ES⁺) 401.

EXAMPLE 144

3-(3,5-Difluoropyridin-2-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine

To a stirred solution of the 2-bromo-3,5-difluoropyridine (0.5g; 2.57mmol) in ether (5 ml) at -78°C was added n-butyllithium (1.77ml; 2.83mmol; 1.6 M in hexanes) and the mixture stirred for 15 min, zinc chloride (3.866ml; 3.8664mmol; 1M soln in ether) was added and the mixture stirred at -78°C for 15 min then allowed to warm to room temperature. 3-Chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine (0.33g; 1.03mmol) was dissolved in DMF (6 ml) and degassed for 15 minutes, tetrakis(triphenylphosphine)palladium (0) (0.148g; 0.128mmol) was added and the mixture added to the aryl zinc prepared above and heated at 80°C for 14 h. The reaction was partitioned between water (50 ml) and DCM (100 ml). The organic phase was separated dried (MgSO₄) filtered and evaporated to give a brown oil. The product was chromatographed on silica eluted with DCM to 40% ethyl acetate in DCM to give the product as a white solid (182 mg) δ_H (500 MHz, DMSO) 7.61-7.65 (1H, m), 8.16-8.24 (4H, m), 8.48 (1H, s), 8.75 (2H, d, *J* 12.2), 9.79 (1H, s); *m/z* (ES⁺) 401.

EXAMPLE 145**5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(2,4,6-trifluorophenyl)-pyridazine**


5 To a degassed mixture of 3-chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine (0.3 g, 0.95 mmol), hexamethylditin (0.366 g, 1.1 mmol) and lithium chloride (0.116 g, 2.7 mmol) in 1,4-dioxane (12 ml) was added tetrakis(triphenylphosphine)palladium(0) (0.053 g, 0.04 mmol) and the mixture heated at 100°C for 2 h. Mass spectroscopy showed formation
10 of the intended stannane. 1-Bromo-2,4,6-trifluorobenzene (0.393 g, 1.8 mmol) was added, followed by tetrakis(triphenylphosphine)palladium(0) (0.01 g, 0.0082 mmol), and the mixture heated at 100°C for 18 h. The reaction was cooled to room temperature, filtered and evaporated. The crude product was chromatographed on silica eluted with 30% ethyl
15 acetate in DCM to give a brown solid, which was triturated with diethyl ether and the solid collected by filtration to give the product as an off-white solid (12 mg). δ_H (500 MHz, $CDCl_3$) 6.86 (2H, t, J 8.2), 7.34-7.41 (2H, m), 7.81 (2H, t, J 6.4), 7.94 (1H, dd, J 2.2, 6.4), 8.51 (1H, d, J 2.2), 9.47-9.57 (1H, m); m/z (ES^+) 418.

20

CLAIMS:

1. A compound of formula I, or an *N*-oxide thereof or a pharmaceutically acceptable salt thereof:

5



(I)

wherein

10 X^1 represents hydrogen, halogen, C_{1-6} alkyl, trifluoromethyl or C_{1-6} alkoxy;

X^2 represents hydrogen or halogen;

Z represents hydrogen, halogen, cyano, cyanomethyl, trifluoromethyl, nitro, hydroxy, C_{1-6} alkoxy, formyl, C_{2-6} alkoxycarbonyl, or an optionally substituted aryl, heteroaryl or heteroaryl(C_{1-6})alkoxy group;


15 R^1 represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, $-OR^a$, $-OSO_2CF_3$, $-SR^a$, $-SOR^a$, $-SO_2R^a$, $-SO_2NR^aR^b$, $-NR^aR^b$, $-NR^aCOR^b$, $-NR^aCO_2R^b$, $-COR^a$, $-CO_2R^a$, $-CONR^aR^b$ or $-CR^a=NOR^b$;

R^2 represents hydrogen or C_{2-6} alkoxycarbonyl; and

20 R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group.

2. A compound as claimed in claim 1 represented by formula IIA, and *N*-oxides thereof and pharmaceutically acceptable salts thereof:

25



(IIA)

wherein


Z is as defined in claim 1;

5 X¹¹ represents hydrogen, fluoro, chloro, methyl, trifluoromethyl or methoxy;

X¹² represents hydrogen or fluoro; and

R¹¹ represents phenyl, halophenyl, dihalophenyl, trihalophenyl, (C₁₋₆ alkyl)(halo)phenyl, (trifluoromethyl)(halo)phenyl, C₁₋₆ alkoxyphenyl, (C₁₋₆ alkoxy)(halo)phenyl, cyanophenyl, (cyano)(halo)phenyl, C₃₋₇ heterocycloalkyl (optionally substituted by oxo), C₃₋₇ heterocycloalkenyl, heteroaryl (optionally substituted by one or more halogen atoms, and/or by oxo), C₁₋₆ alkoxy, C₂₋₆ alkenyloxy, aryl(C₁₋₆)alkoxy, triflyloxy, C₁₋₆ alkylthio, C₁₋₆ alkylamino, C₂₋₆ alkenylamino, C₃₋₇ cycloalkylamino, 10 aryl(C₁₋₆)alkylamino (optionally substituted by C₁₋₆ alkoxy) or C₂₋₆ alkoxycarbonyl.

3. A compound as claimed in claim 2 represented by formula IIB, and *N*-oxides thereof and pharmaceutically acceptable salts thereof:




(IIB)

wherein X^{11} , X^{12} and R^{11} are as defined in claim 2; and
 R^3 represents hydrogen or fluoro.

5

4. A compound as claimed in claim 2 represented by formula
 IIC, and *N*-oxides thereof and pharmaceutically acceptable salts thereof:




(IIC)

10

wherein X^{11} , X^{12} and R^{11} are as defined in claim 2; and
 R^4 represents hydrogen, fluoro, cyano or methyl.

5. A compound as claimed in claim 2 represented by formula
 15 IID, and *N*-oxides thereof and pharmaceutically acceptable salts thereof:




(IID)

wherein X^{11} , X^{12} and R^{11} are as defined in claim 2;

R^4 is as defined in claim 4; and

5 R^5 represents hydrogen or fluoro.

6. A compound as claimed in claim 5 represented by formula IIE, and *N*-oxides thereof and pharmaceutically acceptable salts thereof:



(IIE)

wherein

V represents N and W represents CF; or

V represents CF and W represents N; or

15 V and W both represent CF;

X^{12} is as defined in claim 2; and

R⁵ is as defined in claim 5.

7. A compound selected from:

- 3,5-diphenylpyridazine-4-carboxylic acid ethyl ester;
5 3,5-diphenylpyridazine-4-carboxylic acid methyl ester;
3,5-diphenylpyridazine;
5-[2-fluoro-3-(pyridin-3-yl)phenyl]-3-phenylpyridazine;
5-(3-isopropoxyphenyl)-3-phenylpyridazine;
3-(6-phenylpyridazin-4-yl)benzaldehyde;
10 4,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;
5-(3-cyanophenyl)-3-phenylpyridazine;
5-(3-bromophenyl)-3-phenylpyridazine;
3-phenyl-5-[3-(pyridin-3-yl)phenyl]pyridazine;
3-phenyl-5-(3-[1,2,4]triazol-4-ylphenyl)pyridazine;
15 5-[2,4-difluoro-3-(pyridin-4-yl)phenyl]-3-phenylpyridazine;
5-[3-(2-methyl-2*H*-[1,2,4]triazol-3-ylmethoxy)phenyl]-3-phenylpyridazine;
6,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;
5-[4-fluoro-3-(pyridin-4-yl)phenyl]-3-phenylpyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-phenylpyridazine;
20 3-phenyl-5-[3-(pyridin-2-ylmethoxy)phenyl]pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-4-yl)phenyl]-3-phenylpyridazine;
5-[2-fluoro-3-(pyridin-4-yl)phenyl]-3-phenylpyridazine;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-phenylpyridazine;
5-[4-fluoro-3-(pyridin-3-yl)phenyl]-3-phenylpyridazine;
25 [3-(6-phenylpyridazin-4-yl)phenyl]acetonitrile;
2-fluoro-5-(6-phenylpyridazin-4-yl)benzonitrile;
5-(3-nitrophenyl)-3-phenylpyridazine;
3-(6-phenylpyridazin-4-yl)benzoic acid methyl ester;
3-(6-phenylpyridazin-4-yl)benzaldehyde;
30 5-(3-fluorophenyl)-3-phenylpyridazine;
3-phenyl-5-(3-trifluoromethylphenyl)pyridazine;

- 5-(3-methoxyphenyl)-3-phenylpyridazine;
5,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;
3,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;
5-(4-fluoro-3-methoxyphenyl)-3-phenylpyridazine;
5 6,2'-difluoro-5'-[6-(4-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
4-fluoro-3'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;
6,2'-difluoro-5'-[6-(thien-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
6,2'-difluoro-5'-[6-(4-methoxyphenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
5'-[6-(3-chlorophenyl)pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile;
10 6,2'-difluoro-5'-[6-(pyridin-3-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
5'-[6-(4-chlorophenyl)pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile;
6,2'-difluoro-5'-[6-(pyridin-4-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(4-fluorophenyl)-
pyridazine;
15 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(2-fluorophenyl)pyridazine;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)-
pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-3-yl)pyridazine;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluorophenyl)-
20 pyridazine;
3-(2,4-difluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-
pyridazine;
5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-methoxyphenyl)-
pyridazine;
25 6,2'-difluoro-5'-[6-(2-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
6,2'-difluoro-5'-[6-(3-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
3-[6-(3-fluorophenyl)pyridazin-4-yl]benzonitrile;
3-[6-(2-fluorophenyl)pyridazin-4-yl]benzonitrile;
3-[6-(4-fluorophenyl)pyridazin-4-yl]benzonitrile;
30 3-[6-(4-methoxyphenyl)pyridazin-4-yl]benzonitrile;
3-[6-(3,4-difluorophenyl)pyridazin-4-yl]benzonitrile;

- 3-[6-(2,4-difluorophenyl)pyridazin-4-yl]benzonitrile;
5'-[6-(2-chlorophenyl)pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile;
3-(4-methoxyphenyl)-5-phenylpyridazine;
4-fluoro-3'-[6-(4-methoxyphenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
5 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(4-methoxyphenyl)-
pyridazine;
3-(4-chlorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-
pyridazine;
2-{5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazin-3-yl}-5-
10 fluorobenzonitrile;
3-(4-chlorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(furan-3-yl)pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(furan-2-yl)pyridazine;
3-(2,3-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-
15 pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thien-3-yl)pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thien-2-yl)pyridazine;
3-(2,5-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-
pyridazine;
20 3-(3,4-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-
pyridazine;
4-{5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazin-3-yl}benzonitrile;
N-[5-(3-bromophenyl)pyridazin-3-yl]-*N*-methylaniline;
N-[5-(3-bromophenyl)pyridazin-3-yl]-*N*-isopropylaniline;
25 *N*-[5-(3-bromophenyl)pyridazin-3-yl]-*N*-cyclopropylaniline;
N-allyl-*N*-[5-(3-bromophenyl)pyridazin-3-yl]aniline;
N-[5-(3-bromophenyl)pyridazin-3-yl]-*N*-ethylaniline
N-benzyl-*N*-[5-(3-bromophenyl)pyridazin-3-yl]aniline;
N-[5-(3-bromophenyl)pyridazin-3-yl]-*N*-(2-methoxybenzyl)aniline;
30 5-(3-bromophenyl)-3-(2,5-dihydropyrrol-1-yl)pyridazine;
5-(3-bromophenyl)-3-ethoxypyridazine;

- 3-allyloxy-5-(3-bromophenyl)pyridazine;
3-(6-isopropylaminopyridazin-4-yl)benzonitrile;
3-(6-benzylaminopyridazin-4-yl)benzonitrile;
3-[6-(2-methoxybenzylamino)pyridazin-4-yl]benzonitrile;
5 3-(6-benzyloxy-pyridazin-4-yl)benzonitrile;
3'-(6-ethylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
4-fluoro-3'-(6-isopropylaminopyridazin-4-yl)biphenyl-2-carbonitrile;
4-fluoro-3'-(6-propylaminopyridazin-4-yl)biphenyl-2-carbonitrile;
3'-(6-cyclopropylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
10 3'-(6-allylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
3'-(6-benzylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
4-fluoro-3'-(6-methylaminopyridazin-4-yl)biphenyl-2-carbonitrile;
4-fluoro-3'-(6-methoxypyridazin-4-yl)biphenyl-2-carbonitrile;
3'-(6-ethoxypyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
15 3'-(6-benzyloxy-pyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
5-(4-fluoro-3-hydroxyphenyl)-3-phenylpyridazine;
5-[4-fluoro-3-(2-methyl-2*H*-[1,2,4]triazol-3-ylmethoxy)phenyl]-3-phenylpyridazine;
5-[4-fluoro-3-(1-methyl-3-trifluoromethyl-1*H*-pyrazol-4-ylmethoxy)phenyl]-
20 3-phenylpyridazine;
5-[4-fluoro-3-(pyridin-4-ylmethoxy)phenyl]-3-phenylpyridazine;
5-[4-fluoro-3-(pyridin-3-ylmethoxy)phenyl]-3-phenylpyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-4-yl)pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyrazin-2-yl)pyridazine;
25 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thiazol-2-yl)pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-2-yl)pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-4-yl)pyridazine;
5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(1*H*-[1,2,3]triazol-4-yl)pyridazine;
30

5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine-3-carboxylic acid ethyl ester;

5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)-pyridazine-1-oxide;

5 3-(2,6-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine;

and pharmaceutically acceptable salts thereof.

8. A compound selected from:

10 3-(4-chloro-2-fluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;

5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-trifluoromethylphenyl)pyridazine;

15 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-methylphenyl)-pyridazine;

3-(3,5-difluoropyridin-2-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;

trifluoromethanesulfonic acid 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazin-3-yl ester;

20 3-ethylsulfanyl-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;

3-*tert*-butylsulfanyl-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;

5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-4-yl)-pyridazine;

25 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-2-yl)-pyridazine;

5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-2-yl)-pyridazine;

5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-4-yl)-pyridazine 1-oxide;

30 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoro-1-oxypyridin-4-yl)-pyridazine;

5-[2,4-difluoro-3-(3,5-difluoropyridin-2-yl)phenyl]-3-(3,5-difluoropyridin-4-yl)pyridazine;

5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-methoxyphenyl)pyridazine;

5 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(2-fluoro-4-methoxyphenyl)-pyridazine;

3-(3,5-difluoropyridin-4-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;

10 3-(3,5-difluoropyridin-2-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;

3-(3,5-difluoropyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;

and pharmaceutically acceptable salts thereof.

15 9. A compound selected from:

3-(3,5-difluoro-1-oxypyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;

5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2'-fluorobiphenyl-2-carbonitrile;

20 5'-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]-2'-fluorobiphenyl-2-carbonitrile;

4,2'-difluoro-5'-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;

25 4,2'-difluoro-5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;

2-{5-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]-2-fluorophenyl}-nicotinonitrile;

2-{5-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2-fluorophenyl}-nicotinonitrile;

30 2'-fluoro-5'-[6-(2-oxopyrrolidin-1-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;

2'-fluoro-5'-[6-(2-oxo-2*H*-pyridin-1-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;

6,2'-difluoro-5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;

5 3-(3,5-difluoropyridin-2-yl)-5-(4-fluoro-3-trifluoromethylphenyl)pyridazine;
3-(3,5-difluoropyridin-2-yl)-5-(6-fluoro-2'-trifluoromethylbiphenyl-3-yl)-pyridazine;

5-(6,2'-difluorobiphenyl-3-yl)-3-(3,5-difluoropyridin-2-yl)pyridazine;

3-(3,5-difluoropyridin-2-yl)-5-(6,2',4'-trifluorobiphenyl-3-yl)pyridazine;

10 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2,4,6-trifluorophenyl)-pyridazine;


and pharmaceutically acceptable salts thereof.

10. A pharmaceutical composition comprising a compound of
15 formula I, or an *N*-oxide thereof or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.


11. The use of a compound as defined in claim 1, or an *N*-oxide thereof or a pharmaceutically acceptable salt thereof, for the manufacture
20 of a medicament for the treatment and/or prevention of neurological disorders.

12. A process for the preparation of a compound as claimed in claim 1, which comprises:

25 (A) reacting a compound of formula III with a compound of formula IV:



(III)




(IV)


wherein X¹, X², Z, R¹ and R² are as defined in claim 1, L¹ represents a
 suitable leaving group, and M¹ represents a boronic acid moiety -B(OH)₂ or
 5 a cyclic ester thereof formed with an organic diol, or M¹ represents
 -Sn(Alk)₃ in which Alk represents C₁-₆ alkyl, or M¹ represents -ZnHal in
 which Hal represents halogen; in the presence of a transition metal
 catalyst; or

(B) reacting a compound of formula V with a compound of formula

10 VI:




(V)




(VI)

wherein X¹, X², Z, R¹ and R² are as defined in claim 1, and L¹ and M¹ are
 15 as defined above; in the presence of a transition metal catalyst; or

(C) reacting a compound of formula VII with a compound of formula
 VIII:




(VII)




(VIII)

wherein X^1 , X^2 , Z , R^1 and R^2 are as defined in claim 1, and L^1 and M^1 are as defined above; in the presence of a transition metal catalyst; or

- 5 (D) reacting a compound of formula IX with a compound of formula X:




(IX)



(X)

- 10 wherein X^1 , X^2 , Z , R^1 and R^2 are as defined in claim 1, and L^1 and M^1 are as defined above; in the presence of a transition metal catalyst; or

- (E) reacting a compound of formula XI with a compound of formula XII:




(XI)




(XII)

wherein X^1 , X^2 , R^1 and R^2 are as defined in claim 1, and Z^1 represents C_{1-6} alkyl or optionally substituted heteroaryl(C_{1-6})alkyl; in the presence of triphenylphosphine and a dialkyl azodicarboxylate; or

5 (F) reacting a compound of formula XIV with a compound of formula XV:



(XIV)




(XV)

10

wherein X^1 , X^2 , Z and R^2 are as defined in claim 1, L^1 and M^1 are as defined above, and R^{1a} represents an aryl or heteroaryl moiety; in the presence of a transition metal catalyst; or


(G) reacting a compound of formula XVI with a compound of

15 formula XVII:



wherein X^1 , X^2 , Z and R^2 are as defined in claim 1, and R^{1a} , L^1 and M^1 are as defined above; in the presence of a transition metal catalyst; or

5 (H) reacting a compound of formula XVIII:



10 wherein X^1 , X^2 , Z and R^2 are as defined in claim 1, and TMS is an abbreviation for trimethylsilanyl; with sodium azide; or

(J) reacting a compound of formula XV as defined above with a compound of formula R^a-OH , wherein R^a is as defined in claim 1; or


(K) reacting a compound of formula XV as defined above with a salt of formula $R^aS\cdot Na^+$, wherein R^a is as defined in claim 1; or

15 (L) reacting a compound of formula XV as defined above with a compound of formula $H-NR^aR^b$, wherein R^a and R^b are as defined in claim 1; or

(M) reacting a compound of formula XV as defined above with carbon dioxide and a compound of formula $R^a\text{-OH}$, wherein R^a is as defined in claim 1; in the presence of a transition metal catalyst; or

(N) reacting a compound of formula VII above wherein L^1 represents a halogen atom with zinc cyanide; in the presence of a transition metal catalyst; or


(P) reacting a compound of formula XXII:



(XXII)

wherein X^1 , X^2 , Z and R^1 are as defined in claim 1; with diazomethane; or

(Q) reacting a compound of formula XXIII:



(XXIII)

wherein X^1 , X^2 , Z and R^1 are as defined in claim 1, and R^{2a} represents C_{2-6} alkoxy carbonyl; with diazomethane; and

(R) subsequently, if required, converting a compound of formula I initially obtained into a further compound of formula I by standard methods.

- 5 13. A method for the treatment and/or prevention of neurological disorders which comprises administering to a patient in need of such treatment an effective amount of a compound of formula I as defined in claim 1, or an *N*-oxide thereof or a pharmaceutically acceptable salt thereof.

This Page Blank (uspto)

PCT/G 03/03376

IPC 7	C07D237/24	C07D237/08	C07D237/20	C07D237/14	C07D401/10
	C07D405/10	C07D403/10	C07D403/12	C07D401/12	C07D409/04
	C07D401/04	C07D405/14	C07D409/14	C07D401/14	C07D417/14

According to International Patent Classification (IPC) or to both national classification and IPC

Minimum documentation searched (classification system followed by classification symbols) :

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, WPI Data, BIOSIS

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02 38568 A (HALLETT DAVID JAMES ;MERCK SHARP & DOHME (GB); RUSSELL MICHAEL GEO) 16 May 2002 (2002-05-16) example 93 claim 13 ---	1,10,11
X	WO 02 22605 A (KNEGTEL RONALD ;BEBBINGTON DAVID (GB); CHARRIER JEAN DAMIEN (GB);) 21 March 2002 (2002-03-21) Table 7, examples VIII-1, VIII-14, VIII-33 ---	1,10
X	EP 0 072 726 A (SANOFI SA) 23 February 1983 (1983-02-23) table I ---	1,10,13
	--- -/--	

·X ~ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

16 October 2003

Date of mailing of the international search report

03/11/2003

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer _____

Fanni, S

INTERNATIONAL SEARCH REPORT

PCT/03/03376

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D403/04 A61K31/4965 A61K31/497		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WERMUTH, CAMILLE GEORGES ET AL: "Synthesis and structure-activity relationships of a series of aminopyridazine derivatives of gamma.-aminobutyric acid acting as selective GABA-A antagonists" JOURNAL OF MEDICINAL CHEMISTRY (1987), 30(2), 239-49, XP002257939 Scheme I, compound III; Scheme II, compound 9a --- -/--	1
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search 16 October 2003		Date of mailing of the international search report
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Fanni, S

INTERNATIONAL SEARCH REPORT

PCT/GB 03/03376

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AURICCHIO, SERGIO ET AL: "New cleavage of the azirine ring by single electron transfer: the synthesis of 2H-imidazoles, pyridazines and pyrrolines" EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2001), (6), 1183-1187, XP002257940 examples 3A-3C ---	1
X	RIVAL, YVELINE ET AL: "5-HT ₃ Antagonists Derived from Aminopyridazine-type Muscarinic M ₁ Agonist" JOURNAL OF MEDICINAL CHEMISTRY (1998), 41(3), 311-317, XP002257941 scheme 1 ---	1,10
X	SOUTH, MICHAEL S. ET AL: "Synthesis and Reactions of Haloazodienes. A New and General Synthesis of Substituted Pyridazines" JOURNAL OF ORGANIC CHEMISTRY (1996), 61(25), 8921-8934, XP002257942 examples 9,10; table 1 ---	1
X	BLY, RUTA K. ET AL: "Heterocyclic studies. XIII. The aldol condensation of 2,3-dihydro-5-methy 6-phenyl-4H-1,2diazepin-4-one and rearrangement to a pyridazine" JOURNAL OF ORGANIC CHEMISTRY (1964), 29(8), 2128-35, XP002257943 examples 15A-D ---	1
X	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ATKINSON, C. M. ET AL: "Triazaphenanthrenes. III. Synthesis of some 9-aryl-2,3,10- triazaphenanthrenes" retrieved from STN Database accession no. 53:67737 XP002257945 abstract & JOURNAL OF THE CHEMICAL SOCIETY, ABSTRACTS (1959) 1-5, ---	1

	-/--	

INTERNATIONAL SEARCH REPORT

PCT/GP 03/03376

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SAMSONOV, V. A. ET AL: "Preparation and reactions of pyrroline N-oxides obtained by reaction of isonitroso ketones with enamines" retrieved from STN Database accession no. 126:18740 XP002257946 abstract & KHIMIYA GETEROTSIKLICHESKIKH SOEDINENII (1996), (8), 1055-1061,</p>	1
X	<p>HARRIS, R.L.N. ET AL.: "The effect of C-2-carboxyphenyl Derivatives of Certain Heterocyclic Compounds on Root Geotropism in Cress Seedlings" PESTICIDE SCIENCE, vol. 11, 1980, pages 439-444, XP009019048 example XV</p>	1
X	<p>OLIVER, J.E ET AL.: "Alkylation and Rearrangement of Lithiated 3-Methyl-1,2-benzisoxazoles" JOURNAL OF ORGANIC CHEMISTRY, vol. 54, 1989, pages 4970-4973, XP002257944 table I</p>	1
X	<p>BREUKELMAN, S.P: "Preparation and some Reactions of 4- and 5-Aryl-4,5-dihydropyrazin-3(2H)-ones" J. CHEM. SOC. PERKIN TRANS., 1985, pages 1627-1635, XP009019047 page 1629; example 25</p>	1
X	<p>JOJMA, T. ET AL.: "Pyridazine I. Novel Intramolecular Cycloaddition of 3-Chloro-6-(2-allylphenoxy)pyridazines" CHEMICAL&PHARMACEUTICAL BULLETIN, vol. 20, no. 10, - 1972 pages 2191-2203, XP009019056 page 2195; example IX</p>	1
X	<p>US 4 810 705 A (CHAMBON JEAN-PIERRE ET AL) 7 March 1989 (1989-03-07) examples I-IX</p>	1
A	<p>US 6 255 305 B1 (GUIBLIN ALEXANDER RICHARD ET AL) 3 July 2001 (2001-07-03) column 3, line 4 - line 18 claim 1</p>	1,10,13

INTERNATIONAL SEARCH REPORT

PCT/GB 03/03376

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 1(partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.1

Although claim 13 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 13

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 1(partially)

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claim(s) is impossible. Consequently, the search has been restricted to compounds of formula I according to present claim 1 for which R1 is always other than hydrogen.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

PCT/ES 03/03376

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0238568	A	16-05-2002	AU 1253002 A	21-05-2002
			CA 2427779 A1	16-05-2002
			EP 1343788 A1	17-09-2003
			WO 0238568 A1	16-05-2002
			WO 03008418 A1	30-01-2003
			US 2003055060 A1	20-03-2003
WO 0222605	A	21-03-2002	AU 9091201 A	26-03-2002
			AU 9091401 A	26-03-2002
			AU 9094401 A	26-03-2002
			AU 9101301 A	26-03-2002
			AU 9267001 A	26-03-2002
			AU 9455801 A	26-03-2002
			AU 9687101 A	26-03-2002
			AU 9687501 A	26-03-2002
			BR 0114088 A	17-06-2003
			CA 2422299 A1	21-03-2002
			CA 2422354 A1	21-03-2002
			CA 2422367 A1	21-03-2002
			CA 2422371 A1	21-03-2002
			CA 2422377 A1	21-03-2002
			CA 2422378 A1	21-03-2002
			CA 2422379 A1	21-03-2002
			CA 2422380 A1	21-03-2002
			EP 1317447 A1	11-06-2003
			EP 1317444 A1	11-06-2003
			EP 1317448 A1	11-06-2003
			EP 1318997 A1	18-06-2003
			EP 1317449 A1	11-06-2003
			EP 1317450 A1	11-06-2003
			EP 1317452 A1	11-06-2003
			EP 1318814 A2	18-06-2003
			HU 0302172 A2	29-09-2003
			HU 0302173 A2	29-09-2003
			NO 20031188 A	13-05-2003
			NO 20031189 A	13-05-2003
			NO 20031190 A	13-05-2003
			NO 20031191 A	13-05-2003
			WO 0222603 A1	21-03-2002
			WO 0222601 A1	21-03-2002
			WO 0222604 A1	21-03-2002
			WO 0222605 A1	21-03-2002
			WO 0222606 A1	21-03-2002
			WO 0222607 A1	21-03-2002
			WO 0222608 A1	21-03-2002
			WO 0222602 A2	21-03-2002
			US 2003073687 A1	17-04-2003
			US 2003083327 A1	01-05-2003
			US 2003064981 A1	03-04-2003
			US 2003064982 A1	03-04-2003
			US 2003055044 A1	20-03-2003
			US 2003078166 A1	24-04-2003
			AU 3116602 A	01-07-2002
			AU 3404702 A	01-07-2002
			BR 0116493 A	30-09-2003
			CA 2432129 A1	25-07-2002
EP 0072726	A	23-02-1983	FR 2510998 A1	11-02-1983

INTERNATIONAL SEARCH REPORT

PCT/GS 03/03376

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0072726 A		AR 231441 A1	30-11-1984
		AR 231637 A1	31-01-1985
		AT 18216 T	15-03-1986
		AT 12227 T	15-04-1985
		AU 548930 B2	09-01-1986
		AU 8655382 A	10-02-1983
		AU 548931 B2	09-01-1986
		AU 8655482 A	10-02-1983
		CA 1174240 A1	11-09-1984
		CA 1179346 A1	11-12-1984
		CS 229940 B2	16-07-1984
		CS 229941 B2	16-07-1984
		DD 202715 A5	28-09-1983
		DD 202549 A5	21-09-1983
		DE 3262671 D1	25-04-1985
		DE 3269383 D1	03-04-1986
		DK 354382 A ,B,	08-02-1983
		DK 354482 A ,B,	08-02-1983
		EG 15788 A	30-09-1986
		EG 15747 A	30-06-1986
		EP 0074863 A1	23-03-1983
		EP 0072726 A1	23-02-1983
		ES 8305737 A1	16-07-1983
		ES 8305738 A1	16-07-1983
		FI 822747 A ,B,	08-02-1983
		FI 822748 A ,B,	08-02-1983
		GR 76429 A1	10-08-1984
		GR 76430 A1	10-08-1984
		HU 189166 B	30-06-1986
		HU 190028 B	28-08-1986
		IE 53387 B1	26-10-1988
		IE 53388 B1	26-10-1988
		IL 66408 A	31-12-1985
		IL 66409 A	29-09-1985
		JP 1771027 C	30-06-1993
		JP 4059312 B	21-09-1992
		JP 58077867 A	11-05-1983
		JP 58077868 A	11-05-1983
		KR 8901569 B1	08-05-1989
		KR 8801624 B1	02-09-1988
		NO 822509 A ,B,	08-02-1983
		NO 822510 A ,B,	08-02-1983
		NZ 201518 A	30-04-1985
		NZ 201520 A	30-04-1985
		OA 7175 A	30-04-1984
		OA 7176 A	30-04-1984
		PH 18545 A	09-08-1985
		PL 237808 A1	28-02-1983
		PL 237809 A1	28-02-1983
US 4810705 A	07-03-1989	FR 2562071 A1	04-10-1985
		CA 1249276 A1	24-01-1989
		EP 0156734 A2	02-10-1985
		JP 60224691 A	09-11-1985
US 6255305 B1	03-07-2001	AT 236904 T	15-04-2003
		AU 724076 B2	14-09-2000
		AU 3551997 A	20-02-1998

INTERNATIONAL SEARCH REPORT

PCT/GB 03/03376

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6255305	B1	AU 723098 B2	17-08-2000
		AU 3553997 A	20-02-1998
		BG 103112 A	30-09-1999
		BR 9710729 A	17-08-1999
		CA 2260774 A1	05-02-1998
		CN 1251589 A	26-04-2000
		CZ 9900181 A3	16-06-1999
		DE 69720732 D1	15-05-2003
		EA 2436 B1	25-04-2002
		EE 9900027 A	16-08-1999
		EP 0915877 A1	19-05-1999
		EP 0915875 A2	19-05-1999
		WO 9804560 A1	05-02-1998
		WO 9804559 A2	05-02-1998
		JP 2002514169 T	14-05-2002
		JP 2000515851 T	28-11-2000
		KR 2000029548 A	25-05-2000
		NO 990304 A	25-03-1999
		NZ 333768 A	29-09-2000
		PL 331072 A1	21-06-1999
		SK 9399 A3	10-04-2000
		TR 9900047 T2	22-03-1999
		US 6465462 B1	15-10-2002
		ZA 9706591 A	18-08-1998
		HR 980035 A1	30-06-1999
		TW 480261 B	21-03-2002

This Page Blank (uspto)